Siv Infected Chimpanzees: Consequences Of Long-Term Infection And Potential Intervention Strategies by Barbian, Hannah J.
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
2016
Siv Infected Chimpanzees: Consequences Of
Long-Term Infection And Potential Intervention
Strategies
Hannah J. Barbian
University of Pennsylvania, hbarbian@gmail.com
Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Molecular Biology Commons, and the Virology Commons
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2180
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Barbian, Hannah J., "Siv Infected Chimpanzees: Consequences Of Long-Term Infection And Potential Intervention Strategies"
(2016). Publicly Accessible Penn Dissertations. 2180.
https://repository.upenn.edu/edissertations/2180
Siv Infected Chimpanzees: Consequences Of Long-Term Infection And
Potential Intervention Strategies
Abstract
Simian immunodeficiency virus of chimpanzees (SIVcpz) is widespread in wild-living chimpanzees and can
cause mortality and AIDS-like immunopathology. However, due to limited access to naturally infected
chimpanzees, little is known about SIVcpz pathogenesis and potential intervention strategies that might be
effective in captivity or in the wild. Given the central role of the intestinal microbiome in mammalian health, I
asked whether gut microbial constituents could reveal any insights into SIVcpz-associated pathogenicity. I
characterized the gut microbiome and virome of SIVcpz infected and uninfected chimpanzees in Gombe
National Park, Tanzania. I found that SIVcpz infected chimpanzees retain a stable gut microbiome throughout
much of their natural infection course, with a significant destabilization of bacterial communities observed
only in individuals with known immunodeficiency within the last several months before their death. I also
explored potential interventions that could be effective in both wild-living and captive chimpanzees. Broadly
cross-reactive neutralizing antibodies (bNabs) represent powerful new tools to combat human
immunodeficiency virus type 1 (HIV-1) infection. I found that some antibodies and antibody-like inhibitors
developed to combat HIV-1 infection are capable of neutralizing genetically diverse SIVcpz and SIVgor strains
with considerable breadth and potency, including in primary chimpanzee CD4+ T cells. Identification of
these reagents provides an important first step toward translating potential intervention strategies currently
developed to treat and prevent AIDS in humans to SIV infected apes. I also report a first case of clinical
immunodeficiency in an experimentally SIVcpz infected captive chimpanzee, which improved markedly
following antiretroviral treatment. These findings provide new insight into SIVcpz pathogenicity and identify
promising new approaches to combat SIVcpz infection.
Degree Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Graduate Group
Cell & Molecular Biology
First Advisor
Beatrice H. Hahn
Keywords
chimpanzee, microbiome, SIVcpz
Subject Categories
Microbiology | Molecular Biology | Virology
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2180
	  	  
	  
SIV INFECTED CHIMPANZEES: CONSEQUENCES OF LONG-TERM INFECTION AND 
POTENTIAL INTERVENTION STRATEGIES 
Hannah J. Barbian 
A DISSERTATION 
in 
Cell and Molecular Biology 
Presented to the Faculties of the University of Pennsylvania 
in 
Partial Fulfillment of the Requirements for the 
Degree of Doctor of Philosophy 
2016 
 
 
 
Supervisor of Dissertation     
______________________      
Beatrice H. Hahn, M.D.       
Professor of Medicine and Microbiology       
 
Graduate Group Chairperson 
______________________ 
Daniel S. Kessler, Ph.D. 
Associate Professor of Cell and Developmental Biology 
 
Dissertation Committee  
Dustin Brisson, Ph.D., Associate Professor of Microbiology 
Frederick D. Bushman, Ph.D., William Maul Measey Professor in Microbiology 
Ronald G. Collman, M.D., Professor of Medicine 
James A. Hoxie, M.D., Professor of Medicine 
	  ii	  
	  
ACKNOWLEDGMENT  
 
 I would like to thank my mentor Dr. Beatrice Hahn.  She provided unwavering guidance, 
taught me to be rigorous in science and to extend that rigor beyond the bench, and inspired a 
desire to constantly improve. I would also like to thank my fellow Hahn lab graduate students 
Elizabeth Loy, Sesh Sundararaman, Ronnie Russell, and especially Shilpa Iyer and Ted Kreider 
for their constant scientific and psychological support and encouragement.  I am immensely 
thankful to Nicholas Parrish, who laid the perfect foundation for my graduate career by showing 
me how to be a thoughtful and creative scientist.  I am fortunate to be surrounded by a number of 
talented scientists who generously shared their wisdom throughout the years: Hui Li, Weimin Liu, 
Yingying Li, and especially Fred Bibollet-Ruche, who lent his experience and creativity on a daily 
basis.  I also thank Erica Parrish, who served as an impromptu therapist in addition to a lab 
manager, and all of the other members of the Shaw and Hahn labs who were always happy to 
lend a helping hand. I am also thankful to my undergraduate research mentors, Dr. Rozalyn 
Anderson and Michael Polewski, who nurtured my initial interest in research, and my committee 
members Dustin Brisson, Rick Bushman, Ron Collman, and Jim Hoxie and also Phil Johnson for 
their thoughtful discussions and creative ideas that have so improved this work. 
 I would also like to thank my classmates for their support and friendship, and MJ Drake, 
Jessica Grindheim, and Dan Schauder for providing me a family in Philadelphia.  I am so thankful 
to my parents, Dean and Jane Barbian, for their unconditional support, even if it meant me being 
too far from home.  I also thank my siblings Rebekah and Joshua, my friend Maggie Yale, and the 
rest of my extended family for providing the loving framework that stabilizes my life.  Finally, I owe 
so much of my happiness and sanity to Sudil Mahendra, who provides limitless encouragement, 
compassion, and humor. Thank you for making me laugh every day, and for including me into 
your wonderful family, who have welcomed me with open arms.  So many people have helped 
foster my graduate career and this body of work; I hope that this dissertation does them justice. 
	  iii	  
	  
ABSTRACT 
	  
SIV INFECTED CHIMPANZEES: CONSEQUENCES OF LONG-TERM INFECTION AND 
POTENTIAL INTERVENTION STRATEGIES 
 
Hannah J. Barbian 
Beatrice H. Hahn 
 
Simian immunodeficiency virus of chimpanzees (SIVcpz) is widespread in wild-living 
chimpanzees and can cause mortality and AIDS-like immunopathology.  However, due to limited 
access to naturally infected chimpanzees, little is known about SIVcpz pathogenesis and potential 
intervention strategies that might be effective in captivity or in the wild. Given the central role of 
the intestinal microbiome in mammalian health, I asked whether gut microbial constituents could 
reveal any insights into SIVcpz-associated pathogenicity. I characterized the gut microbiome and 
virome of SIVcpz infected and uninfected chimpanzees in Gombe National Park, Tanzania. I 
found that SIVcpz infected chimpanzees retain a stable gut microbiome throughout much of their 
natural infection course, with a significant destabilization of bacterial communities observed only 
in individuals with known immunodeficiency within the last several months before their death. I 
also explored potential interventions that could be effective in both wild-living and captive 
chimpanzees. Broadly cross-reactive neutralizing antibodies (bNabs) represent powerful new 
tools to combat human immunodeficiency virus type 1 (HIV-1) infection. I found that some 
antibodies and antibody-like inhibitors developed to combat HIV-1 infection are capable of 
neutralizing genetically diverse SIVcpz and SIVgor strains with considerable breadth and 
potency, including in primary chimpanzee CD4+ T cells. Identification of these reagents provides 
an important first step toward translating potential intervention strategies currently developed to 
treat and prevent AIDS in humans to SIV infected apes. I also report a first case of clinical 
immunodeficiency in an experimentally SIVcpz infected captive chimpanzee, which improved 
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markedly following antiretroviral treatment. These findings provide new insight into SIVcpz 
pathogenicity and identify promising new approaches to combat SIVcpz infection. 
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INTRODUCTION 
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Section 1.1 - Simian immunodeficiency virus of chimpanzees, the precursor of HIV-1 in 
humans  
 
HIV-1 and AIDS 
Acquired Immune Deficiency Syndrome (AIDS) was first identified in the United States in 
1981 (1).  It has since caused more than 70 million infections and 35 million deaths worldwide 
(www.unaids.org).  The causative agent is human immunodeficiency virus type 1 (HIV-1), a 
lentivirus of the Retroviridae family. Members of this family are enveloped, single-stranded, 
positive-sense RNA viruses that utilize a virus-encoded reverse transcriptase to produce DNA 
from its RNA genome. Viral DNA is then integrated into the host genome, resulting in a persistent 
infection. HIV-1 primarily infects CD4+ T cells (2), using the CD4 molecule as its entry receptor 
(3, 4), and CCR5 (5) or CXCR4 (6) as a co-receptor.  HIV-1 infection is spread primarily through 
sexual contact, and is typically associated with a decrease in CD4+ T cell numbers over time and 
eventual progression to AIDS, characterized by the development of an AIDS-defining illness, 
such as opportunistic infections, cancer, and/or a decline in CD4 count to lower than 200 cells/ul 
(7).  
 
The search for the origin of HIV-1 in primate lentiviruses 
Following the sudden emergence of HIV-1 infection in the U.S., researchers sought to 
identify the source of the pandemic.  Zoonotic transmission events are responsible for the 
majority of emerging infectious diseases (9), leading investigators to search for closely related 
viruses in non-human primates.  Identification of a related retrovirus in rehesus macaques, now 
termed simian immunodeficiency virus (SIV), provided the first evidence that HIV-1 may be of 
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primate origin. Outbreaks of AIDS-like disease in captive macaques were noted in the early 
1980’s, which was later associated with a retrovirus featuring similar growth phenotypes, 
cytopathic effects, and morphology to HIV (10). Others found that this macaque retrovirus (now 
termed SIVmac) contained proteins of a similar size as HIV, and could be successfully 
immunoprecipitated with antibodies directed against HIV proteins (11). Another study identified a 
retrovirus that caused AIDS-like illness and displayed antigenic cross-reactivity to HIV-1 in rhesus 
macaques that were experimentally inoculated with tissue from sooty mangabeys (12). However, 
molecular analysis of SIVmac revealed that it was closely related to HIV-2, a virus that is 
phenotypically and genotypically distinct from HIV-1 (13), leaving the precursor of the pandemic 
HIV strain elusive (14, 15). SIV was then detected in captive wild-caught sooty mangabeys (16) 
and African green monkeys (17, 18), broadening the search for SIV strains to African monkeys 
and apes.  Around 40 different primate lentiviruses have since been discovered in African 
primates, including the genera Pan (chimpanzees), Gorilla, Cerocebus (mangabeys), Mandrillus 
(mandrills), Colobus, and Ceropithecus (greater spot-nosed and other monkeys) (19). These 
strains share a similar genomic organization, including the major structural and enzymatic genes 
gag (encoding matrix, capsid, and nucleocapsid proteins), pol (encoding protease, reverse 
transcriptase, and integrase), and env (encoding envelope-associated proteins), and accessory 
genes tat, rev, vif, vpr, and nef, which perform regulatory functions required for viral replication.  
However, the accessory gene vpu is unique to HIV-1, SIVcpz, and SIV strains from the monkeys 
of the genus Ceropithecus, while the vpx gene is unique to SIV strains from mangabeys (20). 
Despite the comparable genomic organization of SIV strains, they exhibit extensive sequence 
diversity, sharing only 40-50% identity in the more conserved Gag and Pol proteins (21).  SIV 
strains in wild-caught Asian primates have not been detected, suggesting that the ancestor of 
primate SIV strains likely emerged after the divergence of African and Asian monkeys.   
The first evidence of a chimpanzee origin of HIV-1 came from the discovery of a 
retrovirus infecting two wild-born chimpanzees from Gabon with close antigenic similarity to HIV-1 
(22).  This virus, termed simian immunodeficiency virus of chimpanzees (SIVcpz), was found to 
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have the same genomic organization as HIV-1, including vpu, which had only been identified in 
HIV-1 at that time, and a sequence more closely related to HIV-1 than any other primate lentivirus 
(23, 24).  A third case of SIVcpz was then discovered in a captive animal from the Democratic 
Republic of Congo (25).  This strain showed remarkable sequence diversity compared to those 
previously described, being as distantly related to each other as they were to HIV-1 (25, 26).  
Extensive screening of captive chimpanzees revealed a scarcity of HIV-1 cross-reactive 
antibodies in these animals, leading some to doubt that it could serve as a true reservoir at such 
low frequencies (23, 25-27).   Gao and colleagues then characterized a fourth SIVcpz strain, 
which was closely related to the SIVcpz strains from Gabon (28). This group also found that 
sizable genetic diversity of the different SIVcpz strains could be attributed to their chimpanzee 
subspecies specificity, and provided the definitive description of the origin of pandemic HIV-1 
from SIVcpz infected chimpanzees (28).  HIV-1 is comprised of 4 phylogenetic lineages, group M, 
the pandemic strain, and groups N (29), O (30), and P (31), which infect far fewer individuals 
(representing less than 1% of global HIV-1 infections).  It was later shown that each HIV-1 group 
originated from an independent cross-species transmission event of ape SIV strains, with groups 
M and N originating from SIVcpz and groups O and P originating from SIV infected gorillas 
(SIVgor) (1).  The exact route of transmission from apes to humans is unknown, however, the 
most likely hypothesis is by exposure to ape blood via bushmeat hunting (32).  
 
The SIVcpz reservoir 
 The common chimpanzee species, Pan troglodytes (P.t.), is composed of four 
subspecies: P. t. verus (located in west Africa), P. t. ellioti (located in Nigeria and Cameroon), P. 
t. troglodytes (located in west-central Africa), and P. t. schweinfurthii (located in east-central 
Africa) (33, 34) (Figure 1.1).  The HIV-1 pandemic strain arose from transmission of SIVcpz 
infecting P. t. troglodytes chimpanzees (SIVcpzPtt) (28). Studies of the SIVcpz reservoir were 
difficult, as wild living chimpanzees are endangered, reclusive, and live in very remote habitats.  
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Anesthetizing wild chimpanzees to collect blood is unethical, because of the health risk 
associated with an animal losing consciousness and falling from a tree after drug administration.  
Thus, noninvasive methods to study SIVcpz in wild chimpanzees had to be developed. An initial 
study of captive and wild-living chimpanzees found that anti-SIVcpz antibodies could be detected 
in chimpanzee urine and feces using commercially available HIV-1 nitrocellulose strips and 
Western blot analysis (35).  This method showed 100% specificity and 65 to 100% sensitivity in 
feces and urine, respectively (35).  RNA extraction from feces and reverse transcriptase 
polymerase chain reaction (RT-PCR) could additionally be used for molecular analysis of the 
infecting strain (35).  Expansion of these methods to dozens of field sites and thousands of 
chimpanzee fecal samples enabled the characterization SIVcpz reservoir (36-40).  SIVcpz has 
been found to infect chimpanzees of the subspecies P. t. troglodytes and P. t. schweinfurthii and 
is absent from chimpanzees of the subspecies P. t. ellioti and P. t. verus (Figure 1.1). P. t. verus 
chimpanzees comprise a vast majority of captive chimpanzees (41), explaining the difficulty in 
identifying SIVcpz-infected captive chimpanzees in earlier studies. The prevalence rates amongst 
P. t. troglodytes and P. t. schweinfurthii chimpanzees varies from 0 – 50% in different 
communities (35, 36, 39, 40, 42).  In contrast, SIV infection in wild monkeys is much more 
prevalent and uniform between communities (43, 44).  These findings suggested a more recent 
ancestor of SIVcpz than other monkey SIVs, likely following the chimpanzee subspecies 
divergence.  Molecular analysis revealed that the SIVcpz genome is a mosaic, with the gag, pol, 
and nef genes being more similar to SIVrcm from red-capped mangabeys, and the vpu, tat, rev 
and env genes being more similar to SIVs infecting members of Ceropithecus (45).  Thus, 
chimpanzees likely acquired SIVcpz through the cross species transmission and recombination of 
two monkey SIV strains (Figure 1.1).  This scenario is plausible, as chimpanzee habitats overlap 
with the those of the related SIV hosts, and chimpanzees are known to hunt and eat monkeys 
(46).  
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Figure 1.1. Origins and distribution of SIVcpz.  a) SIVcpz was acquired from cross-species transmission and 
recombination of two monkey SIVs. HIV-1 group M and N were a result of two cross-species transmission 
events from SIVcpz infected chimpanzees to humans.  b) A map of the distribution of chimpanzee 
subspecies and field sites that have been screened for SIVcpz infection (left).  Sites where SIVcpz has been 
detected are represented by yellow circles; sites were SIVcpz has not been detected are in white.  A map of 
Gombe National Park in Tanzania outlines the ranges of the three chimpanzee communities and the 
approximate population size of each community (right).  The maps were modified from Sharp PM and Hahn 
BH, Cold Spring Harbor Perspectives in Medicine 2012 and Keele BF, Nature 2009.  	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SIVcpz natural history studies at Gombe National Park 
The most important field site for the study of SIVcpz in wild-living chimpanzees is Gombe 
National Park in northwestern Tanzania.  Gombe covers a narrow area (approx. 35 km2) between 
a mountain rift and Lake Tanganyika (Figure 1.1).  This biodiverse area is comprised of rift 
valleys, evergreen and semi-deciduous woodlands, thicket, and grasslands, and is home to P. t. 
schweinfurtii chimpanzees (46). Human deforestation to the north and south of the chimpanzee 
range resulted in geographic isolation of this population.  Jane Goodall began her famous study 
of these animals in 1960, with important discoveries in the first few years including that 
chimpanzees hunt and eat meat, and make and use tools (47, 48).  Since then, Gombe 
chimpanzees have been under continuous observation. There are three communities of 
chimpanzees in Gombe, termed Mitumba, Kasekela, and Kalande (Figure 1.1).  Kasekela is the 
largest community (n≈65) and the first to be habituated to the presence of human observers, 
Mitumba, smaller community (n≈25) at the northern end of the park, was habituated later, and    
Kalande, the smallest community (n≈10) to the south, remains only partially habituated to this day 
(49).  The total population of Gombe chimpanzees has decreased since the onset of study in the 
1960s from around 120-150 to 96-100 in 2013 (50). The major sources of this population decline 
are thought to be poaching, intercommunity violence, habitat disturbance, and disease (49), with 
illness being the most common cause of death of Gombe chimpanzees (51).  Major infectious 
epidemics have been documented in these animals, including sarcoptic mange (52), respiratory 
disease (51), and polio (53).  A comprehensive health monitoring system was established in 2004 
that standardized the recording of observational health data and postmortem necropsy 
evaluations, resulting in frequent and reliable health records of Gombe chimpanzees (54).  With 
over 50 years of observational data, this group of chimpanzees represents a unique and valuable 
source for infectious disease studies. 
 SIVcpz was first discovered in Gombe National Park in the early 2000’s when analysis of 
58 fecal and urine samples from this and two other field sites (located in Cote d’Ivoire and 
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Uganda) found one male Kasekela resident to be infected (35). Expanded fecal screening of 
Gombe chimpanzees revealed that SIVcpz was present in all three communities, with 
prevalences of 5, 17, and 30% for Kasekela, Mitumba, and Kalande, respectively (56).  Molecular 
analysis revealed that full-length SIVcpz genomes could be recovered from fecal samples (55) 
and phylogenetic analysis showed that Gombe viruses form a monophyletic lineage within all 
SIVcpzPts strains (57). However, SIVcpz strains from the three communities do not form distinct 
lineages, suggesting that SIVcpz is transferred between groups, likely through migration of 
infected females (57).  The routes of SIVcpz transmission are similar to HIV-1 infected humans, 
with both vertical and sexual transmission being observed in Gombe.  After biannual screening of 
Gombe chimpanzees for over seven years, Keele and colleagues discovered that SIVcpz is 
actually pathogenic in chimpanzees, contrary to previous reports.  SIVcpz infected animals 
showed a 10 to 16 fold increased risk of death compared to uninfected individuals (57).  SIVcpz 
infected females were three times less likely to give birth than uninfected females, and showed 
high infant mortality, with all four infants born to infected mothers dying in their first year, 
compared to six of 30 babies born to uninfected mothers.  One SIVcpz infected female showed 
signs of lethargy and weakness only three years after acquiring the virus. At necropsy, Keele and 
colleagues found that this female showed severe muscle loss, hepatic atrophy, and abdominal 
abscesses due to parasite infection. Splenic examination revealed severe depletion of CD4+ T 
cells, signs of lymphatic tissue destruction, and collagen deposition (indicative of overall immune 
dysfunction (58)).  Thus, this animal displayed hallmarks of AIDS that are also observed in 
humans.  Analysis of necropsy samples from two SIVcpz uninfected controls confirmed that 
CD4+ T cell depletion is abnormal in wild chimpanzees.  Two SIVcpz infected animals, who died 
due to injuries, also showed CD4+ T cell depletion in the spleen, although to a lesser extent than 
what was seen in the animal with evidence of AIDS.  These findings by Keele and colleagues 
demonstrated that wild-living SIVcpz infected chimpanzees show signs of morbidity and mortality 
similar that observed in HIV-1 infected humans (59-61), and that infected chimpanzees can 
develop AIDS-like illness.  Further natural history studies in Gombe National Park revealed that 
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the community with the highest SIVcpz prevalence (Kalande – 46%) was experiencing population 
decline, while communities with lower prevalences (Mitumba – 13%, Kasekela – 12%) 
experienced positive growth rates (62).  This population decline was not due to habitat quality or 
access to food, and mathematical modeling indicated that even moderate SIVcpz prevalences 
could lead to population decline, suggesting that SIVcpz infection could contribute to the mortality 
burden of already dwindling wild chimpanzee populations.  
 
Conclusions 
 In sum, studies of wild-living chimpanzees have elucidated the origin of HIV-1 and the 
AIDS pandemic, and the effect of SIVcpz infection on chimpanzee mortality and population 
dynamics.  However, important questions remain unanswered. What factors are involved in 
SIVcpz pathogenesis in chimpanzees and how do they differ from HIV-1 in humans? To what 
extent does SIVcpz infection contribute to the catastrophic population decline of wild-living 
chimpanzees in central Africa, and how might SIVcpz transmission be curbed if medical 
intervention were to become necessary to rescue endangered chimpanzee populations? Given 
the phenotypic and genotypic similarities of SIVcpz and HIV-1, as well as chimpanzees and 
humans, further studies to delineate these topics could not only benefit chimpanzees, but would 
also inform studies of HIV-1 in humans.  
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Section 1.2 - Understanding the Consequences of SIVcpz 
 
SIV pathogenesis 
SIV infection of most non-human primates is nonpathogenic. However, SIV infection of 
macaques and chimpanzees, and HIV infection of humans, causes morbidity and mortality.  
While the pathogenic properties of HIV and SIV infection of humans and monkeys are well 
described, the mechanisms of pathogenesis in SIVcpz infected chimpanzees are largely 
unknown. Nonpathogenic hosts of SIV infection, such as sooty mangabeys with SIVsmm or 
African green monkeys with SIVagm, generally do not develop symptoms of AIDS (19).  Their 
viruses, however, are capable of causing disease in rhesus macaques. This interesting disparity 
led researchers to investigate the distinguishing features of HIV/SIV in pathogenic versus non-
pathogenic hosts (Figure 1.2).  Both non-pathogenic and pathogenic hosts show similar kinetics 
of acute infection, with initial log-phase growth leading to robust levels of peak viremia (63).  
Viremia persists at a set point throughout the course of chronic infection in both pathogenic and 
non-pathogenic hosts.  HIV/SIV in both pathogenic and non-pathogenic hosts targets activated, 
short-lived CD4+ T cells, which are depleted in the mucosa during the acute phase of infection 
(64-67).  Peripheral CD4+ T cells, however, are maintained throughout chronic infection in non-
pathogenic hosts, but not pathogenic hosts (68). HIV/SIV infection sparks a robust innate immune 
response regardless of host, including increased levels of proliferating T cells, up-regulation of 
interferon stimulated genes, and production of type I interferons (69-71).   However, unlike 
pathogenic hosts, this innate immune response is rapidly down-regulated after the acute phase in 
non-pathogenic hosts (69-71).  Chronic systemic immune activation, including increased cell 
turnover and pro-inflammatory cytokines, is associated with disease progression in pathogenic 
hosts, but is generally absent from non-pathogenic hosts (72-75).  This may be due to a lack of 
microbial translocation, which triggers immune activation (76), maintenance of Th17 cells, which  
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Figure 1.2. Host-specific pathogenicity. Comparison of the characteristics of pathogenesis in non-
pathogenic hosts of SIV infection, pathogenic hosts of SIV/HIV infection, and chimpanzees with SIVcpz 
infection.	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 are key regulators of mucosal immunity (77), or differential regulation of other inflammatory 
factors (78).  Additionally, non-pathogenic hosts have low frequencies of mucosal CCR5+ CD4+ 
T cells (79), which serve as the main target of SIV infection, indicating that restriction of target cell 
availability may help reduce SIV pathogenicity in addition to dampened chronic immune 
responses. 
The kinetics of viremia, extent of immune activation, presence of microbial translocation, 
levels of CCR5+ CD4+ T cells, and other factors key to HIV-1/SIV pathogenicity are largely 
unknown in naturally SIVcpz infected chimpanzees due to the inaccessibility of blood samples 
from wild-living apes (Figure 1.2). Limited studies of captive chimpanzees have queried some of 
these variables.  Experimental infection of five captive animals with SIVcpz revealed similar 
kinetics of viremia to other hosts of SIV/HIV, with an acute peak then chronic set point viral load 
(80).  A follow-up study of seven SIVcpz infected captive animals showed depletion of CD4+ T 
cells, evidence of lymphoid tissue damage, and increased anti-platelet autoimmune antibodies 
(81).  However, they failed to find significantly increased levels of markers of immune activation 
and gut integrity.  This group thus concluded that SIVcpz infected chimpanzees exhibit less 
marked pathogenesis than HIV-1 infected humans, but more pathogenesis than other natural 
hosts of SIV.  However, despite these limited studies in experimentally infected chimpanzees, 
very little is known about the mechanism and extent of pathogenesis in SIVcpz infected 
chimpanzees.    
 
Immunodeficiency and the microbiome 
Pathogenesis studies in wild-living chimpanzees would require a marker of disease that 
can be detected in fecal material. In recent years, the microbiome, or the community of microbes 
that are present at a certain site, has become a marker for host health. Recent work suggests 
that the microbiome has evolved with its host, with evidence for cospeciation of primates with 
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predominant members of their gut flora, confirming their intimate association (82).  The 
microbiome is inherited at birth, with infants showing compositional similarities to their mother’s 
vaginal tract immediately following delivery (83). Microbiome composition varies greatly by 
anatomical site, with distinct communities present in the nostrils, oral cavity, skin, stomach, 
gastrointestinal and genital tracts. Microbiomes vary between individuals (84) and to a lesser 
extent, within an individual over time (85).   External factors can also impact microbiome 
composition, with diet (86), antibiotic use (87), and even seasonal changes (88) impacting 
microbial communities.   Diseases of multiple anatomic sites can also alter microbiome 
composition, including psoriasis and the cutaneous microbiome (89), and Helicobacter pylori and 
the gastric microbiome (90).  The most well studied microbial communities are those of the gut.  
Studies of the gut microbiome, often utilizing fecal material, revealed the association of multiple 
disease states with alterations in bacterial abundances and/or bacterial diversity, termed 
microbiome dysbiosis.   For example, microbes of the Fusobacterium species are associated with 
colorectal cancer (91), Crohn’s disease is associated with decreased bacterial diversity (92), and 
members of Enterobacteriaceae are associated with ulcerative colitis (93).  The gut microbiome 
may also influence the outcome of infectious diseases, with the composition of the gut 
microbiome being associated with the severity of malarial disease in mice (94). While studies of 
the microbiome are largely observational, understanding these relationships provide important 
insight into the pathogenesis of multiple diseases. 
 The gut is a primary focus HIV-1 research, as it serves as the largest reservoir of CD4+ T 
cells and a primary site of virus replication.  Changes in the gut, including disruption of intestinal 
barriers, depletion of immune cells, translocation of microbial products, and local immune 
activation, serve as key characteristics of disease progression (95).    In addition, late-stage 
disease is often associated with high incidence of diarrheal disease, which can lead to severe 
morbidity and/or mortality (96).  The profound effect of HIV infection on the gut led many 
investigators to examine the gut microbiota of HIV infected individuals.  Multiple studies of HIV 
infected and uninfected individuals found that the gut microbiome of HIV-positive patients were 
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enriched or depleted in certain bacterial strains.  Investigators found increased frequencies of 
Prevotella (97-100) and Proteobacteria (97, 101, 102), and decreased frequencies of Bacteroides 
(97-100, 102) and Ruminococcus (97, 99, 100, 103).  However, likely due to variations in sample 
collection and analysis methods, and the disease state and treatment status of the patients, not 
all results have been confirmatory.   Many groups report significant differences in abundances of 
bacteria that are not observed by others, with increased abundance of Prevotella being the most 
consistently associated with HIV-1 infection.  Inconsistent findings were also reported for alpha 
diversity, which is a marker of bacterial richness and evenness. Some studies report that HIV-1 
infected individuals have decreased alpha diversity (99, 100, 103), while others reported an 
increase (98), or no difference (97, 101, 102). However, most studies find clustering of HIV-1 
infected individuals by beta diversity, a between-individual comparison of bacterial composition; 
leading investigators to conclude that HIV-1 drives the gut microbiome to be distinct from that of 
uninfected individuals (98-103). Some investigators have linked gut microbiome dysbiosis with 
markers of disease progression, including associations with immune cell activation (97, 102), 
plasma markers of inflammation (101, 102), and microbial translocation (97, 100). Correlations 
with HIV-1 associated microbiome changes and the gold standard of disease progression, CD4+ 
T cell counts, were observed in some studies (97, 104, 105), but not others (99, 106).  Thus, 
inconsistent findings leave the role of the gut microbiome in HIV-1 infection unclear. However, 
these studies have revealed interesting associations that suggest a potential role for gut microbes 
in HIV-1 pathogenesis.   
 Using non-invasively collected fecal material, studies of the gut microbiome in wild-living 
chimpanzees are also possible.  Early work showed that chimpanzees and humans have quite 
similar microbiome compositions, with Firmicutes, Bacteroidetes, Proteobacteria, and 
Actinobacteria being the predominant phyla (107).  The microbiota of wild-living chimpanzees are 
also susceptible to environmental factors, with animals of the same community and geographic 
location showing convergent microbiomes (108, 109).  Social behavior also impacts the gut 
composition of wild chimpanzees, with more diverse and convergent microbiomes observed 
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during months where chimpanzees exhibit high social activity (110).  Age, gender, and genealogy 
seem to have less pronounced effects on their gut microbiota (108). A preliminary study by 
Moeller and colleagues investigated the impact of SIVcpz on the chimpanzee gut microbiome.  
Using longitudinal fecal samples from six SIVcpz-infected individuals and pre-infection samples 
as controls, Moeller et al. failed to find any bacterial strain that was significantly associated with 
SIVcpz infection (111).  This finding was in contrast to most studies of HIV-1 infected individuals.  
An increased frequency of some disease-associated genera (Sarcina, Staphylococcus, and 
Selenomonas) was observed in some individuals post-infection; however these genera also 
contain commensal strains and are not indicative of the outgrowth of pathogenic bacteria. No 
difference in microbiome richness or evenness was observed between pre- and post-infection 
samples, similar to some studies of HIV-1 infected individuals (97, 101, 102).  Investigating the 
beta diversity of pre- and post- infection samples, Moeller et al. did observe more variation in 
samples taken after the acquisition of SIVcpz.  This implied that while SIVcpz did not have a 
pronounced effect on the composition of the chimpanzee gut microbiome, it did result in relative 
instability of microbial communities.   
Wild-living gorillas are also infected with SIV, having acquired their strain via cross-
species transmission of SIVcpz from chimpanzees (112).  The ability of SIVgor to cause disease 
in these apes is unknown, as wild-living gorillas are very reclusive, making habituation and 
longitudinal sampling extremely difficult.  To look for signs of SIVgor-associated disease in these 
apes, Moeller and colleagues also investigated the fecal microbiomes of wild gorillas.  Utilizing 69 
SIV positive samples and 96 SIV negative samples, they found no significant differences in the 
frequency of bacterial strains, community richness, evenness, or rate of divergence (113). Thus, 
SIV infection of wild-living apes seems to have a more modest effect on the gut microbiome 
compared to that of HIV-1 and humans. However, given the study of only six SIV infected 
chimpanzees to date, a more comprehensive analysis would be required to determine the effect 
of SIVcpz on the gut microbiome.   
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Immunodeficiency and the virome 
 In addition to the bacterial members of the gut, the resident viruses (comprising the 
virome) may also play a role in HIV/SIV associated pathogenesis.  Immunodeficiency has been 
associated with changes in the virome, including outgrowth of both pathogenic and non-
pathogenic viruses (114-117).   For example, the blood of immunosuppressed transplant 
patients has increased frequencies of anelloviruses, a nonpathogenic virus family with small 
circular DNA genomes (116, 117).  An altered virome has also been implicated in HIV and SIV 
infection.  A study of HIV-1 infected patients from the United States and Uganda found that 
progression to AIDS coincided with the outgrowth of annelloviruses and other commensal viruses 
(115). TT virus, a member of the annellovirus family, was found to be more prevalent in HIV-1 
infected patients by other groups, with TT viremia being inversely associated with CD4+ T cell 
counts and other predictors of survival (118, 119).  Using metagenomic virome analysis, Handley 
and colleagues investigated fecal samples of 35 SIV infected macaques.  They found that SIV 
infection was associated with a 10-fold increase in the number of viral sequences (114). In 
contrast, SIV infected African green monkeys, a nonpathogenic host of SIV, did not show 
expansion of the gut virome.  Multiple families of viruses were significantly increased in infected 
macaques, including picornaviruses and adenoviruses.  Adenovirus-associated enteritis was 
detected by necropsy of SIV infected macaques that had progressed to AIDS, suggesting that the 
viruses detected by molecular analysis were capable of intestinal damage. Handley et al. also 
detected parvovirus in the serum of animals with fecal parvovirus expansion, indicating that 
parvovirus in the gut can invade tissues and enter circulation in the blood. Thus, both 
nonpathogenic and pathogenic members of the virome may be altered by immunodeficiency.  
This work suggests that studies of the fecal virome could not only reveal signatures associated 
with HIV/SIV infection, but could also provide clues to the mechanism of gut pathogenesis.   
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Conclusions 
 In sum, the mechanism of HIV- and SIV- associated pathogenesis is complex, and varies 
depending on the host species. Hosts that have evolved longer with their virus (e.g. African 
monkey species with SIV) show far less morbidity and mortality than hosts who have acquired 
their virus more recently (e.g. humans with HIV-1 and Asian macaques with SIV). Where SIVcpz 
infected chimpanzees lie on this spectrum remains to be determined.  Chimpanzees likely 
acquired their virus relatively recently compared to African monkeys, but thousands of years 
earlier than the introduction of HIV into human populations (120).  Thus, studies of the extent and 
mechanism of SIVcpz pathogenesis in chimpanzees could reveal interesting insights into how 
host-specific adaptation affects SIV/HIV-associated disease.   
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Section 1.4 - Potential Intervention Strategies for SIVcpz Infected Chimpanzees 
 
Introduction 
Chimpanzees are an endangered species, with wild populations rapidly decreasing in 
equatorial Africa (121) in the past several decades.  Population numbers are estimated to have 
decreased from around 1 million chimpanzees in 1990 to around 200,000 in the year 2000 (49).  
Bushmeat hunting, logging and agriculture-driven deforestation, and infectious disease threaten 
wild ape populations.  Infectious diseases play a significant role in ape population decline, with 
estimates suggesting that up to one third of wild ape populations may have been killed by the 
Ebola Zaire strain (121, 122).  Due to the critically sparse populations of African apes and the 
threat of infectious diseases, conservationists and researchers alike have recommended pursuing 
medical intervention strategies for pathogens that could contribute to extinction of wild apes (123, 
124).  Due to the perilously low numbers of mountain gorillas (less than 1,000 animals are 
estimated to remain in the wild), medical treatment of disease has become an integral piece of 
their conservation plan (125, 126).  For example, juvenile mountain gorillas have been treated 
with anti-parasitics to prevent the spread of mange (127). In addition, vaccination of wild gorillas 
in the Virungas was performed in response to a measles outbreak (128).  Given the endangered 
status of wild-living chimpanzee populations, and the potential of SIVcpz to contribute to 
population decline (62), the feasibility of strategies to curb SIVcpz transmission in the wild should 
explored.   
 
Antiretroviral therapy 
Given the genotypic and phenotypic similarities of SIVcpz in chimpanzees to HIV-1 in 
humans, SIVcpz treatment and prevention strategies can be guided by the extensive efforts that 
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have been performed for humans.  The most effective means of treating and preventing HIV-1 to 
date is antiretroviral therapy (ART).  The first antiretrovirals (ARVs) were delivered in the early 
1990s, however, due to the error-prone reverse transcriptase and rapid turnover rate of HIV-1, 
attempts at ARV monotherapy were largely unsuccessful.  However, combination therapy of more 
potent ARVs (cART), led to a significant reduction in HIV-associated morbidity and mortality 
(129).  Dozens of ARVs have since been developed, with the largest fraction targeting the 
reverse transcription process (130).  Two classes of drugs can inhibit this stage of the viral life 
cycle, nucleoside reverse transcriptase inhibitors (NRTIs), which are analogs of native nucleoside 
substrates, or non-nucleoside reverse transcriptase inhibitors (NNRTIs), which act non-
competitively by binding an allosteric pocket of the reverse transcriptase enzyme. The other 
enzymatic activities of HIV-1, such as integration (critical for viral latency and protein production) 
or protease cleavage (involved in virus maturation), are also effective targets of ARVs.  Due to 
the broad activity of these molecules against divergent HIV-1 and even SIVmac strains, and the 
conservation of these proteins between HIV-1 and SIVcpz, these ARVs would likely be effective 
against SIVcpz.  ART is not only a potent means of reducing viral load and disease progression in 
HIV-1 infected patients, it can also dramatically reduce the risk of HIV-1 transmission by both 
sexual and intravenous routes (131-134).  While ART would likely prove highly effective against 
SIVcpz, adherence to daily oral medication is required, making its translation to wild ape 
populations impossible.  Despite promising efforts to generate long-lasting ARVs (135), other 
strategies to reduce SIVcpz transmission may be required.   
  
Broadly neutralizing antibodies 
Monoclonal antibodies have been a recent focus of HIV-1 treatment and prevention 
strategies, and may provide an alternative to ART (136).  Antibody responses to HIV-1 infection 
develop within a week of detectable viral load; however, this initial response has no effect on HIV-
1 viremia (137).  Despite gaining some neutralizing activity over time, antibody responses are 
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Figure 1.3. Types of HIV neutralizing antibodies.  Antibodies targeting the HIV envelope 
include classical bNAbs that are derived from chronically infected individuals, as well as 
antibody-like constructs that are engineered to combine domains 1 and 2 of CD4 with antibody 
constant regions.  Monoclonals binding to the HIV receptor CD4, or co-receptor CCR5, can 
also prevent HIV entry. 	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incapable of controlling HIV-1 infection throughout the course of infection. Neutralizing responses 
are thwarted by viral escape through amino acid substitutions and a dynamic glycan shield, which 
prevents access of antibodies to their conserved epitopes (138). In a subset of HIV-1 infected 
patients, antibodies capable of neutralizing heterologous variants, termed broadly neutralizing 
antibodies (bNAbs), develop after several years of infection (139).  Development of single cell 
cloning techniques allowed for high throughput analysis of HIV-1 envelope-reactive antibodies 
and characterization of bNAbs (140, 141).   
Using these methods to screen thousands of patients, a number of broad and potent 
monoclonal antibodies have been derived. These bNAbs were found to target defined sites of 
vulnerability on the HIV-1 envelope: the CD4 binding site, variable loops 1 and 2 (V1/V2), also 
called the V2 apex, variable loop 3 (V3), also called the high-mannose patch, and the membrane 
proximal external region (MPER). Engineered antibody-like constructs that combine domains of 
the human receptor with antibody constant regions, termed CD4 immunoadhesins, are also 
capable of broad and potent neutralizing activity (142-144) (Fig. 1.3).  One immunoadhesin, 
eCD4-Ig, combines an IgG Fc with domains 1 and 2 of CD4 and a CCR5 mimetic peptide (143).  
This molecule mimics both the HIV-1 receptor and co-receptor and thus binds multiple regions of 
the gp120 molecule.  eCD4-Ig shows the most breadth of any anti-HIV-1 molecule to date, 
neutralizing every HIV and SIV strain tested (143). Binding of antibodies to the envelope protein 
not only blocks the virus from entering cells, it has also been shown to accelerate the clearance 
of bound viruses from plasma (147),  stimulate immune responses via Fc-mediated mechanisms 
(148), and enhance clearance of infected cells (149). Monoclonal antibodies that bind to the HIV 
receptor or coreceptor (instead of the virus) have also been developed (Fig 1.3).  Ibalizumab, a 
CD4-binding monoclonal that does not inhibit MHC class II binding, and PRO 140, a CCR5-
binding monoclonal, are both capable of blocking HIV-1 entry and showed promising results in 
clinical trials (145, 146).   
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The long half-lives of monoclonal antibodies provide their potential as long-lasting 
reagents for both treatment and prevention. Using a chimeric virus that expresses a HIV-1 
envelope in the context of a SIV backbone (SHIV), researchers found that passive transfer of 
monoclonal antibodies prevents virus acquisition after repeated mucosal challenge (150-152).  
This prophylaxis was extremely effective, providing protection even when using an antibody with 
relatively low potency at very low concentrations (150).  A combination of bNAbs were able to 
completely suppress viremia in humanized mice with established HIV-1 infection, with antiviral 
activity lasting for 60 days after the last antibody dose was administered, providing evidence that 
combination bNAb therapy could provide long-lasting viral suppression (153). Later studies in 
SHIV infected macaques revealed the ability of combination bNAb therapy to reduce viremia in 
primates (154, 155).    Clinical trials testing the safety and efficacy of bNAb therapy in humans 
are ongoing.  Initials studies report up to a 2.5 log reduction of viremia in HIV-1 infected 
individuals, with viral suppression lasting up to a month, after administration of a single 
monoclonal antibody (3BNC117) (156).  3BNC117 was also found to delay the time to viral 
rebound for up to 19 weeks after cessation of ART in infected individuals, dramatically longer 
than the average 3-week time to rebound observed without antibody administration (157).  Adding 
to the potential of antibodies for long-term prophylactic or therapeutic activity is the use of 
antibody gene transfer, pioneered by Lewis and colleagues (158). This method involves the 
delivery of a gene encoding a monoclonal antibody to muscle tissue via recombinant adeno-
associated virus (rAAV) gene therapy vector (158).  Skeletal muscle cells are very long-lived, 
enabling antibody expression for years or even decades.  This method proved efficacious as a 
prophylactic against SIV transmission in macaques and HIV transmission in humanized mice 
(159-161).   Such long lasting activity would be critical for translation to wild-living chimpanzees.  
 
Treating captive chimpanzees 
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Chimpanzees are not only susceptible to AIDS in the wild.  Over 100 chimpanzees were 
experimentally infected with HIV as part of early vaccine and pathogenesis studies (80, 162-179).   
Most early transmissions did not result in AIDS-like symptoms, leading researchers to conclude 
that HIV did not cause disease in chimpanzees (162-164, 168, 170, 180). However, later studies 
found that HIV-1 was capable of inducing AIDS in captive chimpanzees, with one animal showing 
rapid reduction in CD4+ T cell numbers to less than 26 cells/ul after only 14 weeks of infection 
(165).  Other chimpanzees showed slower courses of infection, one progressing after 2 years of 
infection, and another after 3 years of infection (165, 166). Serological analyses found CD4+ T 
cell loss and increased levels of multiple markers of immune activation in a number of HIV-1 
infected chimpanzees, suggesting that chimpanzee “progressors” are more common than 
previously thought (167, 181).   Chimpanzees have also been subjected to experimental infection 
with SIVcpz.  One study performed intravenous, intra-rectal, and intra-vaginal inoculation of eight 
animals; six of the eight became viremic after a single inoculation (80).  Long-term follow-up of 
these animals revealed that most displayed CD4+ T cell loss and evidence of thrombocytopenia, 
and those subjected to biopsies all showed evidence of lymphoid pathology (81).  One of these 
chimpanzees had a CD4+ T cell count of 115 cells/ul, and two additional animals showed counts 
fewer than 300 cell/ul.  Thus, a number of captive chimpanzees currently housed in the United 
States are chronically infected with HIV and SIVcpz, and these animals may be at risk of 
developing, or have already developed, AIDS.  Treatment of a captive chimpanzee with ART has 
not been reported.  However, ethical treatment of these animals may call for monitoring their 
disease status, and providing appropriate treatment if necessary.   
 
Conclusions 
Chimpanzee populations are facing population decline at an alarming rate, are 
increasingly threatened by infectious diseases, and will go extinct without a comprehensive 
approach to their conservation.  SIVcpz infection contributes to the disease burden of wild 
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populations, and thus strategies to decrease transmission of SIVcpz should be considered.  
Extensive work has been invested in small molecules, monoclonal antibodies, and vaccines to 
improve the outcome of HIV-1 infected individuals and decrease HIV-1 transmission.  Many 
chimpanzees were subjected to HIV-1 infection in order to develop these reagents and remain in 
captivity without regular monitoring for AIDS progression or efforts to control their viremia.  Given 
the close relation of HIV-1 and SIVcpz, these existing solutions could be easily translated to HIV 
or SIV infected chimpanzees in the wild or in captivity, providing benefit not only to chimpanzees, 
but also informing similar studies of humans.  
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CHAPTER 2 
 
 
DESTABILIZATION OF THE GUT MICROBIOME MARKS THE END-STAGE OF  
SIMIAN IMMUNODEFICIENCY VIRUS INFECTION IN WILD CHIMPANZEES 
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Lonsdorf EV, Bushman FD, Hahn BH. 2015. Destabilization of the gut microbiome marks the end-
stage of simian immunodeficiency virus infection in wild chimpanzees. American Journal of 
Primatology. Advance online publication. doi: 10.1002/ajp.22515 
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Section 2.1 – Abstract 
 
Enteric dysbiosis is a characteristic feature of progressive human immunodeficiency virus type 1 
(HIV-1) infection, but has not been observed in simian immunodeficiency virus (SIVmac) infected 
macaques, including in animals with end-stage disease. This has raised questions concerning the 
mechanisms underlying the HIV-1 associated enteropathy, with factors other than virus infection, 
such as lifestyle and antibiotic use, implicated as playing possible causal roles. Simian 
immunodeficiency virus of chimpanzees (SIVcpz) is also associated with increased mortality in 
wild-living communities, and like HIV-1 and SIVmac, can cause CD4+ T cell depletion and 
immunodeficiency in infected individuals. Given the central role of the intestinal microbiome in 
mammalian health, we asked whether gut microbial constituents could be identified that are 
indicative of SIVcpz status and/or disease progression. Here, we characterized the gut 
microbiome of SIVcpz infected and uninfected chimpanzees in Gombe National Park, Tanzania. 
Subjecting a small number of fecal samples (N=9) to metagenomic (shotgun) sequencing, we 
found bacteria of the family Prevotellaceae to be enriched in SIVcpz infected chimpanzees. 
However, 16S rRNA gene sequencing of a larger number of samples (N=123) failed to show 
significant differences in both the composition and diversity (alpha and beta) of gut bacterial 
communities between infected (N=24) and uninfected (N=26) chimpanzees. Similarly, 
chimpanzee stool-associated circular virus (Chi-SCV) and chimpanzee adenovirus (ChAdV) 
identified by metagenomic sequencing were neither more prevalent nor more abundant in SIVcpz 
infected individuals. However, fecal samples collected from SIVcpz infected chimpanzees within 
five months before their AIDS-related death exhibited significant compositional changes in their 
gut bacteriome. These data indicate that SIVcpz infected chimpanzees retain a stable gut 
microbiome throughout much of their natural infection course, with a significant destabilization of 
bacterial (but not viral) communities observed only in individuals with known immunodeficiency 
within the last several months before their death. 
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Section 2.2 – Introduction 
 
Simian immunodeficiency virus (SIVcpz) of chimpanzees (Pan troglodytes) is the progenitor of 
human immunodeficiency virus type 1 (HIV-1), the causative agent of the human AIDS pandemic 
[Sharp & Hahn 2011]. Although only the central (P. t. troglodytes) and eastern (P. t. 
schweinfurthii) subspecies are naturally infected, SIVcpz is widespread throughout their habitats 
in west-central and eastern Africa, with overall prevalence rates of 6% and 14%, respectively 
[Keele et al., 2006; Li et al., 2012; Rudicell et al., 2011; Santiago et al., 2003; Santiago et al., 
2002; Van Heuverswyn et al., 2007]. Conducting non-invasive natural history studies in Gombe 
National Park, Tanzania, we previously showed that SIVcpz infected chimpanzees have a 
significantly (10 to 16-fold) increased risk of death compared to uninfected chimpanzees, that 
infected females are less likely to give birth and have a much higher infant mortality rate than 
uninfected females, and that SIVcpz can cause CD4+ T lymphocyte depletion and 
histopathological findings consistent with end-stage AIDS [Keele et al., 2009; Terio et al., 2011].  
Moreover, one Gombe community, which exhibited the highest SIVcpz prevalence rate (40%-
50%), suffered a catastrophic population decline [Rudicell et al., 2010]. These data indicated that 
SIVcpz, like HIV-1, is capable of causing substantial morbidity and mortality in infected 
populations. In HIV-1 infected humans, high plasma viral loads, reduced CD4+ T cell counts, and 
general systemic immune activation are markers of disease progression [Brenchley et al., 2006; 
Hazenberg et al., 2003; Mellors et al., 1997]. These parameters cannot be measured in wild-living 
chimpanzees, since even in habituated communities, such as Gombe, it is neither ethical nor 
practical to repeatedly tranquilize chimpanzees for blood collection.  
Many chronic diseases are characterized by changes in the gut microbiota [Cho & Blaser 
2012; Claesson et al., 2012]. In HIV-1 infection, the gastrointestinal tract is a primary site of virus 
replication, with CD4+ T cell depletion, loss of intestinal immune barriers, translocation of 
microbial products, and chronic immune activation representing key features of progressive 
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disease [Brenchley & Douek 2007]. It is thus not surprising that chronic HIV-1 infection has been 
linked to changes of the gut bacteriome, although results have not always been uniform, most 
likely because of differences in the types of samples collected, the sequencing and analysis 
methods used, and the disease and treatment status of the sampled individuals [Dillon et al., 
2014; Dinh et al., 2015; Lozupone et al., 2013; McHardy et al., 2013; Mutlu et al., 2014; Vazquez-
Castellanos et al., 2015; Vujkovic-Cvijin et al., 2013]. For example, several groups reported an 
association between HIV-1 infection and decreased alpha diversity, which describes the variety of 
microbiota (richness) and their relative abundances (evenness) within a sample [McHardy et al., 
2013; Mutlu et al., 2014; Vazquez-Castellanos et al., 2015], while others reported an increase 
[Lozupone et al., 2013], or no effect at all [Dillon et al., 2014; Dinh et al., 2015; Vujkovic-Cvijin et 
al., 2013]. Similarly, different bacterial taxa have been reported to either be enriched or depleted 
(i.e., present at a significantly higher or lower frequency relative to the total microbial content) in 
the gut of HIV-1 infected patients, although several groups found an increase in the relative 
abundance of Prevotella [Dillon et al., 2014; Lozupone et al., 2013; Mutlu et al., 2014; Vazquez-
Castellanos et al., 2015] and Proteobacteria [Dillon et al., 2014; Dinh et al., 2015; Vujkovic-Cvijin 
et al., 2013], and a decrease in the relative abundance of Bacteroides [Dillon et al., 2014; 
Lozupone et al., 2013; Mutlu et al., 2014; Vazquez-Castellanos et al., 2015; Vujkovic-Cvijin et al., 
2013] and Ruminococcus [Dillon et al., 2014; McHardy et al., 2013; Mutlu et al., 2014; Vazquez-
Castellanos et al., 2015]. Despite these differences, there is general agreement that 
compositional changes in gut microbial communities between individuals (beta diversity) are 
associated with progressive HIV-1 infection [Lozupone et al., 2014; Nwosu et al., 2014].   
SIVmac infection of macaques recapitulates many of the clinical sequelae of HIV-1 
infection, including the characteristic gut pathology, and represents an important animal model to 
study HIV-1 pathogenesis [Estes et al., 2010; Li et al., 2005]. It thus came as a surprise when 
macaques with progressive SIVmac infection were found to have a highly stable gut bacteriome 
[Handley et al., 2012; Klase et al., 2015; McKenna et al., 2008], although an expansion of their 
enteric virome was observed [Handley et al., 2012]. These findings raised questions concerning 
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the mechanisms underlying the changes in intestinal microbiota associated with HIV-1 infection, 
with factors such as geographic location [Yatsunenko et al., 2012], antibiotic use [Jernberg et al., 
2007] and antiretroviral treatment [Klase et al., 2015] implicated as playing potential causal roles. 
Wild-living chimpanzees are not exposed to drug therapy and maintain relatively stable 
geographic locations, and thus may represent a more relevant model to examine the impact of a 
pathogenic primate lentivirus infection on gut microbial diversity.   
Previous studies of wild chimpanzees showed that their gut microbiota are very similar to 
those of humans, both with respect to the types of bacterial constituents present [Moeller et al., 
2012] and their modulation by environmental factors such as diet and geographic location 
[Degnan et al., 2012; Moeller et al., 2013a].  We thus reasoned that analyses of the microbiota in 
chimpanzee fecal samples might yield insight into the natural history and pathogenesis of SIVcpz 
infection. Studying a small number (N=6) of Gombe chimpanzees before and after they became 
infected with SIVcpz, we previously found greater fluctuations in bacterial composition as well as 
a higher abundance of disease-associated bacterial genera in fecal samples collected after 
SIVcpz acquisition [Moeller et al., 2013b]. However, an analysis of the gut bacteriome of SIVgor 
infected and uninfected western gorillas (Gorilla gorilla) failed to identify such differences [Moeller 
et al., 2015b], despite the fact that SIVgor originated from the cross-species transfer of SIVcpz 
and may share some of the same pathogenic properties [Takehisa et al., 2009; Van Heuverswyn 
et al., 2007]. Here we used both metagenomic and bacterial 16S rRNA gene sequencing to study 
a much larger number of SIVcpz infected and uninfected chimpanzees in Gombe National Park, 
Tanzania. Our results indicate a surprising robustness of the chimpanzee gut microbiome 
throughout much of the duration of the SIVcpz infection course, with significant compositional 
changes of bacterial, but not viral, constituents observed only in individuals with known (or 
suspected) immunodeficiency within the last several months before their death.  
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Section 2.3 – Methods 
 
Chimpanzee fecal samples  
Fecal samples were collected from wild-living chimpanzees in Gombe National Park, 
Tanzania, including members of habituated (Mitumba and Kasekela) and non-habituated 
(Kalande) communities (for a map of Gombe National Park and the ranges of its three 
communities, see [Lonsdorf et al., 2015a]). The Kasekela and Mitumba chimpanzees have been 
under direct observation since the 1960s and 1980s, respectively [Pusey et al., 2007; van Lawick-
Goodall 1968], with prospective fecal sampling and SIVcpz diagnostics beginning in 1999 
[Santiago et al., 2002]. In Mitumba and Kasekela, stool samples were collected from individually 
known chimpanzees under direct observation. In Kalande, samples were collected 
opportunistically. For individual identification, all samples were subjected to mitochondrial, sex, 
and microsatellite analysis as described elsewhere [Keele et al., 2009; Rudicell et al., 2010]. 
Fecal material (20-50 g) was placed in conical tubes containing 20 ml of RNAlater (Ambion), a 
high salt solution that preserves fecal nucleic acids and allows storage and transport at room 
temperature. The SIVcpz infection status was determined by screening fecal samples for the 
presence of virus-specific antibodies by Western blot analysis and/or virion RNA by nested 
reverse transcriptase polymerase chain reaction (RT-PCR) analysis [Santiago et al., 2003]. AIDS-
like immunopathology was detected by necropsy in recovered bodies of a subset of SIVcpz 
infected individuals as previously described [Terio et al., 2011]. All fieldwork was approved by the 
Tanzania Commission for Science and Technology, the Tanzania Wildlife Research Institute, and 
the Tanzania National Parks, and adhered to the American Society of Primatologists’ Principles 
for Ethical Treatment of Nonhuman Primates. 
Metagenomic (shotgun) sequencing and analysis   
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The fecal samples selected for metagenomic sequencing are listed in Table I. Nucleic 
acids were extracted from fecal samples selected for metagenomic sequencing as described 
[Minot et al., 2013], with modifications to accommodate RNAlater preservation and ensure 
maximal virus nucleic acid recovery. RNAlater preserved fecal material (1 ml) was vortexed (1 
min) and then added to 20 ml phosphate buffered saline (PBS) solution, containing 1% bovine 
serum albumin (BSA), which increased mammalian virus nucleic acid recovery (not shown). 
Samples were again vortexed at maximum speed (1 min) and then centrifuged at 1,800 g (5 min) 
to pellet debris. The supernatant was passed through a 0.45 µm filter (Millipore) to remove 
bacterial cells and subsequently concentrated by passing through a 100 kDa ultracentrifugal unit 
(Millipore). Following treatment with 10U RQ1 DNase (Promega), fecal nucleic acids were 
extracted using the AllPrep DNA/RNA Mini kit (Qiagen), and fecal DNA was quantified using a 
Qubit 2.0 fluorometer (Invitrogen). Filtering and DNase treatment served to remove bacterial 
DNA, while at the same time enriching for particle associated (viral) nucleic acids. Both 
procedures were previously shown not to alter the composition of the fecal bacteriome [Handley 
et al., 2012]. Fecal DNA was prepared for metagenomic sequencing using the Nextera XT DNA 
Library Prep Kit (Illumina). Libraries were quality controlled using the Agilent 2200 TapeStation 
and sequenced on an Illumina MiSeq, using a 500-cycle MiSeq Reagent Kit v2 according to the 
manufacturer’s instructions. Paired-end sequences over 50 base pairs in length were assigned to 
taxa using a nucleotide BLAST search in combination with a customized nucleotide sequence 
database that included all RefSeq bacterial and viral reference genomes 
(http://www.ncbi.nlm.nih.gov/refseq/) as well as all GenBank virus sequence entries. Reads that 
mapped to mammalian viruses were subsequently blasted against the complete NCBI 
nonredundant (nr) database (http://blast.ncbi.nlm.nih.gov/) using BLASTx, and those that mapped 
to non-viral references were removed from the analysis.  Tables of bacterial and viral read counts 
were generated and used for abundance analysis. Bacterial phylogeny was determined using the 
MEGAN version 4.70.4 software [Huson & Mitra 2012].  
Bacterial 16S rRNA gene sequencing and analysis   
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The fecal samples selected for bacterial 16S rRNA gene sequencing are listed in Table II. 
DNA was extracted from 0.5 ml of RNAlater preserved fecal material using the QIAamp DNA 
Stool Mini Kit (Qiagen) and the QIAcube system. 16S rRNA gene amplification was performed as 
described [Caporaso et al., 2011; Song et al., 2013], using 100 ng of fecal DNA, the Accuprime 
Taq DNA Polymerase System (Invitrogen), and V1V2 region directed primers containing Illumina 
adapters, barcode, and linker regions [Song et al., 2013]. Each fecal sample was amplified on 
four independent occasions, with the products pooled and purified using AMPure XP beads 
(Beckman Coulter) before sequencing on the Illumina MiSeq.  16S sequence data were analyzed 
using QIIME v1.7.0 [Caporaso et al., 2010] and default QIIME parameters unless specified. 
Sequences were separated by barcode, quality filtered, and operational taxonomic units (OTUs) 
formed using a cutoff of 97% identity and assigned using the Greengenes database.  Samples 
with less than 50,000 sequences per sample were removed from the analysis. After taxonomic 
assignment, within-sample (alpha) diversity was calculated using observed species, Chao1 [Chao 
1984], Shannon Index [Shannon 2001] and Simpson’s Diversity measures [Simpson 1949].  
Chao1 is a nonparametric richness calculator, and Shannon and Simpson indices measure 
diversity both in terms of richness and evenness. Between-sample (beta) diversity was calculated 
using Bray-Curtis dissimilarity [Bray & Curtis 1957], which measures compositional dissimilarity, 
as well as Euclidean and weighted UniFrac distances [Lozupone & Knight 2005], which measure 
the compositional distance between microbial communities. Euclidean and weighted UniFrac 
distances were also used for principal coordinates analysis.   
Detection of chimpanzee stool-associated circular virus and chimpanzee adenovirus in 
fecal samples 
 The presence of chimpanzee stool-associated circular virus (Chi-SCV) and chimpanzee 
(simian) adenovirus (ChAdV) in fecal samples was determined by nested PCR.  Primers used to 
amplify a 214 bp fragment of the Chi-SCV replicase gene included: F1 5’- GGC TTG GTG TTT 
GTT AGC ACG ATC -3’ and R1 5’- GAG ATG GAA CCA AGA AGG GGC -3’ for the first round, 
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and F2 5’- CKA TAG CCG TGT ATA GCT CGG -3’ and R2 5’- GGC AAC ATG GGC AAA TCG 
TGG C -3’ for the second round of PCR. First-round PCR amplifications included 35 cycles of 
denaturation (94°C, 15 sec), annealing (55°C, 30 sec), and elongation (68°C, 1 min) using 
Platinum Taq DNA Polymerase High Fidelity (Invitrogen).  One µl of the first-round product was 
used for the second round PCR, including 45 cycles of denaturation (94°C, 15 sec), annealing 
(58°C, 30 sec), and elongation (68°C, 1 min). Primers used to amplify a 379 bp fragment of the 
ChAdV DNA polymerase gene included: F1 5’- TGA TGC GYT TCT TAC CTY KGG TYT CCA 
TGA G -3’ and R1 5’- GAC AGC GAT SCG GAA GAS AGT G -3’ for the first round, and F2 5’- 
GTG ACR AAG AGG CTG TCC GTG TCY CCG TA -3’ and R2 5’- TCA CGT GGC MTA CAC 
YTA CAA GCC AAT CAC -3’ for the second round of PCR. Cycling conditions were the same as 
above. All amplicons were sequenced without interim cloning.  
Quantitation of chimpanzee stool-associated circular virus and chimpanzee adenovirus  
 Chi-SCV and ChAdV viral loads in fecal samples (Table II) were determined by real time 
PCR, using cloned fragments of the Chi-SCV replicase and the ChAdV polymerase as standards, 
respectively. Fecal DNA (5 µl) was added to TaqMan Fast Advanced master mix (Applied 
Biosystems) and amplified using virus specific forward (Chi-SCV: 5’- CGG AAT GTC GAT GAC 
TAT GAG G -3’; ChAdV: 5’- CKC GGT CCT CCT CGT AGA G -3’) and reverse (Chi-SCV: 5’- 
CTA CAT ACC GCC GTA CAT GAC G -3’; ChAdV: 5’- TGG ACA ACG ACC GCT ACC C -3’) 
primers (750 nM) as well as a virus-specific (Chi-SCV: 5’- FAM-CGC GGT CTT GTA GGA CTA 
GGC TCG CTA C-BHQ1a -3’; ChAdV: 5’- FAM-CCG GGT CCA GGC CAG CAC GAA GGA 
AGG-BHQ1a -3’) probe (250 nM). Each sample was tested in triplicate. PCR cycling conditions 
were chosen according to manufacturer’s instructions on a 7900HT Fast Real-Time PCR System. 
Sequence Detection Systems version 2.3 software (Applied Biosystems) was used to quantify 
viral copy numbers, which were normalized based on the total amount of DNA in the respective 
fecal sample. 
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Statistical analysis  
 The abundances of bacterial and viral taxa in fecal samples from SIVcpz infected and 
uninfected chimpanzees were compared using the Mann-Whitney test and Prism version 5.0d 
software (GraphPad). Bonferroni correction was applied when multiple tests were simultaneously 
performed using Prism or QIIME software.  Statistical analysis of bacterial 16S alpha and beta 
diversity measures was performed using the default parameters of the QIIME v1.7.0 software. 
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Section 2.4 – Tables 
             
aKK, Kasekela; MT, Mitumba; KL, Kalande. 
bpos, positive; neg, negative 
 
Table 1. Metagenomic sequencing of microbial communities in chimpanzee fecal samples. 
 
Sample 
 
 
Chimpanzee 
 
Sex Communitya Sample date 
SIVcpz  
statusb 
Minimum 
number of 
years infected 
GM1586 Ch-64 F KL 25-Jun-09 pos 13 
GM2984 Ch-48 M MT 31-May-12 pos 13 
GM3018 Ch-22 F KK 28-Jun-12 pos 12 
GM2423 Ch-80 F KK 11-Apr-11 pos 10 
GM3149 Ch-52 M KK 7-Sep-12 pos 12 
GM2522 Ch-88 F KL 11-Jun-11 neg - 
GM2856 Ch-59 M MT 6-Mar-12 neg - 
GM3028 Ch-09 F KK 3-Jul-12 neg - 
GM2954 Ch-15 F KK 13-May-12 neg - 
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Table 2. 16S rRNA gene sequencing of bacterial communities in chimpanzee fecal 
samples 
Samplea  Chimpanzeeb Sexc Communityd Sample date SIVcpz Statuse 
Observable signs of ill 
health near the time of 
samplingf 
GM2541 39 F MT 18-Jun-11 pos None 
GM2935 39 F MT 21-Apr-12 pos None 
GM3193 39 F MT 24-Sep-12 pos None 
GM1425 106 F KL 5-Nov-07 pos n/a 
GM1542 106 F KL 19-Jan-09 pos n/a 
GM2321 106 F KK 11-Jan-11 pos n/a 
GM889 107 F KL 13-Aug-05 pos n/a (presumed dead) 
GM3256 137 F KL 9-Oct-12 pos n/a 
GM3483 137 F KK 15-Apr-13 pos n/a 
GM715 99 F KK 11-May-05 pos None 
GM783 99 F KK 12-Jul-05 pos None 
GM958* 99 F KK 15-Mar-06 pos None (DOD 30-Nov-06) 
GM3401 119 M KK 12-Jan-13 pos None 
GM3427 119 M KK 16-Mar-13 pos n/a 
GM3521* 119 M KK 8-Jun-13 pos None (DLS 15-Aug-2013) 
GM3186 4 M KK 20-Sep-12 pos None 
GM3429 4 M KK 21-Mar-13 pos None 
GM3551 4 M KK 9-Jul-13 pos n/a 
GM329 6 M KK 20-Aug-03 pos n/a 
GM414 6 M KK 16-Jul-04 pos None 
GM981 6 M KK 5-Nov-05 pos None (DLS 23-Jan-07) 
GM944 89 F KL 26-Apr-06 pos n/a 
GM1277 89 F KL 6-Aug-07 pos n/a 
GM3496 71 F KK 25-Apr-13 pos None 
GM2556 133 M KK 3-Jul-11 pos None 
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GM3188 133 M KK 21-Sep-12 pos None 
GM3492 133 M KK 25-Apr-13 pos None 
GM1163 21 F KK 11-Feb-07 pos Diarrhea 
GM1471 21 F KK 23-Oct-08 pos None 
GM1602* 21 F KK 12-Aug-09 pos None (DOD 5-Jan-2010) 
GM1598 103 F KK 25-Aug-09 pos None 
GM2437 103 F KK 18-Apr-11 pos None 
GM2736* 103 F KK 7-Oct-11 pos n/a (DLS 7-Dec-11) 
GM3251 22 F KK 24-Oct-12 pos n/a 
GM3505 22 F KK 20-Apr-13 pos None 
GM3595 22 F KK 11-Aug-13 pos n/a 
GM3392 100 M KL 25-Dec-12 pos n/a 
GM3477 100 M KL 15-Apr-13 pos n/a 
GM3543 100 M KL 2-Jul-13 pos n/a 
GM1376 64 F KL 9-Jun-08 pos n/a 
GM1532 64 F KL 17-Sep-08 pos n/a 
GM1618 64 F KL 24-Aug-09 pos n/a (presumed dead) 
GM3066 86 F KL 19-Jul-12 pos n/a 
GM3328 86 F KL 29-Nov-12 pos n/a 
GM3590 86 F KL 29-Jul-13 pos n/a 
GM2678 48 M MT 5-Sep-11 pos None 
GM3217 48 M MT 10-Oct-12 pos None 
GM3453* 48 M MT 7-Jun-13 pos None (DLS 1-Nov-2013)  
GM84 30 F KK 13-Dec-01 pos n/a 
GM145 30 F KK 2-Jul-02 pos n/a 
GM337* 30 F KK 7-Aug-03 pos n/a (DLS 8-Dec-03) 
GM1030 33 F KK 23-Feb-06 pos None 
GM1320* 33 F KK 9-Aug-07 pos None (DLS 2-Mar-08) 
GM3075 80 F KK 30-Jul-12 pos Weight loss 
GM3326 80 F KK 29-Nov-12 pos n/a 
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GM3530 80 F KL 11-Jun-13 pos n/a 
GM350 45 M MT 21-Sep-03 pos n/a 
GM704* 45 M MT 27-Nov-04 pos Weight loss, diarrhea (DOD 22-Dec-04) 
GM1037 36 F KK 15-Mar-06 pos None 
GM1325* 36 F KK 28-Jun-07 pos None (DOD 7-Nov-07) 
GM2675 52 M KK 10-Sep-11 pos None 
GM3167 52 M KK 14-Sep-12 pos Diarrhea 
GM3333 52 M KK 5-Dec-12 pos n/a 
GM1718 7 M KK 7-Sep-09 neg None 
GM2469 7 M KK 11-May-11 neg None 
GM2673 7 M KK 7-Sep-11 neg n/a 
GM1389 78 F KK 22-Jun-08 neg Diarrhea 
GM1624 78 F KK 5-Aug-09 neg None 
GM1348 109 F KL 12-Mar-08 neg n/a 
GM1462 109 F KL 14-Oct-08 neg n/a 
GM1705 109 F KL 9-Jul-09 neg n/a 
GM3096 97 F KK 12-Aug-12 neg None 
GM3343 97 F KK 12-Dec-12 neg n/a 
GM2619 2 F KK 4-Aug-11 neg None 
GM3508 2 F KK 14-Apr-13 neg None 
GM295 49 F MT 18-Oct-03 neg n/a 
GM622 49 F MT 12-Dec-04 neg None (DOD 12-Jun-2010) 
GM2861 68 M MT 7-Mar-12 neg None 
GM3027 131 M KK 3-Jul-12 neg Respiratory illness 
GM3351 131 M KK 22-Dec-12 neg None 
GM3457 131 M KK 16-May-13 neg None 
GM195 13 M KK 14-Jun-02 neg n/a 
GM1238 13 M KK 28-Jun-07 neg None 
GM3146 51 M KK 8-Sep-12 neg n/a 
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GM3421 51 M KK 26-Feb-13 neg n/a 
GM3550 51 M KK 9-Jul-13 neg n/a 
GM719 14 M KK 4-May-05 neg None 
GM858 14 M KK 29-Oct-05 neg n/a 
GM975 14 M KK 12-Mar-06 neg None 
GM3236 15 F KK 21-Oct-12 neg None 
GM3548 15 F KK 6-Jul-13 neg None 
GM1104 77 M KK 1-Jul-06 neg None 
GM1241 77 M KK 25-Jun-07 neg None 
GM3355 53 F KK 2-Jan-13 neg None 
GM3475 53 F KK 7-May-13 neg None 
GM3124 17 F KK 24-Aug-12 neg None 
GM3402 17 F KK 15-Jan-13 neg n/a 
GM3511 17 F KK 7-Apr-13 neg None 
GM87 1 F KK 31-Dec-01 neg n/a 
GM196 1 F KK 28-Apr-02 neg n/a 
GM327 1 F KK 6-Aug-03 neg n/a 
GM1128 93 F KL 6-Jun-06 neg n/a 
GM1295 93 F KL 12-Aug-07 neg n/a 
GM3065 110 M KL 23-Jul-12 neg n/a 
GM3311 110 M KL 20-Nov-12 neg n/a 
GM3591 110 M KL 29-Jul-13 neg n/a 
GM881 108 F KL 25-Jul-05 neg n/a 
GM1000 108 F KK 16-Mar-06 neg n/a 
GM2632 98 F MT 14-Aug-11 neg None 
GM3162 98 F MT 11-Sep-12 neg None 
GM3532 98 F MT 25-Jun-13 neg None 
GM3386 88 F KL 20-Dec-12 neg n/a 
GM3572 88 F KL 16-Jul-13 neg n/a 
GM3620 88 F KL 15-May-13 neg n/a 
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GM1019 54 M KK 25-Jan-06 neg Respiratory illness 
GM333 25 F KK 5-Aug-03 neg n/a 
GM445 25 F KK 30-Jun-04 neg None 
GM1010 25 F KK 19-Jan-06 neg None 
GM3292 26 F KK 10-Nov-12 neg None 
GM3503 26 F KK 11-Apr-13 neg None 
GM1151 27 M KK 30-Jan-07 neg None 
GM2363 27 M KK 6-Mar-11 neg n/a 
GM168 36 F KK 8-Jun-02 neg n/a 
 
aAsterisks highlight samples that were collected from nine SIVcpz infected chimpanzees within 8 
months of their death.  
bChimpanzees Ch-21 and Ch-36 died of AIDS-related causes as determined by necropsy; Ch-45 
died of conspecific aggression and Ch-99 died of conditions resulting from spinal cord injury 
[Keele et al., 2009]; the cause of death of the other chimpanzees was not determined because 
their bodies were not recovered. 
cF, female; M, male. 
dKK, Kasekela; MT, Mitumba; KL, Kalande. 
epos, positive; neg, negative. 
fSigns of illness observed within one month before or after the date of sample collection [Lonsdorf 
et al., 2015a]; n/a, data not available. DOD, date of death; DLS, date last seen. 
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Section 2.5 – Results 
 
Study design  
To test for associations between gut microbial communities and SIVcpz infection and/or 
disease progression, we used both metagenomic (shotgun) and targeted (bacterial) 16 rRNA 
gene sequencing approaches. Metagenomic sequencing is performed on randomly fragmented 
DNA and thus provides genetic information for all organisms present in a sample, including 
bacteria and viruses. However, metagenomic sequencing requires large quantities of fecal 
material and is computationally intensive.  For this reason, we analyzed only a small number of 
samples (N=9, Table I) with the goal of identifying potential microbial indicator species, which 
could then be studied in a larger number of samples from more individuals using real time PCR.  
As a second approach, we performed bacterial 16S rRNA gene sequencing, which requires only 
small amounts of starting material and thus allowed us to use the full range of samples collected 
from the Gombe chimpanzees over the past 15 years. We also took advantage of the well-
validated analysis pipeline that exists for 16S rRNA sequence data [Caporaso et al., 2010], which 
facilitated a direct comparison with results previously obtained for HIV-1 infected humans [Dillon 
et al., 2014; Dinh et al., 2015; Lozupone et al., 2013; McHardy et al., 2013; Mutlu et al., 2014; 
Vazquez-Castellanos et al., 2015; Vujkovic-Cvijin et al., 2013] and SIVcpz infected chimpanzees 
[Moeller et al., 2013b]. For 16S rRNA gene sequencing, we included up to three fecal samples 
per individual to control for temporal fluctuations in gut microbial diversity (Table II). The 
combination of these approaches was intended to ensure unbiased results, while taking full 
advantage of the contextual knowledge of the sampled chimpanzee hosts. 
 
Metagenomic sequencing fails to identify significant compositional differences between 
the gut bacteriome of SIVcpz infected and uninfected chimpanzees.  
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 Metagenomic sequencing was performed on fecal samples from four uninfected and five 
infected Gombe chimpanzees (Table I). To detect both viral (particle-associated) and bacterial 
nucleic acids, each fecal sample was filtered and DNase treated prior to analysis. Although these 
procedures resulted in an overall reduction of bacterial DNA, a previous study demonstrated that 
this decrease was proportional and did not skew the composition of bacterial constituents in the 
sample [Handley et al., 2012]. The nine fecal samples yielded 15,900,990 high quality paired-end 
reads, with an average of 1,766,777 reads per sample. Sequences were assigned to bacterial 
taxa by performing a BLAST search of a database that included all bacterial reference genomes. 
Consistent with previous results [Degnan et al., 2012], we found that the bacterial phylum 
Firmicutes comprised the largest proportion of the fecal bacteriome in all nine chimpanzees, with 
Bacteroidetes, Actinobacteria, Proteobacteria, and Spirochaetes constituting the majority of the 
remaining bacterial phyla (Fig. 1a). Interestingly, fecal samples from the five SIVcpz infected 
chimpanzees were enriched for members of the family Prevotellaceae (P=0.04), although this 
result was not statistically significant when corrected for multiple tests (Fig. 1b). Nonetheless, this 
trend was consistent with results from previous studies that had shown an increased abundance 
of members of the genus Prevotella (of the Prevotellaceae family) in the intestinal microbiome of 
HIV-1 infected individuals [Dillon et al., 2014; Lozupone et al., 2013; Mutlu et al., 2014; Vazquez-
Castellanos et al., 2015]. None of the other bacterial taxa differed in their relative abundance 
between SIVcpz infected and uninfected chimpanzees (Fig. 1b).  
 
Chronic SIVcpz infection is not characterized by a distinct gut bacteriome.  
Since previous 16S rRNA sequencing was performed on samples from only six Gombe 
chimpanzees [Moeller et al., 2013b], we designed a follow-up study that included a larger number 
of samples and individuals. Targeting the V1V2 region of the 16S rRNA gene, we characterized 
the composition and diversity of gut bacterial communities in 123 fecal samples from 24 SIVcpz 
infected and 26 uninfected chimpanzees (Table II). Whenever possible, we included two or three  
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Fig. 1. Composition of the fecal bacteriome in nine Gombe chimpanzees as determined by 
metagenomic sequencing. (a) Taxonomy bar chart indicating the relative abundance of major 
bacterial phyla in fecal samples from SIVcpz infected (Ch-64, Ch-48, Ch-22, Ch-52, Ch-80) and 
uninfected (Ch-88, Ch-59, Ch-9, Ch-15) chimpanzees (see Table I for more information).  Only 
phyla comprising more than 1% of the fecal bacteriome are included and further classified into 
major families as indicated by different colors (minor Bacterioidetes and Firmicutes families are 
combined into “Other” categories). A grey box (“Other”) combines bacteria that could not be 
classified at the phylum level. (b) Relative abundance of major bacterial taxa in fecal samples 
from SIVcpz infected (closed circles) and uninfected (open circles) chimpanzees. Values are 
shown as a fraction of the total bacteria detected within each individual. Color-coding is as in (a).  
Black bars indicate the mean and colored bars the standard error of the mean (SEM). A statistical 
difference (***) was observed when the relative abundance of the bacterial family Prevotellaceae 
was compared between infected and uninfected chimpanzees using the Mann-Whitney U-test 
(P=0.04); however, this value did not reach statistical significance (P<0.05) after Bonferroni 
correction for multiple tests.  
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samples per individual to control for intra-individual diversity. We also matched each virus positive 
fecal sample with a virus negative sample from the same community, gender, and collection 
month to control for environmental, social, and dietary differences [Degnan et al., 2012]. For 
SIVcpz infected chimpanzees, the last available sample was included to cover as much of the 
natural disease course as possible. Very few chimpanzees had signs of ill health at or near the 
time of sampling (Table II) as determined by observational health surveys [Lonsdorf et al., 2015a; 
Lonsdorf et al., 2015b; Wolf et al., 2015a; Wolf et al., 2015b]. However, 9 SIVcpz infected 
chimpanzees, including Malaika (Ch-21), Skosha (Ch-30), Titania (Ch-33), Yolanda (Ch-36), 
Vincent (Ch-45), Rudi (Ch-48), Echo (Ch-99), Mambo (Ch-103), and Eriki (Ch-119) died within 
eight months of the last sample collection. Previous necropsy studies showed that both Yolanda 
and Malaika exhibited histopathological findings consistent with full-blown AIDS, while Vincent 
and Echo died of conspecific aggression and spinal cord injury, respectively [Keele et al., 2009; 
Terio et al., 2011]. The cause of death for the other five infected chimpanzees as well as one 
uninfected ape (Ch-49), who died 6 years after the last sample collection, could not be 
determined because their bodies were not recovered, although Rudi (Ch-48) is suspected to have 
also died of conspecific aggression (Table II). 
Similar to the results obtained from metagenomic sequencing (Fig. 2a), 16S rRNA gene 
sequencing revealed a predominance of Bacteroidetes, Firmicutes, Proteobacteria and 
Spirochaetes in fecal samples from both SIVcpz infected and uninfected chimpanzees (Fig. 2). 
However, there also was a high degree of compositional variability when longitudinal samples 
from the same individual were compared. For example, bacteria of the family Spirochaetacea 
comprised 27% of the fecal bacteriome when chimpanzee Ch-80 was sampled in July 2012 
(GM3075), but represented only 0.4% and 3% of bacterial communities when the same 
chimpanzee was sampled again four (GM3326) and 10 (GM3530) months later, respectively. 
When analyzed in a phylogenetic tree constructed from weighted UniFrac distances, the three 
samples from chimpanzee Ch-80 did not cluster together (not shown), and this was also true for  
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Fig. 2. Composition of the fecal bacteriome in 50 Gombe chimpanzees as determined by 
16S rRNA gene sequencing. The relative abundance of major bacterial families (color coded) 
comprising more than 1% of the fecal bacteriome in at least half of the fecal samples (GM 
numbers) is shown for SIVcpz infected (top panel) and uninfected (bottom panel) chimpanzees 
(Ch numbers). Operational taxonomic units (OTUs) are labeled with the highest taxonomic rank 
as determined by the QIIME software, with those that could not be further classified identified. 
Brackets denote fecal samples from the same individual (see Table II for more information). Minor 
bacterial taxa that comprised less than 1% of the microbiome in more than half of the fecal 
samples are grouped into “Other Bacteria.” 
 
longitudinal samples from other chimpanzees. In general, weighted UniFrac distances were not 
significantly different between longitudinal samples from the same individual and temporally 
matched samples from different individuals (not shown). Thus, the fecal microbiome of Gombe 
chimpanzees sampled at different times exhibited as much compositional diversity as did the 
microbiomes of different chimpanzees sampled at the same time. 
To investigate whether Prevotellaceae enrichment was a common phenotype of SIVcpz 
infection, we compared the relative abundance of this family in samples from infected and 
uninfected individuals. Although the mean Prevotellaceae abundance was higher in SIVcpz 
infected chimpanzees, the difference was not statistically significant (P=0.79). Moreover, a broad 
search failed to identify bacterial families that were specifically associated with SIVcpz infection 
status. Thus, there was no significant enrichment or depletion of any bacterial phylum associated 
with chronic SIVcpz infection.   
In addition to changes in bacterial abundances, changes in microbiome alpha and beta 
diversity have been reported to be associated with HIV-1 infection [Dillon et al., 2014; Dinh et al., 
2015; Lozupone et al., 2013; McHardy et al., 2013; Mutlu et al., 2014; Vazquez-Castellanos et al., 
2015; Vujkovic-Cvijin et al., 2013]. Alpha diversity is an indicator of both the number (richness) 
and distribution (evenness) of bacterial taxa within a single sample [Morgan & Huttenhower 
2012]. Using Shannon or Simpson indices to summarize alpha diversity, we found no difference 
between samples of SIVcpz infected and uninfected chimpanzees (not shown). Similarly, there 
was no difference in richness (observed species, P=0.17) (Fig. 3a) or population size inferred  
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Fig. 3. SIVcpz infected and uninfected chimpanzees are not characterized by a distinct 
fecal bacteriome. (a) Absence of differences in alpha diversity. The number of observed species 
of rarefied (sampled at an even depth) OTUs was calculated from 16S rRNA sequencing data for 
fecal samples from SIVcpz infected (red) and uninfected (black) chimpanzees and plotted using 
QIIME software.  Error bars indicate standard deviation. (b) Absence of differences in beta 
diversity. Bray-Curtis dissimilarity distances were calculated using the QIIME software for all 
samples from SIVcpz infected (red) and uninfected chimpanzees (grey), as well as between 
samples from SIVcpz infected from uninfected individuals (striped). Box plots show the median, 
upper, and lower quartile ranges for each comparison (indicated by brackets), with whiskers 
indicating minimum (top) and maximum (bottom) dissimilarities. Statistical analyses were 
performed using the Mann-Whitney U-test and corrected for multiple comparisons. NS, not 
significant. (c) Principal coordinates analysis plot (PCoA) constructed from weighted UniFrac 
distances indicating a lack of primary clustering of bacteriomes from SIVcpz infected (red) and 
uninfected (black) chimpanzees. (d) Identical PCoA plot as shown in (c), with fecal bacteriomes 
from the same chimpanzee identified by connecting colored solid (SIVcpz infected) or broken 
(uninfected) lines. 
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using the Chao1 estimator (not shown). In addition, there was no significant difference in beta 
diversity, which measures the extent of similarity between microbiota from different samples 
[Morgan & Huttenhower 2012]. Comparing Bray-Curtis dissimilarity values (Fig. 3b), we found no 
significant differences between infected and uninfected groups (P=0.17 and P=0.07 for SIVcpz 
infected and uninfected groups, respectively). This was also apparent in a principal coordinates 
analysis (PCoA) of weighted UniFrac distances, which revealed no specific grouping of samples 
from SIVcpz infected versus uninfected chimpanzees (Fig. 3c). Rather, the intra-individual 
diversity dominated the beta diversity, with consecutive samples from the same individual 
spanning the entire PCoA plot (Fig. 3d). Thus, in contrast to HIV-1 infected humans, the fecal 
microbiota of SIVcpz infected and uninfected chimpanzees were indistinguishable by these 
measures. 
 
Destabilization of the fecal bacteriome marks the end-stage of SIVcpz infection. 
In HIV-1 infected humans, the destabilization of the intestinal microbiome is believed to 
be caused by a progressive loss of gut immune function [Lozupone et al., 2014], with a normal 
gut microbiome observed early [Lozupone et al., 2013], but not late [Vujkovic-Cvijin et al., 2013] 
in infection. Since most of the fecal material subjected to 16S rRNA sequencing was derived from 
seemingly healthy chimpanzees (Table II), we asked whether samples obtained closer to the time 
of death might exhibit signs of gut microbiome destabilization. To test this, we calculated all 
pairwise weighted UniFrac distances between fecal samples from Yolanda (GM1325) and 
Malaika (GM1602) collected five months before their AIDS-related deaths and fecal samples from 
all other (infected and uninfected) chimpanzees (N=98) collected more than 8 months before their 
death (Table II). This analysis revealed a significant compositional change in each of the two 
immunodeficient chimpanzees relative to the controls, regardless whether samples were 
analyzed individually (not shown) or in combination (Fig. 4a).  However, this same compositional  
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Fig. 4.  Pronounced compositional shifts in the gut bacterial communities of SIVcpz 
infected chimpanzees shortly before their AIDS-related death. (a) Pairwise weighted UniFrac 
distances of the last fecal samples from Yolanda and Malaika (test group), who died of (necropsy 
confirmed) AIDS-like disease within five months of sampling, and fecal samples (N=98) from all 
chimpanzees who were sampled more than 8 months before their death (control group). Box 
plots show the median, upper, and lower quartile ranges with whiskers indicating 95% confidence 
intervals (CI). Statistical analyses were performed using the Mann-Whitney U-test. Red indicates 
significantly increased beta diversity.  (b) Analysis as in (a), but comparing pairwise weighted 
UniFrac distances from earlier fecal samples (collected more than 8 months before death) from 
Yolanda and Malaika (test group) to the same controls. (c) Analysis as in (a), but comparing 
pairwise weighted UniFrac distances from the last two fecal samples of two SIVcpz infected 
chimpanzees (Vincent and Echo) who died of trauma-related causes (test group) to the same 
controls. NS, not significant. (d) Analysis as in (c), but comparing pairwise weighted UniFrac 
distances from earlier fecal samples (collected more than 8 months before death) from Vincent 
and Echo (test group) to the same controls. See text and Table II for more details.
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shift was not observed when earlier samples from Yolanda (GM1037) and Malaika (GM1163, 
GM1471) were compared to the same controls (Fig. 4b). Moreover, fecal samples from Vincent 
and Echo, both of whom died of trauma-related deaths [Terio et al., 2011], did not exhibit 
destabilization of their gut community composition, regardless of whether they were collected 
before death (GM704, GM958) (Fig. 4c) (P=0.62), or much earlier during their infection (GM715, 
GM783, GM350) (Figs. 4d) (P=0.21). Using Euclidean and unweighted UniFrac distances and 
Bray-Curtis dissimilarity values to measure beta diversity yielded identical results (not shown). 
Although the number of confirmed AIDS cases in Gombe is small, these data suggest that 
pronounced compositional changes in the fecal bacteriome portends rapid disease progression 
and death.  
Five additional SIVcpz infected chimpanzees, including Rudi, Skosha, Titania, Mambo 
and Eriki, disappeared within 7 months of their last fecal sampling (Table II). To examine whether 
they also experienced a destabilization of their gut bacteriome, we compared the weighted 
UniFrac distances of their last fecal samples to those of the same controls. Interestingly, fecal 
samples from Mambo (GM2736) and Eriki (GM3521), both of which were collected two months 
before their disappearance, also exhibited a significant compositional shift of their bacterial 
communities (Fig. 5a and 5b), which was not observed when prior samples from these same two 
individuals (GM3401, GM1598, GM2437) were analyzed (Fig. 5c) (P=0.46). Given these findings, 
it is possible that Mambo and Eriki also died of AIDS, although this could not be confirmed 
because their bodies were not recovered.  In contrast, no significant compositional changes 
(P=0.20) were seen for the last fecal samples from Rudi (GM3453), Skosha (GM337) and Titania 
(GM1320) (Fig. 5d-f).  Since these three chimpanzees did not disappear until 4 to 7 months after 
their last fecal collection (Table II), they may not have been sampled sufficiently close to the time 
of their death to see compositional changes in their gut bacteriome.  Alternatively, they may have 
died of causes unrelated to their SIVcpz infection.  In fact, Rudi was attacked by another 
chimpanzee shortly before his disappearance and may have died of the inflicted injuries, although  
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Fig. 5.  Pronounced compositional shifts in the gut bacterial communities of two SIVcpz 
infected chimpanzees shortly before their disappearance. (a) Pairwise weighted UniFrac 
distances from the last fecal sample of Mambo (test group), an SIVcpz infected chimpanzee who 
disappeared two months after sample collection, were compared to pairwise weighted UniFrac 
distances of fecal samples (N=98) from all chimpanzees who were sampled more than 8 months 
before their death (control group). Box plots show the median, upper, and lower quartile 
ranges with whiskers indicating 95% confidence intervals (CI). Statistical analyses were 
performed using the Mann-Whitney U-test.  Red indicates significantly increased beta diversity.  
(b) Analysis as in (a), but comparing pairwise weighted UniFrac distances from the last fecal 
sample of Eriki (test group), an SIVcpz infected chimpanzee who also disappeared two months 
after sample collection, to the same controls. (c) Analysis as in (a), but comparing weighted 
UniFrac distances from earlier fecal samples (collected more than 8 months before death) from 
Mambo and Eriki (test group) to the same controls. (d, e, f) Analysis as in (a), but comparing 
pairwise weighted UniFrac distances from the last fecal sample of Rudi, Skosha and Titania (test 
groups), SIVcpz infected chimpanzees who disappeared 5, 4 and 7 months after sample 
collection, respectively, to the same controls.
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this was not confirmed by necropsy.  The same results were obtained when Euclidean distances, 
unweighted UniFrac distances, and Bray-Curtis dissimilarity values were used to calculate beta 
diversity, except for the last sample from Eriki, which did not show significantly increased 
unweighted UniFrac distances, and the last sample from Skosha, which did show significantly 
increased unweighted UniFrac distances.  Since unweighted UniFrac distances indicate the 
presence and absence of bacterial OTUs, without accounting for changes in their relative 
abundances, these data indicate that the last sample from Eriki likely contained similar microbial 
taxa as the control chimpanzees, but exhibited significant differences in their relative 
abundances.  In contrast, the last sample from Skosha exhibited differences in some microbial 
taxa, but the overall composition of her fecal microbiome remained stable.   
 
Absence of an expanded gut virome in SIVcpz infected chimpanzees  
Previous studies of SIVmac infected macaques showed that clinical immunodeficiency 
can also be manifested by an expansion of the fecal virome [Handley et al., 2012]. To determine 
whether a similar expansion was occurring in SIVcpz infected chimpanzees, we searched our 
metagenomic sequences for reads that mapped to mammalian viruses. This analysis identified 
only a very small number of paired reads (N=29), which either mapped to chimpanzee stool 
associated circular virus (Chi-SCV) (N=22) or chimpanzee adenovirus (ChAdV) (N=7). Both Chi-
SCV [Blinkova et al., 2010] and ChAdV [Cross 2013; Lonsdorf et al., 2014] infections have 
previously been documented in Gombe chimpanzees. Moreover, most of the virus-specific reads 
(93%) were recovered from fecal samples of SIVcpz infected chimpanzees (Fig. 6a), which is 
consistent with data from SIVmac infected macaques, which also had a greater abundance of 
simian adenoviruses in their shotgun sequenced fecal samples [Handley et al., 2012]. However, 
the paucity of mammalian virus reads in the metagenomic sequencing data came as a surprise. 
Although the reasons for this are not entirely clear, partial virus degradation likely played a role,  
	  82	  
	  
Figure 6 
SIVcpz infected
 chimpanzees
(78% positive)
 
SIVcpz uninfected
 chimpanzees
(79% positive)
SIVcpz infected
 chimpanzees
(76% positive)
SIVcpz uninfected
 chimpanzees
(66% positive)
SIVcpz infected
 chimpanzees
 
SIVcpz uninfected
 chimpanzees
Ch-64 Ch-48 Ch-22 Ch-52 Ch-80 Ch-88 Ch-59 Ch-9 Ch-15
N
um
be
r o
f v
ira
l r
ea
ds
 
0
5
10
15
20
25a
b
c
Adenovirus
Stool-associated 
circular virus
102
103
104
105
106
107
108
C
hi
-S
C
V
 c
op
ie
s/
m
l 
101
102
103
104
105
106
107
A
de
no
vi
ru
s 
co
pi
es
/m
l 
NS
NS
 
Fig. 6. Absence of an expanded 
virome in fecal samples from 
SIVcpz infected chimpanzees. 
(a) Detection of chimpanzee 
adenovirus (ChAdV) and 
chimpanzee stool associated 
circular virus (Chi-SCV) viral reads 
in fecal samples by metagenomic 
sequencing, with the number of 
paired-end viral reads (color 
coded) indicated for each 
individual. Virus infection was 
independently confirmed by nested 
PCR amplification and sequencing 
of ChAdV and Chi-SCV sequences 
from fecal DNA. (b, c) Chi-SCV (b) 
and ChAdV (c) viral loads were 
determined for all fecal samples 
listed in Table II using a virus-
specific real time PCR and 
expressed as copies per ml of 
fecal sample (normalized by total 
sample DNA). The percentage of 
positive samples in each group is 
indicated, with the limit of detection 
denoted by a broken line. For each 
group, the median and standard 
error of the mean (SEM) are 
shown. Fecal samples from four 
chimpanzees that exhibited a 
compositional shift in their fecal 
bacteriome (Figs. 4 and 5) are 
highlighted (Eriki, blue; Mambo, 
purple; Malaika, green; Yolanda, 
orange). Statistical analyses were 
performed using the Mann-
Whitney U test. NS, not significant.	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since in contrast to the macaque study Gombe fecal samples were not flash frozen and were 
shipped (in RNAlater) at room temperature. Moreover, most of the SIVmac infected macaques 
were sampled within days of death, while this was clearly not the case for the SIVcpz infected 
chimpanzees. Reads from plant viruses and bacteriophages were detected, but not further 
analyzed with respect to SIVcpz infection. 
To quantify Chi-SCV and ChAdV infection rates and fecal viral loads in a larger number of SIVcpz 
infected and uninfected chimpanzees, we developed virus-specific nested and real-time PCR 
assays. Testing all fecal samples (N=123) listed in Table II, we found a high prevalence of Chi-
SCV in both SIVcpz infected and uninfected chimpanzees, but no significant difference in fecal 
viral loads in either group (Fig. 6b).  Although both ChAdV infection rates and fecal viral loads 
were slightly higher in SIVcpz infected than uninfected chimpanzees (Fig. 6c), these differences 
were not significant (P=0.07 and P=0.31 for Chi-SCV and ChAdV, respectively), including when 
values from the known and/or suspected immunodeficient chimpanzees were compared (colored 
in Fig. 6c). Thus, unlike in SIVmac infected macaques, we did not observe an expansion of the 
fecal virome in SIVcpz infected chimpanzees, including in the last samples from individuals who 
died of AIDS-related illness. 
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Section 2.6 – Discussion 
Enteric dysbiosis is recognized as a characteristic feature of progressive HIV-1 infection 
[Lozupone et al., 2014; Nwosu et al., 2014], but the underlying mechanisms have been the 
subject of debate [Brenchley 2013; Nwosu et al., 2014]. In particular, the absence of an altered 
gut bacteriome in macaques with progressive SIVmac infection seemed to argue against lentiviral 
infection as the main driver of HIV-1 associated enteropathy [Handley et al., 2012; McKenna et 
al., 2008]. However, SIVmac infection is not an ideal model to assess primate lentivirus induced 
alterations of host-bacterial interactions since its disease course is greatly accelerated [Staprans 
et al., 1999]. Moreover, captive macaques differ in lifestyle and diet from naturally infected 
primates, and are prone to enteritis even in the absence of SIVmac infection [McKenna et al., 
2008]. Reasoning that SIVcpz infection constitutes a physiologically more relevant “pathogenic 
SIV model”, we examined the composition of the fecal microbiome in infected (N=24) and 
uninfected (N=26) chimpanzees in Gombe National Park. Using both metagenomic and 16S 
rRNA gene sequencing, we failed to identify significant differences in the abundance, alpha 
diversity and beta diversity of bacterial communities between SIVcpz infected and uninfected 
groups (Fig. 3). However, fecal samples from two chimpanzees, who died of an AIDS-like illness, 
exhibited significant compositional changes five months before their death (Fig. 4). Since earlier 
samples from these same individuals failed to exhibit the same compositional shifts, it seems 
likely that effective immune control prevented the destabilization of their gut bacteriome until 
shortly before their death. These findings are consistent with observational health data that failed 
to find an association between signs of illness and SIVcpz infection in these same communities 
[Lonsdorf et al., 2015b; Wolf et al., 2015a]. These findings are also consistent with the absence of 
gut bacteriome alterations in SIVgor infected western gorillas, the great majority of whom would 
not have been sampled shortly before their death [Moeller et al., 2015b]. The new data thus 
provide a plausible explanation for previous discrepant gut microbiome results. It now seems 
clear that SIVcpz infected chimpanzees are able to maintain a stable gut microbiome for many 
years, but seem to die relatively rapidly (within only a few months) after the compositional 
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divergence of their gut microbiome marks the loss of effective immune control.  In contrast, HIV-1 
infected humans seem to tolerate a more prolonged course of declining immune functions, most 
likely because of effective medical interventions, which independently contribute to alterations of 
gut bacterial communities [Jernberg et al., 2007; Klase et al., 2015]. Thus, both HIV-1 and SIVcpz 
infection are capable of causing a disruption of gut microbial homeostasis, but the timing and 
circumstances of this disruption and the associated health consequences differ between humans 
and apes.  
Comparing 16S rRNA gene sequences, we noted that the gut bacterial communities from 
both infected and uninfected chimpanzees exhibited extensive compositional variability when 
compared over time (Figs. 2 and 3). While this may seem surprising, these results are consistent 
with a recent study that identified social interactions as the main driver of chimpanzee gut 
microbiome species richness and compositional fluctuation [Moeller et al., 2015a]. This study 
showed that the community memberships of individual chimpanzee gut microbiomes were more 
similar and more species-rich during seasons of high social interaction [Moeller et al., 2015a]. 
Thus, our failure to identify particular bacterial taxa and/or combinations of taxa to be associated 
with SIVcpz infection may not be that surprising. Although metagenomic sequencing identified an 
increased frequency of the bacterial family Prevotellaceae in a small number of number of SIVcpz 
infected chimpanzees, this association did not reach significance when 16S rRNA gene 
sequences from a larger sample set were compared. Similarly, we previously reported increased 
bacterial diversity after SIVcpz acquisition in six Gombe chimpanzees, all of whom were also 
included in the current study [Moeller et al., 2013b]. Again, samples from a small number of 
individuals allowed detection of microbiome compositional changes, while these same samples 
(except the very last ones collected before death) failed to show an increased compositional 
diversity when compared to a much larger number of controls (Figs. 3 and 4). Thus, the extensive 
compositional variability of the fecal bacteriome in the same individuals over time precludes the 
identification of subtle differences between infected and uninfected chimpanzees.  
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In addition to the gut bacteriome, we also investigated the gut virome of SIVcpz infected 
and uninfected chimpanzees. Metagenomic sequencing identified chimpanzee adenovirus 
(ChAdV) and chimpanzee stool-associated circular virus (Chi-SCV) in fecal samples from four 
Gombe chimpanzees (Fig. 6a).  Suppression of the human immune system is frequently 
associated with an outgrowth of both pathogenic and non-pathogenic viruses [De Vlaminck et al., 
2013; Handley et al., 2012; Li et al., 2013; Young et al., 2015]. For example, human torque teno 
(TT) virus, a small nonpathogenic DNA virus similar to Chi-SCV, is more prevalent in HIV-1 
infected humans and replicates to higher titers in the blood of immunosuppressed individuals 
[Christensen et al., 2000; Shibayama et al., 2001]. Similarly, anelloviruses (a viral family that 
includes TT viruses) were more abundant in blood samples from immunosuppressed transplant 
patients, with an increase in viral titers determined by metagenomic sequencing [De Vlaminck et 
al., 2013; Young et al., 2015]. Finally, SIVmac infected macaques exhibited higher fecal viral 
titers of circoviruses, which are related to Chi-SCV, and simian adenoviruses [Handley et al., 
2012].  In light of these data, the absence of significant differences in fecal Chi-SCV and ChAdV 
abundance in SIVcpz infected and uninfected chimpanzees was unexpected (Fig. 6b), especially 
when this was also the case for the last fecal samples of the four chimpanzees (Yolanda, 
Malaika, Mambo, Eriki) who exhibited increased bacterial diversity (Figs. 4 and 5).  Although 
there was a trend towards increased titers of adenovirus in fecal samples from SIVcpz infected 
chimpanzees (Fig. 6c), this finding was nowhere close to the fecal virome expansion observed in 
SIVmac infected macaques, where mammalian viruses constituted up to 90% of fecal 
metagenomic reads [Handley et al., 2012]. Unlike the SIVcpz infected chimpanzees studied here, 
the SIVmac infected macaques were moribund at the time of sampling, with many requiring 
euthanasia before the completion of the study, which may have influenced the metagenomic 
results. Nonetheless, adenovirus infection of the intestine is associated with diarrhea, and may 
therefore contribute to the higher levels of diarrhea observed in SIVcpz infected female 
chimpanzees [Lonsdorf et al., 2015b]. 
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Noninvasive studies of habituated chimpanzees have revealed much of the natural 
history of the precursor of the human AIDS virus. While the effects of SIVcpz infection on 
chimpanzee longevity and population dynamics can be readily monitored, disease progression is 
difficult to assess without frequent access to blood and tissue samples.  The aim of this study was 
to explore whether characteristic gut microbiome changes could be found that might be suitable 
to noninvasively monitor disease progression.  Although we failed to identify particular bacterial 
taxa and/or microbiome compositional changes that correlated with SIVcpz infection status, we 
found an increased beta diversity to mark the end-stage of SIVcpz infection in a small number of 
apes with necropsy confirmed immunodeficiency.  The practical importance of this finding for the 
management of chimpanzee communities with endemic SIVcpz infection remains to be 
determined. Fecal microbiome analyses seem of little value in non-habituated communities where 
longitudinal sampling and observational studies of known individuals are not possible. In contrast, 
monitoring the fecal microbiome may prove useful in habituated communities, such as in Gombe, 
where a spike in beta diversity may foreshadow rapid disease progression and death.  This could 
prompt intensified observational studies to more closely monitor signs of ill health, more focused 
sample collection to identify additional markers of disease progression, and enhanced 
surveillance to increase the likelihood of recovering tissues for necropsy. Monitoring disease 
progression in habituated chimpanzees could also be used to identify individuals that might 
benefit from therapy, provided that the intended intervention is truly necessary, practical in wild 
settings, and known to be efficacious in chimpanzees [Barbian et al., 2015]. As ape populations 
continue to dwindle in the wild, such an approach may become increasingly important to ensure 
their survival [Ryan & Walsh 2011; Walsh et al., 2003; Warfield et al., 2014]. 
 
	  88	  
	  
 
Section 2.7 – Chapter Acknowledgements 
 
We thank the Jane Goodall Institute field staff at the Gombe Stream Research Centre for 
collecting behavioral and observational health data as well as fecal samples from wild-living 
chimpanzees; Jacque Young, Christel Chehoud and Paul Sharp for expert advice; Andrew Smith, 
Andrew Caffro, Eric Ruff and Aubrey Bailey for technical assistance; Shivani Sethi for artwork and 
manuscript preparation; the Tanzania Commission for Science and Technology (COSTECH), the 
Tanzania Wildlife Research Institute (TAWIRI), and the Tanzania National Parks Association 
(TANAPA) for their support and permission to conduct research in Gombe. This work was 
supported by grants from the National Institutes of Health (R01 AI50529, R01 AI58715; P30 AI 
045008), the National Science Foundation (IOS-LTREB-1052693), and the Jane Goodall 
Institute. HJB was funded by a training grant in Emerging Infectious Diseases (T32 AI 055400). 
The authors have no conflicts of interest to disclose. 
 
	  89	  
	  
 
Section 2.8 – Chapter References  
 
 
Barbian HJ, Decker JM, Bibollet-Ruche F et al. 2015. Neutralization properties of simian 
immunodeficiency viruses infecting chimpanzees and gorillas. MBio 6:e00296-15. 
Bray JR, Curtis JT. 1957. An ordination of the upland forest communities of Southern Wisconsin. 
Ecological Monographs 27:326-349. 
Brenchley JM. 2013. Mucosal immunity in human and simian immunodeficiency lentivirus 
infections. Mucosal Immunology 6:657-665. 
Brenchley JM, Douek DC. 2007. HIV infection and the gastrointestinal immune system. Mucosal 
Immunology 1:23-30. 
Brenchley JM, Price DA, Schacker TW et al. 2006. Microbial translocation is a cause of systemic 
immune activation in chronic HIV infection. Nature Medicine 12:1365-1371. 
Caporaso JG, Kuczynski J, Stombaugh J et al. 2010. QIIME allows analysis of high-throughput 
community sequencing data. Nature Methods 7:335-336. 
Caporaso JG, Lauber CL, Walters WA et al. 2011. Global patterns of 16S rRNA diversity at a 
depth of millions of sequences per sample. Proceedings of the National Academy of 
Sciences 108:4516-4522. 
Chao A. 1984. Nonparametric estimation of the number of classes in a population. Scandinavian 
Journal of Statistics 11:265-270. 
Cho I, Blaser MJ. 2012. The human microbiome: at the interface of health and disease. Nature 
Reviews Genetics 13:260-270. 
	  90	  
	  
Christensen JK, Eugen-Olsen J, Sørensen M et al. 2000. Prevalence and prognostic significance 
of infection with TT virus in patients infected with human immunodeficiency virus. Journal 
of Infectious Diseases 181:1796-1799. 
Claesson MJ, Jeffery IB, Conde S et al. 2012. Gut microbiota composition correlates with diet and 
health in the elderly. Nature 488:178-84. 
Cross KE. 2013. Factors affecting enteric adenovirus infection dynamics in wild chimpanzees 
(Pan troglodytes) in Gombe National Park, Tanzania: Implications for global health and 
biodiversity conservation [Honors thesis]: Emory University. 31 p. 
De Vlaminck I, Khush Kiran K, Strehl C et al. 2013. Temporal response of the human virome to 
immunosuppression and antiviral therapy. Cell 155:1178-1187. 
Degnan PH, Pusey AE, Lonsdorf EV et al. 2012. Factors associated with the diversification of the 
gut microbial communities within chimpanzees from Gombe National Park. Proceedings 
of the National Academy of Sciences 109:13034-13039. 
Dillon SM, Lee EJ, Kotter CV et al. 2014. An altered intestinal mucosal microbiome in HIV-1 
infection is associated with mucosal and systemic immune activation and endotoxemia. 
Mucosal Immunology 7:983-94. 
Dinh DM, Volpe GE, Duffalo C et al. 2015. Intestinal microbiota, microbial translocation, and 
systemic inflammation in chronic HIV infection. Journal of Infectious Diseases 211:19-27. 
Estes JD, Harris LD, Klatt NR et al. 2010. Damaged intestinal epithelial integrity linked to 
microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS 
Pathogens 6:e1001052. 
Handley Scott A, Thackray Larissa B, Zhao G et al. 2012. Pathogenic simian immunodeficiency 
virus infection is associated with expansion of the enteric virome. Cell 151:253-266. 
	  91	  
	  
Hazenberg MD, Otto SA, van Benthem BH et al. 2003. Persistent immune activation in HIV-1 
infection is associated with progression to AIDS. AIDS 17:1881-1888. 
Huson DH, Mitra S. 2012. Introduction to the analysis of environmental sequences: 
metagenomics with MEGAN. In: Anisimova M, editor. Evolutionary Genomics: Statistical 
and Computational Methods, Volume 2: Humana Press. p 415-429. 
Jernberg C, Lofmark S, Edlund C, Jansson JK. 2007. Long-term ecological impacts of antibiotic 
administration on the human intestinal microbiota. ISME Journal 1:56-66. 
Keele BF, Jones JH, Terio KA et al. 2009. Increased mortality and AIDS-like immunopathology in 
wild chimpanzees infected with SIVcpz. Nature 460:515-9. 
Keele BF, Van Heuverswyn F, Li Y et al. 2006. Chimpanzee reservoirs of pandemic and 
nonpandemic HIV-1. Science 313:523-6. 
Klase Z, Ortiz A, Deleage C et al. 2015. Dysbiotic bacteria translocate in progressive SIV 
infection. Mucosal Immunology doi:10.1038/mi.2014.128. 
Li L, Deng X, Linsuwanon P et al. 2013. AIDS alters the commensal plasma virome. Journal of  
Virology 87:10912-10915. 
Li Q, Duan L, Estes JD et al. 2005. Peak SIV replication in resting memory CD4+ T cells depletes 
gut lamina propria CD4+ T cells. Nature 434:1148-1152. 
Li Y, Ndjango JB, Learn GH et al. 2012. Eastern chimpanzees, but not bonobos, represent a 
simian immunodeficiency virus reservoir. Journal of Virology 86:10776-91. 
Lonsdorf E, Travis D, Ssuna R et al. 2014. Field immobilization for treatment of an unknown 
illness in a wild chimpanzee (Pan troglodytes schweinfurthii) at Gombe National Park, 
Tanzania: findings, challenges, and lessons learned. Primates 55:89-99. 
	  92	  
	  
Lonsdorf EV, Travis DA, Gillespie T et al. 2015a. Annual and seasonal patterns of observable 
clinical signs of ill health in two communities of wild chimpanzees (Pan troglodytes 
schweinfurthii) at Gombe National Park, Tanzania. American Journal of Primatology, 
submitted. 
Lonsdorf EV, Travis DA, Gillespie T et al. 2015b. Social and demographic patterns of observable 
clinical signs of ill health in wild chimpanzees (Pan troglodytes schweinfurthii) at Gombe 
National Park, Tanzania. American Journal of Primatology, submitted. 
Lozupone C, Knight R. 2005. UniFrac: a new phylogenetic method for comparing microbial 
communities. Applied and Environmental Microbiology 71:8228-8235. 
Lozupone CA, Li M, Campbell TB et al. 2013. Alterations in the gut microbiota associated with 
HIV-1 infection. Cell Host Microbe 14:329-39. 
Lozupone CA, Rhodes ME, Neff CP et al. 2014. HIV-induced alteration in gut microbiota. Gut 
Microbes 5:562-570. 
McHardy IH, Li X, Tong M et al. 2013. HIV Infection is associated with compositional and 
functional shifts in the rectal mucosal microbiota. Microbiome 1:26. 
McKenna P, Hoffmann C, Minkah N et al. 2008. The macaque gut microbiome in health, lentiviral 
infection, and chronic enterocolitis. PLoS Pathog 4:e20. 
Mellors JW, Munoz A, Giorgi JV et al. 1997. Plasma viral load and CD4+ lymphocytes as 
prognostic markers of HIV-1 infection. Annals of Internal Medicine 126:946-954. 
Minot S, Bryson A, Chehoud C et al. 2013. Rapid evolution of the human gut virome. Proceedings 
of the National Academy of Sciences 110:12450-12455. 
Moeller AH, Degnan PH, Pusey AE et al. 2012. Chimpanzees and humans harbour 
compositionally similar gut enterotypes. Nature Communications 3:1179. 
	  93	  
	  
Moeller AH, Foerster S, Wilson M et al. 2015a. Social behaviour promotes diversity in the 
chimpanzee gut microbiome. Science Advances, submitted. 
Moeller AH, Peeters M, Ayouba A et al. 2015b. Stability of the gorilla microbiome despite simian 
immunodeficiency virus infection. Molecular Ecology 24:690-7. 
Moeller AH, Peeters M, Ndjango JB et al. 2013a. Sympatric chimpanzees and gorillas harbor 
convergent gut microbial communities. Genome Research 23:1715-20. 
Moeller AH, Shilts M, Li Y et al. 2013b. SIV-induced instability of the chimpanzee gut microbiome. 
Cell Host Microbe 14:340-5. 
Morgan XC, Huttenhower C. 2012. Chapter 12: Human microbiome analysis. PLoS 
Computational Biology 8:e1002808. 
Mutlu EA, Keshavarzian A, Losurdo J et al. 2014. A compositional look at the human 
gastrointestinal microbiome and immune activation parameters in HIV infected subjects. 
PLoS Pathogens 10:e1003829. 
Nwosu FC, Avershina E, Wilson R, Rudi K. 2014. Gut microbiota in HIV infection: implication for 
disease progression and management. Gastroenterology Research and Practice 
2014:803185. 
Pusey AE, Pintea L, Wilson ML, Kamenya S, Goodall J. 2007. The contribution of long-term 
research at Gombe National Park to chimpanzee conservation. Conservation Biology 
21:623-634. 
Rudicell RS, Holland Jones J, Wroblewski EE et al. 2010. Impact of simian immunodeficiency 
virus infection on chimpanzee population dynamics. PLoS Pathogens 6:e1001116. 
Rudicell RS, Piel AK, Stewart F et al. 2011. High prevalence of simian immunodeficiency virus 
infection in a community of savanna chimpanzees. Journal of Virology 85:9918-28. 
	  94	  
	  
Ryan SJ, Walsh PD. 2011. Consequences of non-intervention for infectious disease in African 
great apes. PLoS One 6:e29030. 
Santiago ML, Lukasik M, Kamenya S et al. 2003. Foci of endemic simian immunodeficiency virus 
infection in wild-living eastern chimpanzees (Pan troglodytes schweinfurthii). Journal of 
Virology 77:7545-7562. 
Santiago ML, Rodenburg CM, Kamenya S et al. 2002. SIVcpz in wild chimpanzees. Science 
295:465. 
Shannon CE. 2001. A mathematical theory of communication. SIGMOBILE Mobile Computing 
Communications Review 5:3-55. 
Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harbor 
Perspectives Medicine 1:a006841. 
Shibayama T, Masuda G, Ajisawa A et al. 2001. Inverse relationship between the titre of TT virus 
DNA and the CD4 cell count in patients infected with HIV. AIDS 15:563-70. 
Simpson EH. 1949. Measurement of diversity. Nature 163:688. 
Song SJ, Lauber C, Costello EK et al. 2013. Cohabiting family members share microbiota with 
one another and with their dogs. eLife 2:e00458. 
Staprans SI, Dailey PJ, Rosenthal A et al. 1999. Simian immunodeficiency virus disease course 
is predicted by the extent of virus replication during primary infection. Journal of Virology 
73:4829-4839. 
Takehisa J, Kraus MH, Ayouba A et al. 2009. Origin and biology of simian immunodeficiency 
virus in wild-living western gorillas. Journal of Virology 83:1635-48. 
	  95	  
	  
Terio KA, Kinsel MJ, Raphael J et al. 2011. Pathologic lesions in chimpanzees (Pan trogylodytes 
schweinfurthii) from Gombe National Park, Tanzania, 2004-2010. Journal of Zoo and 
Wildlife Medicine 42:597-607. 
Van Heuverswyn F, Li Y, Bailes E et al. 2007. Genetic diversity and phylogeographic clustering of 
SIVcpzPtt in wild chimpanzees in Cameroon. Virology 368:155-71. 
van Lawick-Goodall J. 1968. The behaviour of free-living chimpanzees in the Gombe Stream 
Reserve. Animal Behaviour Monographs 1:161-311. 
Vazquez-Castellanos JF, Serrano-Villar S, Latorre A et al. 2015. Altered metabolism of gut 
microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal 
Immunology 8:760-72. 
Vujkovic-Cvijin I, Dunham RM, Iwai S et al. 2013. Dysbiosis of the gut microbiota is associated 
with HIV disease progression and tryptophan catabolism. Science Translational Medicine 
5:193ra91. 
Walsh PD, Abernethy KA, Bermejo M et al. 2003. Catastrophic ape decline in western equatorial 
Africa. Nature 422:611-614. 
Warfield KL, Goetzmann JE, Biggins JE et al. 2014. Vaccinating captive chimpanzees to save 
wild chimpanzees. Proceedings of the National Academy of Sciences 111:8873-8876. 
Wolf TM, Singer RS, Lonsdorf EV et al. 2015a. Epidemiology of syndromic respiratory disease in 
chimpanzees of Gombe Stream National Park, Tanzania, 2004-2012. American Journal 
of Primatology, submitted. 
Wolf TM, Singer RS, Lonsdorf EV et al. 2015b. Syndromic surveillance of respiratory disease in 
free-living chimpanzees: A qualitative assessment of the performance of a novel disease 
detection system for wild primates. American Journal of Primatology, submitted. 
	  96	  
	  
Yatsunenko T, Rey FE, Manary MJ et al. 2012. Human gut microbiome viewed across age and 
geography. Nature 486:222-7. 
Young JC, Chehoud C, Bittinger K et al. 2015. Viral metagenomics reveal blooms of anelloviruses 
in the respiratory tract of lung transplant recipients. American Journal of Transplantation 
15:200-209. 
 
 
	  97	  
	  
 
CHAPTER 3 
 
 
NEUTRALIZATION PROPERTIES OF SIMIAN IMMUNODEFICIENCY VIRUSES  
INFECTING CHIMPANZEES AND GORILLAS  
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Section 3.1 – Abstract 
 
Broadly cross-reactive neutralizing antibodies (bNabs) represent powerful new tools to combat 
human immunodeficiency virus type 1 (HIV-1) infection. Here, we examined whether HIV-1 
specific bNabs are capable of cross-neutralizing distantly related simian immunodeficiency 
viruses infecting chimpanzees (SIVcpz) and gorillas (SIVgor). We found that bNabs directed 
against the CD4 binding site (n=10), peptidoglycans in variable loops 1 and 2 (V1/V2) (n=3) and 
at the base of variable loop 3 (V3) (n=5), and epitopes at the interface of surface (gp120) and 
membrane-bound (gp41) envelope glycoproteins (n=5) failed to neutralize the great majority of 
SIVcpz (n=11) and SIVgor (n=1) strains. Similarly, llama-derived (heavy chain-only) antibodies 
(n=6) directed against gp120 and gp41 epitopes were either completely inactive or neutralized 
only a small fraction (<40%) of SIVcpz strains. In contrast, one antibody targeting the membrane 
proximal external region (MPER) of gp41 (10E8), antibody-like constructs that function as CD4 
and CCR5 receptor mimetics (eCD4-Ig, eCD4-Igmim2, CD4-218.3-E51, CD4-218.3-E51-mim2), as 
well as mono- and bi-specific anti-human CD4 (iMab, LM52) and CCR5 (PRO140, PRO140-
10E8) receptor antibodies neutralized >90% of SIVcpz and SIVgor strains with low nanomolar 
(0.13 – 8.4 nM) potency. Importantly, the latter antibodies blocked virus entry not only in TZM-bl 
cells, but also in Cf2Th cells expressing chimpanzee CD4 and CCR5, and neutralized SIVcpz in 
chimpanzee CD4+ T-cells with IC50 values ranging from 3.6 to 40.5 nM. These findings provide 
new insight into the protective capacity of anti-HIV-1 bNabs and identify candidates for further 
development to combat SIVcpz infection. 
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Section 3.2 – Introduction 
 
Simian immunodeficiency virus (SIVcpz) of chimpanzees (Pan troglodytes) is the 
precursor of human immunodeficiency virus type 1 (HIV-1), the causative agent of AIDS (1).  Like 
HIV-1 in humans, SIVcpz is pathogenic in chimpanzees and can cause substantial morbidity and 
mortality in its natural host (2, 3). Long-term observational health studies in Gombe National Park, 
Tanzania, revealed that SIVcpz infected chimpanzees have a 10- to 16-fold increased risk of 
death compared to uninfected chimpanzees, and that infected females are less likely to give birth 
and have a much higher infant mortality rate than uninfected females (2). Necropsy studies 
showed that SIVcpz infected chimpanzees can develop severe CD4+ T lymphocyte depletion and 
a histopathology consistent with end-stage AIDS (2, 4). Most importantly, the Gombe community 
with the highest SIVcpz prevalence rate suffered a catastrophic population decline (3). Thus, 
SIVcpz infection has a substantial negative impact on the health, reproduction and life span of 
wild-living chimpanzees.  
Chimpanzees acquired SIVcpz by cross-species transmission and recombination of SIVs 
infecting monkeys on which they prey (5). Although only the central (P. t. troglodytes) and eastern 
(P. t. schweinfurthii) subspecies are naturally infected, SIVcpz is widespread throughout their 
ranges in west-central and eastern Africa, with prevalence rates reaching 30% to 50% at certain 
field sites (6-11). Transmission of SIVcpz occurs by sexual routes and from infected mothers to 
their infants (2, 3). In addition, virus spreads efficiently between communities through the 
migration of infected females (3).  Thus, SIVcpz has the potential to disperse over long distances 
and penetrate uninfected populations (7, 10, 12). SIVcpz is also the source of SIVgor, which 
emerged in western lowland gorillas (Gorilla gorilla gorilla) following a single cross-species 
transmission of a SIVcpz strain from sympatric chimpanzees (13). Although less prevalent than 
SIVcpz, SIVgor has been identified at several locations throughout southern Cameroon, with 
some gorilla troops exhibiting high infection rates (14-16). Given its recent emergence from 
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SIVcpz, SIVgor may share some of the same pathogenic properties. Thus, SIVcpz, and possibly 
also SIVgor, contribute to the infectious disease burden of wild apes, which are already highly 
endangered due to extensive habitat destruction and relentless poaching (7, 10, 16-19).  
Historically, chimpanzees have been used as an animal model to test new therapies and 
vaccines for humans, including AIDS vaccines (20-23), a practice that is no longer considered 
ethical (24). However, the opposite has not been explored, i.e., whether treatment and prevention 
strategies developed for HIV-1 infected humans could benefit SIVcpz infected chimpanzees. As 
chimpanzee and gorilla populations are dwindling in the wild, primatologists and conservation 
groups have become interested in exploring novel avenues to curb the spread of ape pathogens 
(19, 25). In this context, broad and potent neutralizing antibodies (bNabs) may be of utility (26-
29). Although immunogens capable of eliciting such antibodies do not yet exist, several studies 
have shown that bNabs can prevent the acquisition and/or suppress the replication of HIV-1 and 
simian-human immunodeficiency viruses (SHIVs) in humanized mice and rhesus macaques, 
respectively (30-37). For example, antibody-mediated immunotherapy was effective in reducing 
systemic viral loads and improving immune responses in chronically SHIV infected rhesus 
macaques (36, 37). Administration of bNabs as purified proteins or transgenes also prevented 
virus infection in animal models (30-34, 38). Since antibody infusions in wild settings are not 
feasible, delivery through recombinant vectors, such as adeno-associated virus (AAV), may 
represent an alternative. AAV has an outstanding safety record in humans as well as other animal 
species (39-42). Moreover, a single administration by dart or equivalent has the potential to 
induce long-lasting antibody expression (30, 31, 38, 43). Recombinant (r)AAV vectors could also 
be used to deliver cocktails of potent neutralizing antibodies, which may be able to reduce 
systemic viral loads.  
 First generation bNabs failed to control HIV-1 replication when administered to infected 
patients, suggesting that they were of little or no clinical value (44, 45). However, recent 
advances in HIV-1 specific B cell isolation and antibody cloning techniques have led to the 
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discovery of a large number of additional bNabs (46), many of which neutralize HIV-1 with much 
improved breadth and potency (26-29, 47-49). All bNabs target structurally conserved regions on 
the trimeric HIV-1 envelope (Env) spike, including (i) the CD4 binding site (CD4bs), (ii) 
peptidoglycans in variable region 1 and 2 (V1V2) and at the base of variable region 3 (V3), (iii) 
the membrane-proximal external region (MPER), and (iv) glycan associated epitopes at the 
interface of exterior (gp120) and membrane bound (gp41) Env glycoproteins (50-55). In addition, 
antibodies directed against the host receptors CD4 and CCR5 (56-59) as well as 
immunoadhesins containing domain 1 and 2 (D1D2) of CD4 (60-62) have been shown to have 
substantial anti-HIV-1 activity. While these reagents inhibit a large number of globally circulating 
HIV-1 strains (63), their capacity to neutralize related lentiviruses from chimpanzees and gorillas 
has not been examined. Here, we used a panel of SIVcpz and SIVgor infectious molecular clones 
(IMCs) to show that some, but not all, anti-HIV-1 bNabs and immunoadhesins are capable of 
neutralizing these viruses. Since the Env proteins of SIVcpz and SIVgor strains are nearly twice 
as divergent as those of the various HIV-1 group M subtypes, these data yield new insight into 
the breadth and protective efficacy of anti-HIV-1 antibodies. 
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Section 3.3 – Results 
 
Plasma samples of long-term HIV-1 and SIVcpz infected chimpanzees lack heterologous 
neutralization breadth. Almost 50% of HIV-1 positive humans develop some degree of 
heterologous neutralization breadth within two to four years post infection (64), indicating that the 
human immune system is capable of targeting conserved epitopes in the HIV-1 envelope (Env) 
glycoprotein. To determine whether this is also true for chronically infected apes, we tested 
plasma samples from eight chimpanzees that had been inoculated with HIV-1 and/or SIVcpz 17 
to 30 years earlier as part of vaccine and/or pathogenesis studies (Table 1). Although three of 
these individuals had undetectable plasma virus at the time of sampling, all had high titer 
antibodies that reacted with HIV-1 Gag, Pol and Env proteins on Western immunoblots, indicating 
that they were once productively infected (not shown).  The remaining five chimpanzees were 
viremic, with plasma viral loads ranging from 337 to >1,000,000 RNA copies/ml (Table 1). Among 
the animals with the highest viral loads, Tika (>200,000 RNA copies/ml) was infected with HIV-
1/NC, a pathogenic chimpanzee-adapted strain of HIV-1 (21, 23, 65). In contrast, Debbie 
(>20,000 RNA copies/ml) and Cotton (>1,000,000 RNA copies/ml) were infected with SIVcpzANT 
(20), an SIVcpzPts strain originally isolated from a wild-caught chimpanzee from the Democratic 
Republic of the Congo (66). Although Cotton was also exposed to HIV-1/LAV (Table 1), RT-PCR 
analysis identified SIVcpzANT as the only replicating virus in his plasma. Thus, the latter two 
animals represent rare examples of captive chimpanzees with chronic SIVcpz infection.  
To screen available plasma samples for neutralization breadth, we generated a panel of 
infectious molecular clones (IMCs) of SIVcpz and SIVgor strains by amplifying viral consensus 
sequences from fecal samples of wild apes (Fig. 1A). Members of both the SIVcpzPtt and the 
SIVcpzPts lineage were included, which differed in up to 48% of their Env protein sequence 
(three previously reported strains of HIV-1 were used for control). All IMCs, except for the T cell 
line adapted, CXCR4-tropic HIV-1/SG3 strain, used CCR5 as the co-receptor and replicated  
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FIG 1. Neutralizing antibody responses in long-term HIV-1 and SIVcpz infected chimpanzees. (A) 
Phylogenetic relationship of HIV-1, SIVcpz and SIVgor strains used for infectious molecular clone 
(IMC) construction. A maximum-likelihood phylogenetic tree of Env (gp160) protein sequences is 
depicted, with sequences color-coded to differentiate HIV-1 (black), SIVgor (green), SIVcpzPtt 
(red) and SIVcpzPts (blue) strains. Bootstrap values ≥ 70% are shown; the scale bar represents 
0.1 amino acid replacements per site. (B) Plasma samples from eight long-term chimpanzees 
(listed on the right; also see Table 1)) were tested against HIV-1 (n=3), SIVcpzPtt (n=6), SIVgor 
(n=1), and SIVcpzPts (n=5) strains (bottom) in the TZM-bl neutralization assay (collection date 
are indicated for samples from the same individual). IC50 values (expressed as plasma dilutions) 
averaged from three replicate experiments are shown, with a heatmap indicating the relative 
neutralization potency. 
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efficiently in primary human and chimpanzee CD4+ T cells (6, 7, 11, 15, 67-69). Testing available 
plasma samples in the TZM-bl assay, we found that seven of eight chimpanzees, including the 
two SIVcpzANT infected individuals, had activity against the easy-to-neutralize (tier 1) HIV-1/SG3 
strain (Fig. 1B). All chimpanzee plasmas, except for one (Tika), also neutralized SIVcpzGAB1, 
with IC50 titers exceeding 1:1,000 in three animals. Since SIVcpzGAB1 was cloned from a viral 
isolate that was extensively propagated in human PBMCs (67), it likely also represents an easy-
to-neutralize (tier 1) chimpanzee virus. In contrast, little cross-reactivity was observed against the 
remaining primary (tier 2) HIV-1 and SIVcpz strains, with most plasma samples containing very 
low level (<1:50) or no neutralizing activity (Fig. 1B). Longitudinal plasma samples were available 
for two chimpanzees, one of whom (Cotton) showed no neutralization breadth after over 12 years 
of infection. The second animal (Debbie) developed antibodies that neutralized all SVcpz strains, 
but with very low titers (<1:70). Thus, despite the long duration of their infection (Table 1), none of 
the chronically infected chimpanzees, including the two SIVcpzANT infected animals, developed 
appreciable neutralization potency against heterologous HIV-1, SIVcpz and SIVgor strains (Table 
1). 
Anti-HIV-1 CD4 binding site bNabs fail to neutralize SIVcpz and SIVgor strains.  
Since all primate lentiviruses identified to date use the human CD4 receptor to gain entry into 
target cells (7, 15, 69, 70) and since the CD4 molecules from humans, chimpanzees and gorillas 
are closely related (71), we asked whether CD4 binding site (CD4bs) antibodies from HIV-1 
infected humans could cross-neutralize SIVcpz and SIVgor strains. Testing VRC01 (28), VCR03 
(28), VRC-PG04 (48), VRC-CH30 (48), VRC-CH31 (48), F105 (72), b13 (73), 45-46G54W (74), 45-
46m2 (75) and 45-46m7 (75) in the TZM-bl assay, we found that most of these antibodies 
neutralized the three HIV-1 Env controls potently, with IC50 values ranging from of 0.004 to 1.2 
µg/ml (a monoclonal antibody directed against herpes simplex virus glycoprotein D served as a 
negative control). The two exceptions were F105 and b13, which are known to have only limited 
neutralization breadth and potency (76). In contrast, none of these CD4bs antibodies neutralized  
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FIG 2. Neutralizing capacity of CD4 binding site antibodies. (A) The ability of CD4 binding site 
monoclonal antibodies (listed on the right) to neutralize HIV-1, SIVcpz and SIVgor strains (listed 
on the bottom) is shown. Numbers indicate IC50 values (µg/ml) in TZM-bl cells, averaged from 
three different experiments, with a heatmap indicating the relative neutralization potency. The 
highest antibody concentration was 10 µg/ml. A herpes virus antibody (anti-HSV-gD) was used as 
a negative control. (B) Conservation of HIV-1, SIVcpz and SIVgor strains in the CD4 binding 
region. An alignment of Env protein sequences (left) in regions surrounding the CD4 binding site 
is shown.  CD4 and VRC01 contact resides (indicated in the HXB2 reference strain) are 
highlighted in orange and green, respectively. A logo plot above the alignment denotes the 
conservation of each amino acid, with the height of each letter indicating the proportion of the 
sequences that contain the residue at that site. Dots indicate identity to the HXB2 reference 
sequence and dashes represent gaps introduced to improve the alignment.
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any SIVcpz or SIVgor strain at concentrations of up to 10 µg/ml (Fig. 2A).  This was the case 
despite the fact that the panel included some of the most potent CD4bs bNabs, such as 45-
46G54W, which is known to neutralize highly diverse HIV-1 strains with IC50 values of <0.05 µg/ml 
(74). 
To examine the reasons for this resistance, we compared viral Env sequences for 
conservation of previously identified CD4 and VRC01 contact residues (77, 78). Not surprisingly, 
most amino acid residues required for CD4 binding were relatively well conserved, but this was 
not the case for many VRC01 contact residues (Fig. 2B). For example, residues 461-467 in 
variable loop 5 (V5), which are known to be critical for VRC01 binding (77), were present in all 
HIV-1 strains, but exhibited considerable length variations in SIVcpz and SIVgor strains (Fig. 2B). 
Although the CD4 binding site of SIVcpz and SIVgor strains must be conserved to maintain 
function, amino acid diversity in neighboring Env regions were likely causing clashes with anti-
HIV-1 CD4bs antibodies. 
 Glycan-dependent variable loop bNabs lack neutralization breadth against SIVcpz 
and SIVgor. In addition to the CD4 binding site, HIV-1 envelope glycoproteins contain conserved 
peptidoglycans in variable loops V1 and V2, and at the base of V3, which represent targets for 
broadly cross-reactive neutralizing antibodies (50, 51). To examine the ability of glycan 
dependent anti-HIV-1 bNabs to neutralize SIVcpz and SIVgor strains, we tested V1V2-directed 
antibodies PG9 (26), PG16 (26) and PGT145 (27) as well as the V3 directed antibodies 10-1074 
(49), PGT121 (27), PGT128 (27), PGT135 (27) and 2G12 (79) in the TZM-bl assay. Like the 
CD4bs bNabs, the glycan V3-associated bNabs failed to cross-neutralize SIVcpz and SIVgor 
strains at concentrations of 10 µg/ml, except for PGT128, which neutralized a single SIVcpzPtt 
(EK505) virus with an IC50 of 0.02 µg/ml (0.13 nM) (Fig. 3A). The V1V2-directed quaternary 
bNabs PG9 (26), PG16 (26) and PGT145 (27) were slightly more cross-reactive and potently 
neutralize four of six SIVcpzPtt strains (GAB1, EK505, MB897, MT145) (Fig. 3A).  However,  
	  108	  
	  
Figure 3 
A
S
G
3
Y
U
-2
JR
C
S
F
G
A
B
1
G
A
B
2
E
K
50
5
LB
71
5
M
B
89
7
M
T
14
5
B
F
11
67
TA
N
1
TA
N
2
TA
N
3
TA
N
13
C
P
21
39
2G12
PGT135
PGT128
PGT121
í
3*7
PG16
PG9
HIV-1 SIVcpzPtt SIVgor SIVcpzPts
IC50 value
(ug/ml)
<0.01
0.01 - 0.1
0.1 - 1.0
1.0 - 5.0
5.0 - 10.0
>10.0
 
>10.0 2.45 0.01 0.10 >10.0 0.48 >10.0 0.09 0.08 >10.0 5.74 >10.0 >10.0 >10.0 >10.0
>10.0 0.08 0.002 0.01 >10.0 0.39 >10.0 0.05 0.02 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0
>10.0 0.53 0.03 0.58 >10.0 0.06 >10.0 0.29 1.00        1.99 >10.0 >10.0 >10.0 >10.0 >10.0
0.13 0.27 0.12 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0
0.15 0.16 0.09 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0
>10.0 0.15 0.02 >10.0 >10.0  0.02 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0
0.12 >10.0 0.99 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0
0.69 >10.0 1.04 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0 >10.0
SG3
YU-2
JRCSF
GAB1
GAB2
EK505
LB715
MB897
MT145
BF1167
TAN1
TAN2
TAN3
TAN13
CP2139
HIV-1
SIVcpzPtt
SIVcpzPts
SIVgor
N156 N160 N301 N332 N386 N392
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EIKNCS FNVL--
EIKNCS FNITTS
EIKNCS FNITKS
EMKNCS FNVTTE
DMRNCT FNTTTE
QMQNCS FNVTTE
DLRNCS FNAG-D
-QYNCS FNVTTE
DMRNCS FNVTTE
DIYNCS FNVTTV
EMYECF FNQTTE
EVYNCS FNQTTE
EIFNCS FNQTTE
ELFNCS FQQTTE
KVLNCS FNQTTE
CTRPN KKTRKRITTGPGRVYYTTGEIVGDIR
CTRPN NNTRKSINIGPGRALYTTGEIIGDIR
CTRPS NNTRKSIHIGPGRAFYTTGEIIGDIR
CHRPG NNTRGEVQIGPGMTFYNIENVVGDTR
CSRPG NNTGRAINLSPGTTFFNTEALIGNPR
CTRPG NKTRGQVQIGPGMTFYNIENIIGDTR
CIRPG NNTIKGIPIGPGQHFYGTETVVGDTR
CTRLG NKTIEGIPIGPGQIFYRTKTVVGDTR
CRRPG NNTRGQIQIGPAMTFYNIENVVGDTR
CERTG NNTRGQIQIGP-MTIYNSENIVGNTR
CVRPG NNTRGQVQIGPGMTFYNIRNVIGDTR
CERTG NNTRGQVQIGPGMTFYNIENVVGDTR
CERTG NNTRGQVQIGPGMTFYNIENVVGDTR
CGRTG NNVRGQVQIGPGMTFYNTENVFGDTR
CERTG NNTRGQVQIGPGMTFYNRENIFGDTR
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QAHCNLSRAK
 QAHCNLSKTQ
 QAHCNISRAQ
 SAYCKINGTT
 KASCHLNGTL
 QAYCEVNRT-
 KAYCKINGTQ
 GAECRINGTA
 KAYCEINGTQ
 KAFCKYNETN
 KAFCYVNKTL
 KAYCSVNATT
 KAYCHVNATL
 KAYCWVNATL
 KAFCYVNATE
V3
C KSTQLFNSTW AGNNTWN
C NSTQLFTWND TRKLNN-
C NSTQLFNSTW NDTEKSS
C NTSQIFTDNI TNGI---
C NTSRLITCNG SD-----
C NTSQLFTNQN GNTTGN-
C ETSSLFNATI DITPNTT
C NTSNLFNQS- TIN----
C NTSEIINITK INKTENM
C NTTKMFSYNC TTEGCN-
C DLKNWTNNG- IEIDG--
C NLTNWTNT-W TANRTNN
C NLTGWTNP-W NNTNHRN
C NLTTWTGNWT RNRTHQT
C NLTKWINETW LNETDQT
V4
B
V1/V2  
 
 
 
 
FIG 3. Neutralizing capacity of glycan associated neutralizing antibodies. (A) The ability of 
peptidoglycan-associated monoclonal antibodies (listed on the right) to neutralize HIV-1, SIVcpz 
and SIVgor strains (bottom) is shown. Numbers indicate IC50 values (µg/ml) in TZM-bl cells, 
averaged from three different experiments, with a heatmap indicating the relative neutralization 
potency. Colored circles to the right of each antibody indicate the N-linked glycans that are 
important for their neutralizing activity (orange - N156, purple - N160, pink - N301, green - N332, 
red - N386, yellow - N392) (26, 27, 49, 80). The highest antibody concentration used was 10 
µg/ml. (B) Conservation of glycans associated with antibody neutralizing activity. An alignment of 
HIV-1, SIVcpz and SIVgor Env protein sequences is shown, with predicted N-linked glycans 
(NXS/T) highlighted in red. N-linked glycans known to influence bNab binding are highlighted 
above the alignment, with HXB2 numbering in black. The position of variable loops (V1/V2, V3 
and V4) is shown in grey below the alignment.
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 these same antibodies lacked activity against the more divergent SIVgor and SIVcpzPts strains. 
V1/V2 quaternary and glycan V3 bNabs neutralize by engaging the glycan shield and removal of 
key glycans can abrogate this neutralization (27, 80).  For example, 10-1074, PGT121, PGT128, 
PGT135, and 2G12 all bind a high mannose patch at the base of V3 that is centered around the 
conserved N332 glycan, while PG9, PG16, and PGT145 contact the N156 and N160 glycans and 
insert between them to interact with glycan-obscured protein regions (26, 27, 49, 80). Examining 
SIVcpz and SIVgor Env sequences for NXS/T sequons, we found varying degrees of 
conservation of these and other relevant N-linked glycosylation sites (Fig. 3B). For example, 
N332 was conserved in all three HIV-1 Envs, but absent from all SIVcpz and SIVgor Envs, 
potentially explaining the lack of cross-neutralization of 10-1074, PGT121, PGT128, PGT135 and 
2G12. However, SIVcpzEK505 was potently neutralized by PGT128 (Fig. 3A) despite the 
absence of the N332 glycan (EK505 is also the only strain with a deletion at position 337). 
Moreover, all SIVcpz and SIVgor strains encode an NXS/T sequon at position 334, which could 
potentially compensate for the absence of N332 (81). Thus, the lack of N332 is unlikely to be the 
sole reason for the inability of glycan V3-directed bNabs to cross-neutralize SIVcpz and SIVgor. 
Similarly, 10 of 12 SIVcpz and SIVgor Envs contained an N-linked glycosylation site at position 
160, which is required for neutralization by PG9, PG16 and PGT145 (26, 27). However, these 
antibodies neutralized only four of the 10 SIVcpz strains, again implicating lack of conservation in 
other Env regions as a reason for the absence of neutralization breadth.  
HIV-1 bNabs directed against the interface of gp120 and gp41 fail to cross-
neutralize SIVcpz and SIVgor. The most recently discovered class of anti-HIV-1 bNabs targets 
glycan associated epitopes at the interface of gp120 and gp41 (52-55). Testing several 
representatives of this bNab group, including 8ANC195 (53), 35022 (52), PGT151 (55), PGT152 
(55) and PGT158 (55), we found that none had cross-neutralization potential (Fig. 4A).  With the 
exception of 35O22, which neutralized a single SIVcpz strain (LB715) at an IC50 of 0.5 µg/ml (3.3 
nM), all other antibodies failed to block SIVcpz and SIVgor infection at concentrations of up to 10  
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FIG 4. Neutralizing capacity of antibodies targeting the interface of HIV-1 gp120 and gp41 
regions. (A) The ability of glycan-associated antibodies (right) to neutralize HIV-1, SIVcpz and 
SIVgor strains (bottom) is shown. Numbers indicate IC50 values (µg/ml) from TZM-bl cells, 
averaged from three different experiments, with a heatmap indicating the relative neutralization 
potency. Colored shapes to the right of each antibody indicate the N-linked glycans that are 
associated with antibody neutralizing activity. Antibody 8ANC195 contacts N234 (green circle) 
and N276 (green square); 35O22 utilizes N88 (blue circle), N230 (blue square), N241 (blue 
triangle), and N625 (blue star); and PGT151 requires N611 (pink circle) and N637 (pink square) 
for optimal neutralization (52-55). The highest antibody concentration used was 10 µg/ml. (B) 
Conservation of glycans associated with antibody neutralizing activity. An alignment of HIV-1, 
SIVcpz and SIVgor Env protein sequences is shown, with predicted N-linked glycans (NXS/T) 
highlighted in red. N-linked glycans known to influence bNab binding are highlighted above the 
alignment, with HXB2 numbering in black. The position of various Env regions is shown in grey 
below the alignment.
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µg/ml (Fig. 4A). Since these bNabs are also dependent on the presence of certain glycans, we 
examined the extent of sequence conservation in the corresponding Env regions (Fig. 4B). For 
example, 8ANC195 requires N-linked glycosylation sites at positions 234 and 276 (53), both of 
which are highly variable in SIVcpz and SIVgor strains (Fig. 4B).  Similarly, 35O22 utilizes N-
linked glycosylation sites at positions 88, 230, 241 and 625 (Fig. 4B), one of which (N230) is 
absent from all SIVcpz and SIVgor strains. Thus, the absence of key N-linked glycosylation sites 
may be one reason for the lack of cross-neutralizing capacity of this class of bNabs.  However, 
variation in other Env regions must also be involved, since the glycosylation site contacts for 
PGT151 (N611 and N637) were conserved in all viruses, yet this monoclonal also failed to cross-
neutralize. 
 Camelid antibodies have limited cross-neutralization breadth. Members of the 
Camelidae family produce antibodies that lack light chains and thus comprise much smaller 
(heavy-chain only) antibodies with long complementarity-determining regions. It has thus been 
proposed that these single-chain antibodies may be better equipped to bind to small occluded 
sites on the HIV/SIV Env trimer than full-sized antibodies (82). Indeed, several camelid single-
domain antibodies have been shown to potently neutralize genetically divergent strains of HIV-1 
(75, 83, 84).  To examine whether this cross-reactivity extends to SIVcpz and SIVgor, we tested a 
panel of llama-derived antibodies, including single domain JM4 (85), J3 (75), 3e3 (86), 2E7 (83) 
and 11F1F (86) as well as the bivalent Bi-2H10, which contains two molecules of 2H10 joined by 
a glycine-serine linker (87). Of these, JM4 recognizes a region in gp120 that overlaps both the 
CD4 and CCR5 binding sites, J3 and 3E3 target the CD4 binding site, 2E7 and 11F1F recognize 
epitopes in the ectodomain of gp41 (75, 83, 85, 86), and 2H10 targets the membrane proximal 
external region (MPER) (87). Interestingly, J3 and 3E3 were able to neutralize a limited number of 
SIVcpzPtt strains at IC50 values <5 µg/ml (<13 nM) (Fig. 5A), thus exhibiting greater activity than 
conventional CD4bs antibodies, which were completely inactive (Fig. 2A). This was also true for 
the anti-gp41 antibodies 2E7 and 11F1F, which neutralized four SIVcpzPtt and one SIVcpzPts  
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FIG 5. Neutralizing capacity of camelid antibodies. (A) The ability of llama-derived (heavy chain-
only) antibodies (listed on the right) to neutralize HIV-1, SIVcpz and SIVgor strains (bottom) is 
shown. Numbers indicate IC50 values (mg/ml) from TZM-bl cells, averaged from three different 
experiments, with a heatmap indicating the relative neutralization potency. The highest antibody 
concentration used was 10 mg/ml. (B-D) Conservation of antibody binding epitopes shown in (A). 
Alignments of HIV-1, SIVcpz and SIVgor Env protein sequences are depicted, with residues 
identical to the HXB2 reference shown in grey. Logo plots denote the conservation of individual 
amino acids within each epitope, with the height of each letter indicating the proportion of 
sequences that contain the residue at that site. An X indicates residues within the 2H10 epitope 
that do not impact neutralization. JM4 contact residues are indicated on top of the alignment. 
Sequences are numbered according to the HXB2 reference. 
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strain at IC50 values <10 µg/ml (<40 nM). However, this breadth did not extend to the more 
divergent SIVcpzPts and SIVgor viruses, and the bivalent MPER antibody Bi-2H10 was unable to 
neutralize any SIVcpz and SIVgor strains (Fig. 5A).  
Since the epitopes of 2H10, 2E7, 11F1F and JM4 have been mapped, we examined the 
corresponding amino acid sequences in SIVcpz and SIVgor strains (Fig. 5B-D).  This analysis 
showed that none was particularly highly conserved among the ape viruses. All SIVcpz and 
SIVgor strains, except BF1167, differed by one or more substitutions in the 2H10 epitope (Fig. 
5B). This was also true for the partially overlapping 2E7 and 11F1F epitopes, where all SIVcpz 
and SIVgor sequences differed from the HIV-1 consensus (Fig. 5C). Finally, there was 
considerable variation in the JM4 epitope (Fig. 5D), with contact residues I326, V372 and M434 
conserved in HIV-1, but mutated in most (V372) or all (I326, M434) SIVcpz and SIVgor strains. 
Thus, epitope variation may explain at least some of the neutralization resistance of SIVcpz and 
SIVgor strains. However, in contrast to conventional CD4bs and glycan dependent antibodies, 
llama-derived antibodies neutralized a subset of SIVcpzPtt strains, possibly because of their 
smaller size. 
 HIV-1 MPER bNabs neutralize SIVcpz and SIVgor strains.  Antibodies targeting the 
MPER region of gp41 represent still another class of potent anti-HIV-1 bNabs (29, 47).  Among 
those, 4E10 and 10E8 exhibit the greatest breadth, having been shown to neutralize 98% of a 
large panel (n=181) of HIV-1 pseudoviruses (29, 47). To examine their ability to cross-neutralize 
ape viruses, we tested 4E10 and 10E8 against our panel of SIVcpz and SIVgor strains. In 
contrast to all other anti-HIV-1 bNabs, 4E10 neutralized 9 of 12 SIVcpz and SIVgor strains with a 
mean IC50 of 2.7 µg/ml (18.1 nM), while 10E8 neutralized all ape viruses with a mean IC50 of 0.7 
µg/ml (4.4 nM) (Fig. 6A).  An amino acid alignment of the corresponding epitopes revealed 
considerable sequence conservation (Fig. 6B), likely explaining the remarkable breadth and 
potency of 10E8 compared to all other anti-HIV-1 bNabs.  
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FIG 6. Neutralizing capacity of MPER antibodies (A) The ability of two MPER antibodies (listed on 
the right) to neutralize a panel of HIV-1, SIVcpz and SIVgor strains (bottom) is shown. Numbers 
indicate IC50 values (µg/ml) from TZM-bl cells, averaged from three different experiments, with a 
heatmap indicating the relative neutralization potency. The highest antibody concentration used 
was 10 µg/ml. (B) Conservation of 4E10 and 10E8 epitopes. An alignment of HIV-1, SIVcpz and 
SIVgor Env protein sequences is depicted, with dots indicating identity to the HXB2 reference 
sequence. A logo plot denotes the conservation of individual amino acids, with the height of each 
letter indicating the proportion of sequences that contain the residue at that site. Contact residues 
of 4E10 (blue) and 10E8 (red) are highlighted above the alignment. 
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Anti CD4 and CCR5 receptor antibodies potently neutralize SIVcpz and SIVgor 
strains. Since CD4 and CCR5 protein sequences are highly conserved between humans and 
apes (71, 88), we asked whether antibodies raised against the human receptors could block 
SIVcpz and SIVgor infection. Both anti-CD4 and anti-CCR5 antibodies were examined, including 
ibalizumab (iMab) and PRO140, which have previously been shown to be safe and efficacious in 
human clinical trials (89-91). Using TZM-bl cells, which express human CD4 and CCR5, we found 
that both the anti-CD4 antibody iMab (90, 92, 93), and its improved version LM52 (58), 
neutralized most or all ape viruses with geometric mean IC50 values of 0.41 µg/ml (2.8 nM) and 
0.12 µg/ml (0.8 nM), respectively (Fig. 7A). PRO140, which targets the CCR5 co-receptor (56), 
also neutralized all SIVcpz and SIVgor strains with an IC50 of 0.34 µg/ml (2.3 nM) (Fig. 7A). 
Finally, bi-specific versions of iMab, LM52 and PRO140, in which these antibodies were linked to 
single-chain variable fragments (scFv) of PG9, PG16, PGT128 and 10E8 (59), were potent 
inhibitors, especially when the fusion partner was also an effective SIVcpz and SIVgor neutralizer. 
For example, the bispecific iMab-PG9 and iMab-PG16 neutralized the PG9/PG16-sensitive GAB1 
and EK505 strains with two orders of magnitude greater potency than iMab alone, but this 
enhancement was not observed for viruses that were resistant to PG9 and PG16  (Figs. 3A and 
7A). By far the most potent anti-receptor antibody was PRO140-10E8, which neutralized SIVcpz 
and SIVgor strains with a mean IC50 value of 0.03 µg/ml (0.13 nM) (Fig. 7A).  
 To determine whether the anti-human receptor antibodies would block virus entry in cells 
expressing chimpanzee CD4 and CCR5, we developed a neutralization assay using transiently 
transfected Cf2Th cells.  This canine thymus cell line lacks CD4 and CCR5, but expresses a tat-
inducible luciferase reporter. Cf2Th cells were co-transfected with either human (Cf2Th-hu) or 
chimpanzee (Cf2Th-ch) CD4 and CCR5 expression plasmids, and then validated by testing the 
neutralizing activity of anti-gp120 bNabs (n=3), which should not be affected by entry molecules, 
against a subset of HIV-1 (YU2) and SIVcpz (GAB1, EK505, MT145, TAN13) strains (Figs. 7B 
and C). The results showed that IC50 values from Cf2Th-hu cells were highly correlated with those
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FIG 7. Neutralizing capacity of anti-host receptor antibodies (A) The ability of mono-specific anti-human CD4 
(iMab, LM52) and anti-CCR5 (PRO140) antibodies as well as their bi-specific derivatives (iMab-PG9, iMab-
PG16, LM52-PGT128, PRO140-10E8) (listed on the right) to neutralize a panel of HIV-1, SIVcpz and SIVgor 
strains (bottom) is shown. Numbers indicate IC50 values (µg/ml) from TZM-bl cells, averaged from three 
different experiments, with a heatmap indicating the relative neutralization potency. The geometric mean 
IC50 is shown for each antibody (only values for SIVcpz and SIVgor strains that were below 10 µg/ml were 
included into the calculation). (B) Correlation of TZM-bl and Cf2Th-hu derived neutralization data. Three 
bNabs (10E8, PG16, eCD4-Igmim2) were used to neutralize a subset of HIV-1 and SIVcpz strains (YU-2, 
GAB1, EK505, MT145, TAN13) in TZM-bl and Cf2Th cells expressing human CD4v and CCR5 receptors 
Cf2Th-hu). IC50 values from TZM-bl (x-axis) and Cf2Th-hu (y-axis) cells were plotted and analyzed using the 
Spearman correlation test.  (C) Correlation of Cf2Th-hu  and Cf2Th-ch neutralization data. The same three 
bNabs shown in (B) were used to neutralize the same subset of HIV-1 and SIVcpz strains in Cf2Th cells 
expressing human (Cf2Th-hu) and chimpanzee (Cf2Th-ch) CD4 and CCR5 receptors. IC50 values from 
Cf2Th-hu (x-axis) and Cf2Th-ch (y-axis) cells were plotted and analyzed using the Spearman correlation.  
(D) The ability of anti-receptor antibodies (listed on the right) to neutralize a subset of HIV-1 and SIVcpz 
strains (bottom) in Cf2Th cells expressing either human (left panel) or chimpanzee (right panel) CD4 and 
CCR5 receptors is shown. Numbers indicate IC50 values (µg/ml) averaged from three different experiments, 
with heatmaps indicating relative neutralizing potencies. The geometric mean IC50 is shown for each 
antibody (only values from SIVcpz strains were included).  
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from TZM-bl cultures (Fig. 7B), and this was also true for IC50 values from Cf2Th-hu and Cf2Th-ch 
cells (Fig. 7C). Having validated the Cf2Th-ch cell assay, we next examined the neutralizing 
capacity of the anti-receptor antibodies using a subset of SIVcpz strains (Fig. 7D). Both mono and 
bi-specific antibodies blocked these viruses in chimpanzee CD4 and CCR5 expressing cells with 
mean IC50 values ranging from 0.30 µg/ml (PRO140) to 0.02 µg/ml (LM52-PGT128). Thus, 
several anti-human receptor antibodies that potently neutralized SIVcpz strains in cells 
expressing human CD4 and CCR5 also neutralized these viruses in cells expressing chimpanzee 
CD4 and CCR5.  
 CD4 containing antibodies and immunoadhesins potently neutralize SIVcpz and 
SIVgor strains. Soluble CD4 (sCD4) as well as immunoadhesins, which contain the first two 
immunoglobulin-like domains (D1 and D1) of CD4 linked to antibody constant regions, are known 
to have broad anti-HIV-1 activity in vitro and in vivo (60, 61, 94). To examine their breadth and 
potency against ape viruses, we tested several members of this inhibitor class. Soluble (s)CD4 
(95) and the more bioavailable CD4-Ig (96), in which the D1D2 domains of CD4 are linked to an 
IgG Fc region (Fig. 8A), neutralized nearly all ape viruses with mean IC50 values of 2.0 µg/ml 
(47.7 nM) and 2.1 µg/ml (23.1 nM), respectively (Fig. 8B). The tetravalent PRO542, in which 
D1D2 domains are linked to both the constant heavy (CH) and light (CL) chains of IgG1 (Fig. 8A), 
was slightly more potent and neutralized 10 of 12 ape viruses with a mean IC50 of 1.1 µg/ml (5.2 
nM) (Fig. 8B). Finally, CD4-218.3-E51, a CD4 induced (CD4i) neutralizing antibody (E51) linked 
to D1D2 via the VH chain (Fig. 8A), neutralized all SIVcpz and SIVgor strains with a geometric 
mean IC50 of 1.68 µg/ml (8.4 nM) (Fig. 8B).  Interestingly, other E51-based constructs that 
differed in the length or amino acid composition of their linkers (CD4-GS7-E51 (61), CD4-L1-E51, 
CD4-L14-E51, CD4-L17-E51) were much less broadly acting and/or potent (Fig. 8B), and this 
was also true for a construct in which the D1D2 domains were linked to an anti-herpes simplex 
virus antibody (CD4-anti-HSV-gD). 
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FIG 8. Neutralizing capacity of human CD4 containing immunoadhesins. (A) Schematic representation of six 
constructs.  Human CD4 D1 and D2 domains are shown in green; immunoglobulin (IgG) Fc as well as 
constant heavy and light (CH/CL) regions are shown in black; E51 variable heavy and light (VH/VL) regions 
are shown in blue, CCR5 mimetic peptides are shown in yellow, and the T20 fusion inhibitor is shown in red. 
(B) The ability of human CD4 containing antibody-like constructs (listed on the right) to neutralize a panel of 
HIV-1, SIVcpz and SIVgor strains (bottom) is shown. Numbers indicate IC50 values (µg/ml) from TZM-bl 
cells, averaged from three different experiments, with a heatmap indicating the relative neutralization 
potency. The highest antibody concentration used was 10 µg/ml. The geometric mean IC50 is shown for 
each construct (only values for SIVcpz and SIVgor strains that were below 10 µg/ml were included into the 
calculation).
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Some HIV-1 bNabs use tyrosine sulfation of their complementarity determining regions 
(CDRs) to mimic CCR5 sulfation and thereby inhibit virus entry (97).  Sulfopeptides derived from 
such antibodies, including a 15 amino acid tyrosine sulfated peptide derived from the CD4i 
antibody E51, have been shown to reproduce this effect (98). When linked to an antibody Fc 
domain, this peptide (CCR5mim) was able to block infection of diverse HIV-1 strains (99).  
However, its neutralization capacity was most improved when fused to the carboxy terminus of 
CD4-Ig (Fig. 8A). In fact, this enhanced CD4-Ig, or eCD4-Ig, did not only neutralize a diverse 
panel of HIV-1 strains, but also SIVmac and HIV-2 isolates, with IC50 values of <0.05 µg/ml (62). 
Using TZM-bl cells, we found that eCD4-Ig neutralized SIVcpz and SIVgor strains also more 
potently than CD4-Ig with a mean IC50 of 0.46 µg/ml (4.8 nM). However, this 5-fold enhancement 
was modest compared to the 20- to 200-fold enhancement observed for HIV-1 strains (62).  
Moreover, the use of CCR5mim peptide variants previously shown to bind HIV-1 Envs with 
greater affinity did not improve neutralization: eCD4-Igmim2 was slightly less potent than eCD4-Ig 
(IC50 of 0.62 µg/ml) and eCD4-IgQ40A,mim2 failed to neutralize two SIVcpzPts strains (Fig. 8B). 
Addition of CCR5mim2 to the carboxy terminus of CD4-218.3-E51 (CD4-218.3-E51-mim2) 
resulted in a two-fold increased neutralization potency, while addition of the fusion-inhibiting 
peptide T-20 (100) (CD4-218.3-E51-T20) had very little effect (Fig. 8B). Thus, as previously 
shown for HIV-1, HIV-2 and SIVmac (62), addition of entry-inhibiting peptides to the carboxy 
terminus of D1D2 containing antibody constructs enhanced their ability to neutralize SIVcpz and 
SIVgor strains, although the magnitude of this enhancement was much less pronounced.  
 Neutralization of SIVcpz in primary chimpanzee CD4+ T cells. TZM-bl and CF2Th-ch 
cells identified a number of anti-viral and anti-receptor bNabs that neutralized ape viruses with 
both breadth and potency. To confirm this phenotype in a physiologically more relevant culture 
system, we tested these antibodies in primary chimpanzee lymphocytes. Chimpanzee CD4+ T 
cells were isolated from the blood of three donors, activated using autologous macrophages, and 
used to test the neutralizing capacity of immunoadhesins (CD4-Ig, eCD4-Ig and eCD4-Igmim2), the  
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Figure 9 
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FIG 9. Neutralization of SIVcpz in primary CD4+ T cells. (A) Serial dilutions (red, 10 µg/ml; green, 
3.3 µg/ml; blue 1.1 µg/ml; purple 0.36 µg/ml) of the most potent anti-SIVcpz antibodies and 
immunoadhesins (as determined in TZM-bl cells) were incubated with the SIVcpz strain MT145 
before addition to activated primary chimpanzee CD4+ T cells (anti-receptor antibodies were 
incubated with cells before virus was added). Plots depict MT145 replication after antibody 
removal, with time (days) plotted on the x-axis and RT activity on the y-axis. Antibody VRC01, 
which does not neutralize SIVcpz and SIVgor strains, served as a negative control. CD4+ T cells 
from three different chimpanzee donors were used (one representative experiment is shown). (B) 
Correlation of IC50 values from TZM-bl and primary chimpanzee CD4+ T cells. IC50 values 
averaged from three independent experiments were plotted for chimpanzee CD4+ T cells (x-axis) 
and TZM-bl (y-axis), and analyzed using the Spearman correlation test.
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TABLE 2 Neutralization Potency in Primay CD4+ T Cells  
IC50 (ug/ml) IC50 (nM) IC50 (ug/ml) IC50 (nM)
CD4-Ig 0.02 (±0.02)a 0.22 (±0.22) 6.02 (±3.5) 65.4 (±38.0)
CD4-218.3-E51 0.04 (±0.04) 0.20 (±0.20) 3.74 (±1.4) 18.7 (±7.0)
eCD4-Ig <0.01 (±0.0) <0.10 (±0.0) 3.68 (±1.1) 38.3 (±11.5)
eCD4-Igmim2 <0.01 (n/ab) <0.10 (±0.0) 5.86 (n/a) 61.0 (n/a)
CD4-218.3-E51-mim2 <0.01 (±0.0) <0.05 (±0.0) 3.93 (±1.5) 19.7 (±7.5)
CD4-218.3-E51-T20 <0.01 (±0.0) <0.05 (±0.0) 4.90 (±4.4) 24.5 (±22.0)
VRC01 0.03 (±0.03) 0.20 (±0.20) >10 (±0.0) > 66.7 (±0)
10E8 NDc ND 6.07 (±1.82) 40.5 (±12.1)
iMab ND ND 0.64 (±0.41) 4.3 (±2.7)
LM52 ND ND 0.68 (±0.18) 4.5 (±1.2)
PRO140 ND ND 2.33 (±1.99) 15.5 (±13.3)
PRO140-10E8 ND ND 0.75 (±0.68) 3.6 (±3.2)
SIVcpz MT145HIV-1 SG3  
Average of 3 donors shown (±standard deviation)
 
a  
bn/a, not applicable, only performed in 1 donor
 
cND, not done 
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MPER antibody 10E8, CD4-CD4i constructs (CD4-218.3-E51, CD4-218.3-E51-mim2, CD4-218.3-
E51-T20), and anti-receptor antibodies (iMab, LM52, PRO140, PRO140-10E8) (Fig. 9A). Since 
chimpanzee blood samples were limited, we were able to test only a single SIVcpz strain 
(MT145), which was selected based on its ability to replicate efficiently in CD4+ T cells from 
multiple chimpanzee donors (70). Using serial antibody dilutions (Fig. 9A), we found that MT145 
was most potently neutralized by iMab, LM52 and PRO140-10E8 with mean IC50 values of 0.64 
(4.3 nM), 0.68 (4.5 nM) and 0.75 µg/ml (3.6 nM), respectively (Tables 2). Immunoadhesins were 
roughly 10-fold less potent, with mean IC50 values ranging from 3.7 µg/ml (38.3 nM) for eCD4-Ig 
to 6 µg/ml (65.4 nM) for CD4-Ig. As expected, the CD4bs antibody VRC01 had no inhibitory 
activity (Fig. 9A, Table 2). Thus, all antibody constructs that had broad and potent anti-SIVcpz 
activity in the TZM-bl assay also inhibited SIVcpz infection in chimpanzee CD4+ T cells (Fig. 9B), 
although the observed IC50 values were 10- to 100-fold higher in the primary T cell cultures that 
permitted multiple rounds of replication (Fig. 9B). 
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FIG 10. Breadth and potency for antibody-like constructs with anti-SIVcpz and anti-SIVgor 
neutralizing activity. For each bNab, the percentage of SIVcpz and SIVgor strains neutralized with 
IC50 values of < 10 µg/ml (y-axis) is plotted against the corresponding geometric mean IC50 in nM 
(x-axis). Antibodies and antibody-like constructs are color coded, with those that exhibited no 
anti-SIVcpz and SIVgor activity listed in the left lower corner.  Horizontal and vertical bars denote 
90% breadth and 10nM potency, respectively, and the most potent and cross-reactive reagents 
are circled
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TABLE 3 Neutralization Potency (nM) in TZM-bl Cells
SIVgor Geometric Percentage
SG3 YU-2 JRCSF GAB-1 GAB-2 EK505 LB715 MB897 MT145 CP2139 BF1167 TAN-1 TAN-2 TAN-3 TAN-13 Meana Neutralizedb
CD4bs
VRC-01 0.29 0.84 2.81 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
VRC-03 0.3 0.22 0.63 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
VRC-PG04 0.45 0.76 2.07 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
VRC-CH30 6.73 1.09 3.07 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
VRC-CH31 7.89 0.65 1.28 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
F105 5.3 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
b13 22.2 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
NIH45-46G54W 0.02 0.16 0.41 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
45-46m2 0.14 0.28 0.71 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
45-46m7 1.06 0.34 0.78 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
MPER
4E10 6.68 >67 24.06 7.94 14.25 15.97 12.63 16.30 17.93 >67 32.93 62.30 >67 15.26 >67 18.10 75%
10E8 5.67 19.27 3.07 0.20 1.53 7.27 0.87 7.20 7.20 34.20 6.20 7.20 9.40 1.47 24.40 4.39 100%
Glycan-dependent
PG9 >67 16.33 0.06 0.69 >67 3.19 >67 0.63 0.51 >67 >67 38.30 >67 >67 >67 1.93 42%
PG16 >67 0.55 0.01 0.07 >67 2.58 >67 0.32 0.15 >67 >67 >67 >67 >67 >67 0.30 33%
PGT145 >67 3.50 0.22 3.85 >67 0.39 >67 1.93 6.64 13.28 >67 >67 >67 >67 >67 3.03 42%
10-1074 0.86 1.81 0.83 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
PGT121 0.97 1.05 0.63 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
PGT128 >67 1.01 0.11 >67 >67 0.13 >67 >67 >67 >67 >67 >67 >67 >67 >67 0.13 8%
PGT135 0.77 >67 6.61 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
2G12 4.63 >67 6.92 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
8ANC195 8.67 7.80 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
35O22 0.87 >67 >67 >67 >67 >67 3.33 >67 >67 >67 >67 >67 >67 >67 >67 3.33 8%
PGT151 0.13 14.07 0.47 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
PGT152 0.20 2.00 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
PGT158 0.60 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 >67 0%
Llama
JM4 36.03 67.17 6.82 7.20 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 7.20 8%
J3 0.21 1.35 10.52 1.47 38.65 >100 38.07 >100 >100 >100 >100 >100 >100 >100 >100 12.92 25%
3E3 0.27 0.22 12.42 1.61 27.96 >100 10.83 10.60 >100 >100 >100 >100 >100 >100 >100 8.48 33%
2E7 11.44 >100 46.63 >100 20.14 92.89 20.42 >100 42.66 >100 55.84 >100 >100 >100 >100 39.07 42%
11F1F 11.62 >100 47.42 >100 21.24 91.12 22.56 >100 43.52 >100 54.79 >100 >100 >100 >100 40.13 42%
Bi-2H10 61.42 >75 34.44 >75 >75 >75 >75 >75 >75 >75 >75 >75 >75 >75 >75 >75 0%
Anti-receptor
iMab >67 >67 0.46 34.21 0.86 58.49 0.69 0.36 0.48 >67 22.40 0.98 23.83 0.68 0.96 2.76 92%
LM52 >67 0.64 0.23 1.59 0.50 0.25 0.23 0.22 0.43 22.53 0.46 0.35 1.17 0.76 3.21 0.77 100%
PRO140 >67 2.61 23.81 2.16 0.68 0.80 4.87 1.57 1.02 3.07 1.41 7.97 15.46 1.12 3.43 2.27 100%
iMab-PG9 >48 35.32 0.10 2.56 0.15 0.15 2.08 0.85 0.04 >48 0.09 1.13 3.21 0.67 >48 0.50 83%
iMab-PG16 >48 5.54 0.13 19.68 0.16 0.51 27.24 2.12 0.04 >48 0.15 5.51 5.94 0.83 >48 1.31 83%
LM52-PGT128 >48 0.28 0.14 2.09 0.02 1.94 0.91 0.67 0.12 7.49 0.37 0.95 0.32 0.33 22.52 0.75 100%
PRO140-10E8 0.14 1.65 0.61 0.12 0.08 0.03 0.17 0.10 0.10 0.37 0.03 0.34 0.44 0.10 0.52 0.13 100%
CD4-based
sCD4 3.05 16.97 155.3 4.23 9.70 >244 126.9 >244 32.12 90.61 21.07 221.2 58.27 112.79 130.21 47.66 83%
CD4-Ig 0.21 2.70 24.29 1.19 4.40 84.74 79.09 94.40 12.11 33.46 6.31 >109 19.14 78.49 76.79 23.05 92%
PRO542 0.03 0.55 5.33 0.36 1.41 41.60 36.81 >47 2.06 7.18 1.85 >47 4.82 12.62 11.85 5.24 83%
CD4-anti-HSV-gD 7.50 41.57 30.89 19.84 38.81 40.90 25.87 36.19 42.02 46.19 34.57 42.00 42.30 30.28 43.37 35.92 100%
CD4-GS7-E51 1.01 >50 21.03 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 0%
CD4-L1-E51 0.20 0.35 29.31 0.85 2.69 >50 16.93 >50 4.36 4.80 15.63 >50 1.75 22.69 4.33 5.05 75%
CD4-L14-E51 0.04 1.01 42.31 0.98 3.10 >50 24.49 >50 5.22 11.21 36.27 >50 2.68 35.92 5.84 7.64 75%
CD4-L17-E51 0.47 2.46 >50 0.05 7.26 >50 >50 >50 17.61 26.21 >50 >50 8.08 >50 16.87 5.23 50%
CD4-218.3-E51 0.95 2.39 7.24 2.21 7.08 26.25 9.42 32.14 5.16 4.18 5.66 22.52 3.60 19.73 5.09 8.40 100%
eCD4-Ig 0.01 0.26 2.05 0.19 0.97 23.67 8.84 47.19 2.08 4.95 1.03 35.20 2.07 12.98 7.30 4.75 100%
eCD4-Ig mim2 0.03 0.39 3.78 0.22 1.54 27.36 14.22 70.87 2.34 7.19 1.83 38.18 3.18 16.05 10.18 6.49 100%
eCD4-Ig Q40Amim2 0.02 0.25 0.69 0.20 0.89 23.70 7.45 81.38 4.89 2.07 98.69 >104 103.0 70.15 >104 10.65 83%
CD4-218.3-E51-mim2 0.34 2.64 29.46 14.70 0.38 7.83 3.38 3.30 2.98 4.88 2.22 4.00 44.17 0.76 6.22 3.92 100%
CD4-218.3-E51-T20 1.75 8.75 4.45 4.64 7.86 14.62 14.15 23.38 5.27 8.78 6.33 11.55 1.40 3.91 11.12 7.58 100%
aGeometric mean calculations include only values from SIVcpz and SIVgor strains that reached an IC50 at the highest concentration tested
bIncludes only SIV strains
SIVcpzPtt SIVcpzPtsHIV-1
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Section 3.4 – Discussion 
 
In this study, we examined whether antibodies and immunoadhesins known to potently 
neutralize diverse strains of HIV-1 can cross-neutralize related lentiviruses naturally infecting 
chimpanzees and gorillas to assess their utility for antibody based strategies to combat ape SIV 
infections. We found that the great majority of HIV-1 specific bNabs, including those directed 
against highly conserved Env epitopes such as the CD4 binding site, failed to neutralize SIVcpz 
and SIVgor strains. However, one antibody directed against the MPER region (10E8) as well as 
bi-specific CD4 and CCR5 receptor mimetics (eCD4-Ig, eCD4-Igmim2, CD4-218.3-E51, CD4-
218.3-E51-mim2) neutralized 100% of ape viruses with low nanomolar potency (Table 3, Fig. 10). 
Anti-host receptor antibodies (iMab, PRO140) were also effective neutralizers, especially when 
fused to the antigen binding regions of potent bNabs such as 10E8 (Table 3, Fig. 10). These data 
indicate that pandemic HIV-1 shares an extremely limited number of cross-reactive epitopes with 
its immediate ape precursors. However, the sites of vulnerability that were identified represent 
attractive targets across the entire HIV-1/SIVcpz/SIVgor clade, and may be of utility to combat 
other HIV-1 lineages, including group O viruses, which are estimated to have infected ~100,000 
people in west central Africa (16). 
 
Neutralizing antibody responses in long-term HIV-1 and SIVcpz infected 
chimpanzees. Since bNabs isolated from apes may be more appropriate for certain interventions 
than antibodies derived from humans, we tested plasma samples from eight long-term HIV-1 and 
SIVcpz infected chimpanzees for evidence of neutralization breadth (Table 1). Although all 
animals had high titer Env binding antibodies, their plasma samples neutralized only the easy-to-
neutralize (tier 1) HIV-1/SG3 and SIVcpzGAB1 strains (Fig. 1B). Four animals had very low 
(Joye) or undetectable (Marc, Bucky, Josie) plasma viral loads, suggesting insufficient antigenic 
stimulation as a possible reason for the lack of bNab development (Table 1). In addition, one 
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animal (Tika) had severe CD4+ T cell depletion and thus may have suffered from immune 
exhaustion (Table 1). However, two chimpanzees (Debbie and Cotton) had plasma viral titers 
exceeding 20,000 RNA copies/ml, suggesting sustained productive infection for almost two 
decades (Table 1). Both were experimentally infected with SIVcpzANT, a naturally occurring 
SIVcpzPts strain that was administered by mucosal routes using plasma and/or peripheral blood 
mononuclear cells from a third chimpanzee (20). Despite this “near-natural” infection history, only 
one of these animals (Debbie) exhibited cross-reactive neutralizing activity, albeit with 
exceedingly low titers (<1:70) (Fig. 1B). Since the kinetics of bNab development may vary in 
chimpanzees and humans, it will be important to follow this individual to examine whether 
neutralizing titers will increase and to map the corresponding antibody specificities. It may also be 
informative to study autologous neutralization responses and associated viral escape in this and 
other long-term infected chimpanzees to elucidate why antibody lineages with broad neutralizing 
capacity develop only rarely. Since very few apes and humans can be studied decades after 
HIV/SIV infection in the absence of anti-retroviral therapy, this may provide an opportunity to 
uncover common pathways, as well as roadblocks, to bNab development (101-103).  
 
HIV-1 shares a very limited number of cross-reactive epitopes with SIVcpz and 
SIVgor strains. The envelope glycoprotein of HIV-1 group M viruses contains five regions of 
vulnerability that are targeted by broadly cross-reactive neutralizing antibodies. These include the 
CD4 binding site (28, 48), the MPER region (29, 47), the N332 supersite of vulnerability (27, 49), 
the N160 antigenic site (26), and glycan-associated regions at the interface of gp120 and gp41 
(52, 53, 55). All except the MPER region represent conformational epitopes that span heavily 
glycosylated and/or structurally flexible protein domains. Since even the most cross-reactive 
CD4bs bNabs bind an area that extends well beyond the CD4 binding pocket (104), variation in 
adjacent Env regions can obstruct antibody binding and neutralization (76).  SIVcpz and SIVgor 
Envs vary extensively in regions surrounding the CD4 binding site (Fig. 2B), thus providing an 
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explanation for their resistance to CD4bs bNabs, including the smaller camelid antibodies (Figs. 2 
and 5). Ape viruses also vary in Env regions that are targeted by carbohydrate-associated bNabs, 
all of which require conservation of key N-linked glycosylation sites (Figs. 3 and 4). Since these 
are also variable in ape viruses, it is not surprising that almost all glycan dependent bNabs failed 
to cross-neutralize SIVcpz and SIVgor strains. Nonetheless, antibodies directed against the 
MPER region neutralized even the most divergent ape viruses (Fig. 6). 4E10 neutralized all 
SIVcpzPtt strains with a mean IC50 of 2.7 µg/ml (18.1 nM), but lacked activity against SIVgor and 
some SIVcpzPts strains. In contrast, 10E8 neutralized all 12 SIVcpz and SIVgor strains with an 
IC50 of 0.7 µg/ml (4.4 nM). The latter finding may be of interest for “neutralization finger printing” 
studies (105), since inclusion of SIVgor and select SIVcpzPts Envs into existing pseudovirus 
panels should permit the differentiation of 4E10-like and 10E8-like bNab specificities in polyclonal 
patient plasmas. 
 
Anti-receptor antibodies circumvent SIVcpz and SIVgor Env diversity. Antibodies 
raised against human CD4 and CCR5 receptors are known to inhibit HIV-1 in vitro (106) as well 
as reduce viral loads in infected patients in vivo (90). Here, we show that these antibodies also 
neutralize SIVcpz and SIVgor strains, both in cells expressing human as well as chimpanzee CD4 
and CCR5 receptors (Fig. 7). For example, iMab, which blocks HIV-1 infection by binding to the 
second domain (D2) of human CD4 (107), neutralized nearly all ape viruses with IC50 values 
ranging from 0.41 µg/ml (2.8 nM) in TZM-bl cells to 0.64 µg/ml (4.3 nM) in primary chimpanzee 
CD4+ T cells (Figs. 7 and 9, Tables 2 and 3). Similarly, LM52 a derivative of iMab with increased 
neutralization breadth (58), inhibited all 12 SIVcpz and SIVgor strains with IC50 values ranging 
from 0.12 µg/ml (0.77 nM) in TZM-bl cells to 0.68 µg/ml (4.5 nM) in primary chimpanzee CD4+ T 
cells. Finally, PRO140, which binds a complex epitope spanning multiple extracellular CCR5 
domains (108), neutralized all ape viruses with IC50 values ranging from 0.34 µg/ml (2.3 nM) in 
TZM-bl cells to 2.33 µg/ml (15.5 nM) in primary chimpanzee CD4+ T cells. Thus, anti-receptor 
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antibodies neutralized even the most divergent ape viruses in physiologically relevant target cells 
(Figs. 9 and 10; Tables 2 and 3). 
Although iMab achieved a 1 log reduction in virus titers in chronically HIV-1 infected 
humans (90, 106), a second anti-CD4 antibody (2D5) afforded only partial protection to rhesus 
macaques challenged with a simian/human immunodeficiency virus (SHIV) (109). Because anti-
receptor antibodies have to block all susceptible target cells, they may require antibody 
concentrations at the site of virus entry that are difficult to achieve in vivo (109). We thus tested 
bi-specific constructs, in which iMab, LM52 and PRO140 were linked to the antigen binding 
domains of potent anti-HIV-1 bNabs. Indeed, iMab-PG9, iMab-PG16 and LM52-PGT128 were 
able to outperform iMab and LM52 (Figs. 7, Table 3), but only when used to neutralize the few 
ape viruses that were sensitive to PG9, PG16 and PGT128 (Fig. 3). However, the bi-specific 
PRO140-10E8 neutralized all SIVcpz and SIVgor strains with up to 20-fold increased potency, 
regardless whether TZM-bl, Cf2Th-ch or primary chimpanzee CD4+ T cells were used as target 
cells (Figs. 7, 9, 10; Tables 2 and 3). Of all anti-receptor antibodies tested, PRO140-10E8 was by 
far the most potent, neutralizing 100% of ape viruses with IC50 values ranging from 0.03 µg/ml 
(0.13 nM) in TZM-bl to 0.75 µg/ml (3.6 nM) in chimpanzee CD4+ T cells (Fig. 10). These findings 
are consistent with the idea that bi-specific anti-receptor antibodies exhibit enhanced neutralizing 
capacity because they concentrate anti-Env bNabs at the site of virus entry (59). It will be 
important to test PRO140-10E8 in the SHIV/macaque model to determine whether its in vitro 
potency will translate into in vivo protection.  
 
Bi-specific receptor mimetics confer broad anti-SIVcpz and anti-SIVgor activity. 
Several studies have shown that CD4 containing immunoadhesins exhibit considerable anti-HIV-
1 activity and even protected a subset of macaques from SIVmac infection (31, 110). Among 
these, constructs that use receptor mimicry to simultaneously engage both the CD4 and CCR5 
binding sites are the most potent (61, 62). These include CD4-CD4i reagents, in which the D1D2 
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of CD4 is linked to the heavy chain variable region of a CD4 induced (CD4i) antibody, as well as 
CD4-Ig based constructs that contain short CCR5-mimetic sulfopeptides on their C-terminus (Fig. 
8A). Although both CD4-CD4i and eCD4-Ig constructs neutralized human and ape viruses with 
nanomolar potency (Table 3), we were particularly interested in eCD4-Ig, because of its smaller 
size as well as extensive in vitro and in vivo characterization. Recent studies demonstrated that 
eCD4-Ig not only neutralizes difficult-to-neutralize (tier 2 and 3) strains of HIV-1, but also inhibits 
HIV-2 and SIVmac viruses with IC50 values of less than 0.01 µg/ml (0.1 nM). Moreover, a rhesus 
macaque adapted form of eCD4-Ig (rh-eCD4-Ig) was able to protect monkeys from multiple low 
dose intravenous SHIV challenges when expressed from a recombinant AAV-vector (62). Given 
these findings, we expected eCD4-Ig to inhibit ape viruses with similar breadth and potency. 
However, this was only partially the case. Although eCD4-Ig neutralized 100% of SIVcpz and 
SIVgor strains, IC50 values were ~50-fold higher than those previously reported for HIV-1, HIV-2 
and SIVmac strains (62). Moreover, this potency was not improved when modified versions of 
eCD4-Ig (eCD4-Igmim2, eCD4-IgQ40A) were used that exhibit enhanced anti-HIV-1 activity (Fig. 8B, 
Table 3). Overall, eCD4-Ig neutralized SIVcpz and SIVgor strains only five-fold more potently 
than CD4-Ig, compared to a 20- to 200-fold improvement for HIV-1 strains (62).  Thus, eCD4-Ig 
neutralized ape viruses with the desired breadth, but not with the desired potency.  
Although a crystal structure of eCD4-Ig in complex with the HIV-1 Env is not available, 
modeling suggests that eCD4-Ig binds the HIV-1 Env trimer in a “claw-like” fashion, with two 
sulfopeptides and one CD4 moiety engaging two protomers within the same Env spike (62). 
Cross-linking of spike protomers has recently been shown to increase neutralization potency of 
antibody-like molecules by more than 100-fold (111). It is thus tempting to speculate that the 
architecture of the SIVcpz/SIVgor envelope spike differs from that of HIV-1, HIV-2 and SIVmac 
strains in such a way that one or more of the eCD4-Ig interaction sites are altered or occluded. It 
is also possible that the human CD4i antibody derived E51 peptide does not properly mimic the 
binding of the chimpanzee and gorilla CCR5 co-receptors, which differ from human and macaque 
CCR5 molecules in one or two amino acids near the N-terminus (88). It should be noted that 
	  130	  
	  
replacing the human CD4 D1D2 domains with the corresponding chimpanzee CD4 D1D2 regions 
in eCD4-Ig did not increase its potency against ape viruses (unpublished). Since there are no 
SIVcpz/SIVgor specific bNabs whose Fab fragments could be used for intra-spike crosslinking, it 
will be important to determine whether the ape virus neutralizing capacity of eCD4-Ig can be 
improved by altering the length and/or flexibility of the IgG Fc hinge region and/or by improving 
the binding of the CCR5 mimetic peptide. 
 
Vectored antibody gene transfer to combat ape pathogens. Wild ape populations will go 
extinct unless there is a comprehensive approach to their conservation, which -- under certain 
circumstances -- may need to include medical interventions (19, 25). We have shown in the past 
that SIVcpz infection can have a substantial negative impact on the health, reproductive success 
and longevity of chimpanzees in Gombe (2, 3). Because infected chimpanzees in Gombe are 
individually known, it would be possible to use vectored antibody gene transfer to administer a 
cocktail of neutralizing antibodies. This may not only benefit the infected individuals, but may also 
reduce their ability to transmit SIVcpz, which in an isolated population such as Gombe could lead 
to virus extinction. Vectored antibody gene delivery, alone or in combination with long-acting 
antiretrovirals (112, 113), could also be used to treat SIVcpz infected chimpanzees in African 
sanctuaries (114) and/or to vaccinate orphaned chimpanzees prior to releasing them into the wild 
(115). Finally, vectored antibody gene delivery may be effective against other pathogens, such as 
anthrax and Ebola (116, 117). Obviously, delivered antibodies must be sufficiently potent and 
expression levels must be sufficiently high to be effective in vivo, but this seems achievable. As 
shown recently, AAV-delivered rh-eCD4-Ig protected macaques from repeated low-dose 
intravenous SHIV challenge at serum concentrations as low as 17 µg/ml (62). Moreover, AAV-rh-
eCD4-Ig was much less immunogenic than other antibody-based AAV constructs, and functional 
rh-eCD4-Ig was stably expressed for 40 weeks at concentrations ranging between 17 and 
77 µg/ml (62). Obviously, efforts to treat and/or vaccinate wild ape communities would only be 
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contemplated if their survival was in serious jeopardy and if the safety, efficacy and delivery of the 
particular intervention were first demonstrated in captivity. However, given the increasing threat of 
infectious diseases to ape survival, there is an urgent need to explore new ways to curb the 
spread of pathogens in wild populations. Although further improvements will be necessary, the 
finding of several antibody-like constructs that are capable of neutralizing SIVcpz and SIVgor 
strains with nanomolar potency suggests that this goal can be achieved. 
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Section 3.5 – Materials and Methods 
 
Infectious molecular clones. Full-length infectious molecular clones (IMCs) of HIV-1 strains 
SG3 (118), YU2 (119) and JRCSF (120), SIVcpzPtt strains EK505 (70), GAB1 (67), GAB2 (68), 
MB897 (70), and MT145 (70), SIVcpzPts strains BF1167 (7), TAN1 (69), TAN2 (69), and TAN3 
(69) and the SIVgor strain CP2139 (15) have previously been reported. To generate additional 
IMCs, consensus SIVcpzPtt (LB715) and SIVcpzPts (TAN13) sequences were generated from 
two additional fecal samples (69). Briefly, partially overlapping subgenomic fragments were 
amplified from fecal RNA, gel purified, and sequenced directly. Chromatograms were examined 
for positions of base mixtures, and ambiguous sites were resolved as previously reported (69). 
The resulting proviral consensus sequences were synthesized in 3 non-overlapping fragments 
(Blue Heron Biotechnology) and ligated using internal restriction enzyme enzymes. In addition, 
Not1 and Mlu1 restriction enzyme sites were added to the 5' and 3' termini to enable directional 
cloning into a modified (low copy number) pBR322 vector (15). Since full-length SIVcpz and 
SIVgor molecular clones are notoriously unstable, plasmids were grown in MAX Efficiency Stbl2 
competent cells (Invitrogen) at 30°C, harvested before reaching saturating density, and each IMC 
was completely sequenced prior to biological analyses to confirm its integrity. The newly derived 
SIVcpz clones LB715 and TAN13 have been submitted to the National Institutes of Health 
Research and Reference Program (Rockville, MD) and their nucleotide sequences are available 
at GenBank. 
Phylogenetic analysis. Amino acid sequences inferred from env genes of HIV-1 (YU2, 
GenBank accession number M93258; JRCSF, M38429; and SG3, L02317), SIVgor (CP2139.287, 
FJ424866), and SIVcpz (LB715, JX178450; MB897, EF535994; GAB2, AF382828; MT145, 
DQ373066; EK505, DQ373065; GAB1, X52154; TAN2, EF394357; TAN3, EF394358; TAN1, 
EF394356; TAN13, JQ768416; BF1167, JQ866001) strains were aligned using ClustalW (121), 
with regions that could not be unambiguously aligned excluded from the analysis. PhyML (version 
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3) was used to estimate the phylogeny based on a JTT model of amino acid replacement chosen 
using ProtTest (version 10.2) and a second-order AIC framework (122-124). Ten random-
addition-order trees and a neighbor joining tree were likelihood-optimized using subtree pruning-
regrafting (SPR) searches. Bayesian posterior probabilities were estimated with MrBayes using a 
mixed prior model (125). 
Chimpanzee plasma. Plasma samples were obtained from eight chimpanzees, who had 
been experimentally infected with HIV-1 and/or SIVcpzANT decades earlier as part of AIDS 
pathogenesis and/or vaccine studies (Table 1). Seven of these chimpanzees were sampled at the 
National Chimpanzee Sanctuary Chimp Haven in Keithville, Louisiana, while the remaining 
animal (Debbie) was sampled at the Southwest National Primate Research Center (SNPRC) in 
San Antonio, Texas. For Marc (21), Joye (23), Tika (22), Artica (23), Debbie (20) and Cotton (20), 
detailed infection histories and clinical follow-up studies have been reported; however, this 
information was not available for the remaining two animals. Blood samples were collected for 
veterinary purposes in the context of health examinations. Plasma samples were analyzed for the 
presence of virus-specific antibodies using an enhanced chemiluminescent Western blot assay 
as previously described (9). Plasma samples were also tested for viral loads: For HIV-1 infected 
chimpanzees, this was done using the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 
(Roche). For SIVcpzANT infected chimpanzees, a previously reported quantitative (q)PCR 
designed to detect both HIV-1 and SIVcpz vRNA was used (126). In addition, SIVcpzANT viremia 
was confirmed by amplifying and sequencing a virus-specific 1.3 kb gag-pol fragment from 
plasma viral RNA (Table 1). Sample collection was approved by the Institutional Animal Care and 
Use Committee of Chimp Haven and SNPRC, respectively. 
 Virus stocks. HIV-1, SIVcpz and SIVgor infectious molecular clones (8 µg) were 
transfected into 293T cells and culture supernatants harvested 72 hours later. Viral stocks were 
tested for infectivity using TZM-bl cells, a HeLa-derived line that constitutively expresses CD4, 
CCR5 and CXCR4 receptors, and contains integrated luciferase and b-galactosidase reporter 
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genes under the control of an HIV-1 LTR (127). TZM-bl cells (8,300 cells per well) were seeded in 
96-well plates overnight, incubated with 10-fold serial dilutions of transfection stocks for 48 hours 
to allow single round infection, and infectious units (IU) were determined by counting the number 
of β-galactosidase expressing cells.   
 TZM-bl based neutralization assay. The neutralizing capacity of chimpanzee plasma, 
anti-HIV-1 monoclonal antibodies, and immunoadhesins was assessed using the TZM-bl assay 
as previously described (128, 129). Briefly, TZM-bl cells were seeded in 96 well plates (8,300 
cells per well) overnight in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal 
bovine serum (FBS). Serial (5-fold) dilutions of chimpanzee plasma (1:20, 1:100, 1:500, 1:2,500, 
1:12,500) or anti-HIV-1 monoclonal antibodies and immunoadhesins (10, 2, 0.4, 0.08, 0.016 
µg/ml) were incubated with 4,800 infectious units (IU) of transfection derived virus in a total 
volume of 100 µl in the presence of DEAE-dextran (40 µg/ml) for one hour at 37°C, and this 
mixture was then added to TZM-bl cells in 96 well plates. After 48 hours, TZM-bl cells were 
analyzed for luciferase expression using a Synergy H4 Hybrid microplate reader (Bio-Tek) with 
Gen5 version 1.11 software. To test the neutralization capacity of anti-CD4 and anti-CCR5 
receptor antibodies, 5-fold serial dilutions (10, 2, 0.4, 0.08, 0.016 µg/ml) were incubated with 
TZM-bl cells in a volume of 50 µl for one hour at 37°C, followed by the addition of virus (4,800 IU 
in 50 µl) in the presence of DEAE-dextran (40 µg/ml) and further incubation of 48 hours at 37°C. 
Controls included untreated cells and virus pretreated with normal human plasma or no antibody.  
Relative infectivity was calculated by dividing the number of luciferase units at each plasma and 
antibody/immunoadhesin dilution with values obtained for wells that contained normal human 
plasma or no antibody. Half-maximal inhibitory concentrations (IC50) were determined by linear 
regression. All monoclonal antibodies were tested in duplicate on three independent occasions. 
Since available amounts of chimpanzee plasma were limited, samples were tested only once in 
duplicate. 
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 Cf2Th based neutralization assay. To test the neutralization capacity of anti-host 
receptor antibodies, we transiently transfected Cf2Th cells with plasmids expressing the 
chimpanzee CD4 and CCR5 genes.  These canine thymus derived cells do not naturally express 
CD4 or CCR5, but contain a firefly luciferase reporter gene stably integrated under the control of 
an HIV-1 LTR (2, 3, 130). To generate a chimpanzee CD4 expression plasmid, we extracted RNA 
from chimpanzee peripheral blood mononuclear cells (PBMCs) and used RT-PCR to generate a 
cDNA clone of the entire CD4 coding region. Since the chimpanzee CD4 gene is polymorphic 
(71), we selected one allele that is most predominant in chimpanzees from Gombe National Park. 
Using site-directed mutagenesis, we then “humanized” this cDNA clone by changing three amino 
acids to match the (non-polymorphic) human CD4 protein (T34I, V55A and G88E). To generate a 
chimpanzee CCR5 expression plasmid, we first amplified the human CCR5 gene from PBMC 
RNA, and then introduced a single (chimpanzee-specific) amino acid substitution (N13D) by site-
directed mutagenesis. These expression plasmids were then used to transfect Cf2Th cells in 10 
cm dishes at 50% confluency to generate cells that expressed either chimpanzee or human 
CCR5 and CD4 receptors. 24 hours post-transfection, Cf2Th cells were trypsinized and plated in 
96 well plates at a concentration of 6,000 cells per well in DMEM containing 3.5% FBS. 
Transfected cells were cultured overnight, incubated with serial (5-fold) dilutions (10, 2, 0.4, 0.08, 
0.016 µg/ml) of mono- and bi-specific anti-CD4 (iMab, LM52, iMab-PG9, iMab-PG16, LM52-
PGT128) and anti-CCR5 (PRO-140, PRO-140-10E8) antibodies in a volume of 50 µl DMEM for 
one hour, and then infected with 50 µl of virus stock (5,000 IU) in the absence of DEAE dextran, 
which is toxic to Cf2Th cells. After 48 hours, Cf2Th cells were lysed and analyzed for luciferase 
expression using a Synergy H4 Hybrid microplate reader (Bio-Tek) with Gen5 version 1.11 
software.  Relative infectivity was calculated by dividing the luciferase units of wells containing 
antibodies by the luciferase units of wells lacking antibodies. Half-maximal inhibitory 
concentrations (IC50) were determined by linear regression. HIV-1/SG3, which requires CXCR4 
for entry, was used as a negative control.  All monoclonal antibodies were tested in triplicate and 
the average of 3 replicates is reported. 
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CD4 T cell based neutralization assay.  Left-over blood samples from health 
examinations of uninfected chimpanzees housed at the Yerkes Regional Primate Center were 
shipped at room temperature (131) and peripheral blood mononuclear cells (PBMCS) were 
isolated by gradient centrifugation using Ficoll-Paque Plus (GE Healthcase Life Sciences). 
Chimpanzee CD4+ T cells were enriched using non-human primate CD4 MicroBeads (MACS 
Miltenyi Biotec) and magnetic cell sorting (Militenyi Biotec), stimulated with staphylococcal 
enterotoxin B (Sigma-Aldridge) for 12 to 15 hours (3 µg/ml), and subsequently co-cultivated with 
autologous monocyte-derived macrophages for optimal activation. After 5 to 6 days, CD4+ T cells 
were removed from the macrophage feeder layer, placed into DMEM with 10% FBS, and 
incubated with 30 U/ml interleukin-2 (IL-2). To test the neutralizing capacity of anti-HIV-1 
monoclonal antibodies and immunoadhesins, serial dilutions (10, 3.3, 1.1, 0.36 and 0 µg/ml) were 
incubated with SIVcpzMT145 and HIV-1/SG3 viral stocks (10,000 IU) for one hour at 37°C, and 
the mixture was then added to 5x105 activated chimpanzee CD4+ T cells in a total of 500µl 
DMEM containing 10% FBS and 30 U/ml IL-2. The CD4bs antibody VRC01 and uninfected cells 
were used as negative controls. To test the neutralizing capacity of anti-receptor antibodies, serial 
dilutions (10, 3.3, 1.1, and 0.36 µg/ml) were first incubated with 5x105 activated chimpanzee 
CD4+ T cells for 1 hour at 37°C and then exposed to 10,000 IU of virus stocks. After an overnight 
incubation, cells were washed three times with PBS to remove antibody and non-cell associated 
virus, suspended in DMEM with 10% FBS and 30 U/ml IL-2, and plated in triplicate in 96 well 
plates. Supernatant (50 µl) was harvested every 48 hours, starting at day 3 post infection, and 
replaced with fresh media. To monitor viral replication, supernatants were tested for reverse 
transcriptase (RT) activity using a colorimetric assay (Roche). Neutralization was calculated by 
dividing the infectivity (RT activity) of wells with antibody dilutions by the untreated control wells. 
IC50 values were calculated by linear regression. All monoclonal antibodies were tested in CD4+ T 
cells from three different chimpanzee donors.  
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Statistical analyses. Statistical analyses were performed using Prism version 5.0d 
software (GraphPad) and correlations were assessed using Spearman tests.   Geometric mean 
IC50 values were calculated using Microsoft Excel version 14.3.9 software. 
Nucleotide sequence accession numbers. The nucleotide sequences of SIVcpz 
strains LB715 and TAN13 as well as the chimpanzee CD4 and CCR5 genes used for transfection 
are available under Genbank accession numbers JX178450.1, JQ768416, KP235488 and 
KP235489, respectively. 
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SECTION 4.1 – ABSTRACT 
 
Background: Simian immunodeficiency virus of chimpanzees (SIVcpz), the precursor of human 
immunodeficiency virus type 1 (HIV-1), causes increased mortality and AIDS-like 
immunopathology in infected chimpanzees (Pan troglodytes) in the wild. Surprisingly, however, 
similar findings have not been reported for captive chimpanzees with experimental SIVcpz 
infection, raising question about the intrinsic pathogenic potential of this chimpanzee lentivirus.  
Findings: Here, we report the first case of SIVcpz-associated immunodeficiency in a captive 
western chimpanzee (P. t. verus), who was infected twenty years ago by intrarectal inoculation 
with an SIVcpz strain (ANT) from a wild-caught eastern chimpanzee (P. t. schweinfurthii).  
Maintaining virus loads of 105 to 106 viral copies per ml of plasma for the past 15 years, this 
chimpanzee developed CD4+ T cell depletion (220 cells/µl), thrombocytopenia (90,000 
platelets/µl), and persistent soft tissue infections refractory to conventional antibiotic therapy. 
Combination antiretroviral therapy consisting of emtricitabine (FTC), tenofovir disoproxil fumarate 
(TDF), and dolutegravir (DGV), resulted in a precipitous decline of plasma viremia (<200 copies 
per ml) and the rapid resolution of all soft tissue infections. However, difficulties associated with 
oral administration led to low drug levels in the plasma and the development of FTC resistance 
mediated by escape mutations identical to those observed in HIV-1 infected humans (M184V/I). 
Conclusions:  These data indicate that SIVcpz can cause CD4 T cell decline and AIDS-like 
immunodeficiency in chimpanzees of all major subspecies, including P. t. verus apes that are not 
naturally infected with SIVcpz.  Moreover, SIVcpz-associated immunodeficiency can be 
effectively treated with drugs developed for HIV-1, including infections with strains as divergent as 
SIVcpzANT.  However, just like in HIV-1 infected humans, strict adherence must be ensured to 
prevent the emergence of drug resistance.  
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SECTION 4.2 - FINDINGS 
  
  SIVcpz naturally infects members of two subspecies of the common chimpanzee (Pan 
troglodytes), the central subspecies (P. t. troglodytes) in west central Africa and the eastern 
subspecies (P. t. schweinfurthii) in the Democratic Republic of the Congo (DRC) and countries to 
the east [1-5]. The other two subspecies in west Africa (P. t. verus) and Nigeria/Cameroon (P. t. 
ellioti) are not naturally infected with this virus [3, 6, 7], because SIVcpz represents a complex 
recombinant of ancestors of SIVs infecting monkeys on which chimpanzees prey [8]. This mosaic 
genome structure, which is a hallmark of all SIVcpz strains, indicates that chimpanzees acquired 
SIVcpz by cross-species transmission, but only after P. t. verus and P. t. ellioti had diverged and 
were geographically separated from the other two subspecies [6, 8]. Like HIV-1 in humans, 
SIVcpz has been found to be pathogenic in wild-living chimpanzees. Comprehensive natural 
history studies in Gombe National Park, Tanzania, revealed that SIVcpz-infected chimpanzees 
have a 10-16 fold increased risk of death, and can develop CD4+ T cell depletion and an AIDS-
like immunopathology [9, 10].  Moreover, SIVcpz infected females exhibited lower birth rates and 
higher infant mortality compared to non-infected females [9], and one community with high 
SIVcpz prevalence rates suffered a catastrophic population decline [11].  Thus, SIVcpz differs 
from non-pathogenic SIVs, such as those infecting sooty mangabeys and African green monkeys, 
in its ability to cause clinical immunodeficiency and premature death [9-11]. 
  P. t. verus comprises the great majority of captive chimpanzees worldwide, with 95% of 
founder animals in the United States having originated in West Africa [6, 12].  This explains the 
paucity of SIVcpz infections in US and European primate centers, although a handful of wild-born 
SIVcpz infected P. t. troglodytes and P. t. schweinfurthii apes have been identified in African 
sanctuaries [12-16].  One P. t. troglodytes ape (Goran, CAM155) rescued in Cameroon and 
studied in captivity for several years developed CD4 T+ cell decline, severe thrombocytopenia, 
weight loss, and recurring infections, and ultimately died of an AIDS-like illness [13]. A second P. 
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t. schweinfurthii ape (Noah) captured in the DRC and subjected to immunological and virological 
analyses in a European primate center also exhibited thrombocytopenia and some 
immunopathology [17], but was lost to follow-up after the transfer to a rescue center for exotic 
animals in the Netherlands. A third P. t. troglodytes ape (Marilyn), who was wild-caught in Africa 
and utilized for biomedical research in the US, had normal laboratory and clinical findings, but 
died at age 26 after giving birth to still-born twins [14]. Finally, a number of bushmeat orphans 
identified in Gabon (GAB1 and GAB2) and Cameroon (CAM3, CAM4, CAM5, CAM13) were 
shown to be SIVcpz infected, but none of these were studied prospectively since most died 
shortly after being rescued [15, 16]. Thus, only three naturally SIVcpz infected apes have been 
studied longitudinally for an extended period of time. 
In addition to bushmeat orphans, who acquired SIVcpz prior to their rescue, a handful of 
chimpanzees have also been experimentally infected with SIVcpz in captivity [17, 18].  Of eight P. 
t. verus apes that were exposed to the same strain of SIVcpz (ANT) by various routes (intra-
venous, intra-rectal, and intra-vaginal), six became productively infected [18]. Three of these 
subsequently died of cardiomyopathy, a frequent cause of death in captive chimpanzees 
unrelated to SIV infection, while the other three remained clinically healthy after as many as 16 
years post-infection. The seeming absence of disease progression in these animals prompted 
speculation that the increased mortality associated with SIVcpz in the wild was due to factors 
other than, or in addition to, the lentiviral infection [17].  It was also suggested that members of 
the P. t. verus subspecies, which are not naturally infected, may be relatively more resistant to 
SIVcpz pathogenicity and/or that the SIVcpzANT strain used for experimental infection was 
somehow attenuated [17].  Here, we studied one of these chimpanzees after an additional 4-year 
follow-up, documenting disease progression and clinical immunodeficiency requiring antiretroviral 
therapy.   
 Examining the neutralizing antibody responses in long-term HIV-1 and SIVcpz infected 
chimpanzees [19], we previously discovered that one SIVcpz infected chimpanzee at the Chimp  
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Fig. 1. SIVcpz infection in Cotton.  (a) Cotton (Ch-115) after initiation of antiviral therapy. (b) Determination 
of plasma virus load using a validated RT-qPCR method that detects both SIVcpz and HIV-1 [35]. The date 
when antiretroviral therapy was first initiated (01-19-15) is shown by a red dashed line.  (c) Alignment of HIV-
1 clade B and SIVcpzPts sequences in the LTR region.  Positions where any one of the sequences differs 
from the others are highlighted in red (A), green (T), orange (G), and blue (C), with dashes denoting gaps 
introduced into the alignment.  The locations of the primers used to amplify this region are shown in black. 
Haven sanctuary exhibited particularly high plasma viral loads.  This 39-year old male, named 
Cotton (also termed Ch-115; Fig. 1a), had been experimentally infected with SIVcpz in 1996 after 
an initial inoculation with HIV-1 [18]. The virus stock was generated by transferring blood from an 
infected wild-caught eastern chimpanzee (Noah, Ch-No) [20] to his uninfected cage mate (Niko; 
Ch-Ni), and using plasma collected during the acute phase of the infection for intra-rectal 
inoculation [18].  Follow up studies showed that Cotton experienced an initial drop in CD4+ T 
cells counts immediately after SIVcpz infection, followed by the partial restoration and then 
gradual decline of CD4 T cell counts over time [17].  The most recent CD4+ T lymphocyte counts, 
performed 18 years post-infection, showed 220 cells/µl (Table 1), compared to 1,500 cells/µl 
before the infection [17]. Cotton also had a low platelet count of 90,000/ul (normal range 130,500 
- 379,930/µl) [21], indicating thrombocytopenia, low albumin levels (2.0 g/dL, normal range 3.3-
4.1 g/dL) [21], suggesting malnutrition or chronic inflammatory disease, and persistent soft tissue 
infections (Table 1). The latter were first noted after his arrival at Chimp Haven and included a 
necrotizing infection of the hand as well as purulent anal fistulas of the butt pad that persisted 
despite repeated debridement and administration of multiple rounds of broad-spectrum antibiotics 
over the course of several months (Table 1). The low CD4+ T cell counts, thrombocytopenia, 
hypoalbuminemia, and treatment-refractory soft tissue infections strongly suggested that Cotton 
suffered from SIVcpz induced immunodeficiency. 
To confirm that Cotton’s clinical symptoms were indeed a consequence of long-term 
SIVcpz, and not HIV-1, infection, we determined his virus load in the most recent plasma sample 
as well as in a limited number of archived samples that were still available for the period between  
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Table 1: Clinical history of Ch-115 since his arrival at Chimp Haven sanctuary in 2006 
Date Clinical symptoms Treatment Initiated Platelets (per ul) 
CD4+ T 
cell count 
(cells/ul) 
Viral load 
(copies/ml) 
12/15/09 Wound on hand     
12/19/09 Infection of hand  Oral antibiotics for 7 days    
1/4/10 Necrotizing infection of hand Debridement    
9/15/10    229  
11/20/11 Draining fistula near anus Antibiotic wash    
9/25/12     1,440,622 
10/25/14 Draining fistula near anus 
Oral antibiotics for 7 
days    
11/2/14 Draining fistula near anus 
Oral antibiotics for 7 
days    
11/6/14 
Multiple fistulas 
near anus with 
thick exudate and 
sloughing skin 
Oral antibiotics for 14 
days    
11/10/14 Bloody diarrhea Ulcer medication     
11/19/14 Draining fistula near anus 
Oral antibiotics for 7 
days    
11/25/14 Draining fistula near anus 
i.v. and topical 
antibiotics 101,000 220 861,000 
12/2/14 Draining fistula near anus Antibiotics for 30 days    
12/9/14 Exudate near anus still present     
1/19/15 
Initiation of 
combination 
antiretroviral 
therapy 
Truvada (emtricitabine 
200 mg / tenofovir 
disoproxil fumarate 
300 mg) and 
dolutegravir (50 mg) 
   
2/10/15 Anal fistulas completely healed     
3/12/15 Blood analysis    167 
9/25/15 Blood analysis  90,000  4,760 
3/16/16 Blood analysis  91,000  631 
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1999 to 2014. Since Cotton was exposed to HIV-1 prior to SIVcpzANT inoculation [18], we used a 
sensitive RT-qPCR method designed to amplify both HIV-1 and SIVcpz strains by targeting highly 
conserved regions in the viral LTR [22]. This analysis revealed plasma viral titers ranging from 
54,000 RNA copies/ml in 2001 to 1,441,000 RNA copies/ml in 2012 (Fig. 1b), significantly higher 
than previously reported for some of these same time points [17]. Since our RT-qPCR approach 
was rigorously validated, using both human and chimpanzee plasma samples of known viral 
content as determined independently by a clinical laboratory, the previous results likely represent 
an underestimation of Cotton’s viral loads. To determine whether SIVcpz, HIV-1, or both 
comprised Cotton’s infection, we sequenced the 121 base pair LTR region used for RT-qPCR 
analysis (Fig. 1c). Amplicons were prepared for next-generation sequencing (Nextera DNA 
Library Prep Kit, Illumina, La Jolla, CA, USA), run on a MiSeq (Illumina, La Jolla, CA, USA), and 
the resulting reads were mapped to available HIV-1 and SIVcpz reference sequences 
(SIVcpzANT has not been sequenced in the LTR region).  This approach yielded 11,679 paired 
reads, all of which mapped to SIVcpzPts sequences (Fig 1c), indicating that Cotton was solely 
infected with SIVcpzANT.  
Longitudinal samples for SIVcpz infected chimpanzees are extremely rare. To examine 
the patterns of SIVcpz diversification, we used single genome sequencing (SGS) to characterize 
his env quasispecies over time [23]. Briefly, plasma RNA was extracted, reverse transcribed, and 
the resulting cDNA end-point diluted to single template levels. 3’ half genomes were amplified as 
described [24], subjected to MiSeq sequencing, and amplicons comprising more than one variant 
discarded. Phylogenetic analysis of the resulting env gene sequences revealed progressive 
diversification (Fig. 2a), similar to what has been described for HIV-1 infected individuals [25]. For 
example, the C2-V5 region of the HIV-1 env gene has been shown to diverge at a rate of 
approximately 1% per year, stabilizing after 4 to 6 years at around 4-8% diversity [25]. Using 
DIVEIN [26] to determine env gene diversity in Cotton, we found lower mean diversity values of 
1.5 – 3.5% (Fig. 2b), but a similar rate of divergence of 0.77% per year, as measured by linear  
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Fig. 2. Evolution of the SIVcpzANT env quasispecies over time. (a) Phylogenetic analysis of SGS-derived 
full-length env nucleotide sequences collected at different timepoints following infection.  Samples are 
colored by timepoint and bootstrap values are indicated.  The scale bar indicates 0.005 substitutions per site 
(b) Within sample diversity. The pairwise distance of each sequence shown in panel (a) from other 
sequences within the same sample is plotted.  Mean and SEM are indicated.  (c) Pairwise distance of each 
sequence shown in panel (a) from the year 2000 consensus sequence expressed as % divergence.  A black 
line connects the mean of each timepoint.
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regression (Fig. 2c). Of note, because our earliest sample was collected four years after the initial 
infection, we measured this divergence using the consensus sequence of the year 2000 time 
point. Excluding the last 2014 time point, the divergence rate was 0.92% per year, nearly identical 
to the 1% per year estimate for HIV-1 infected humans.  Estimates of viral divergence rely on 
sufficient sequencing depth, and further analyses may be required for more precise estimates. 
However, these results suggest that the rate of SIVcpz env evolution is very similar to that of HIV-
1.  
Given Cotton’s laboratory and clinical findings, combination antiretroviral therapy (cART) 
was initiated (Table 1), combining the nucleoside reverse transcriptase inhibitors tenofovir 
disoproxil fumarate (TDF) and emtricitabine (FTC) with the integrase strand transfer inhibitor 
dolutegravir (DGV), and administering daily doses of 300, 200 and 50 mg, respectively. This 
regimen was chosen because it potently inhibits HIV-1 and HIV-2 in humans [27-30], as well as 
SIVmac in experimentally infected rhesus macaques, a virus even more distantly related to HIV-1 
than SIVcpzANT [31]. As shown in Fig. 1b, cART reduced SIVcpzANT viremia in Cotton to 
undetectable levels at the first blood draw after initiation of therapy (Table 1).  Moreover, the 
treatment refractory anal fistulas healed completely within 6 weeks of onset of therapy (Table 1), 
demonstrating the effectiveness of this regimen in achieving viral control and clinical 
improvement.  
Cotton received cART daily by oral administration in fruit juice, but caretakers noticed that 
he frequently spit out or did not completely ingest his medication. We thus continued to monitor 
his virus load in blood samples obtained during his bi-annual medical evaluations. Indeed, six 
months following initiation of therapy, viremia became again detectable (4,760 RNA copies/ml) 
(Fig. 1b).  To determine whether this rebound was due to insufficient drug levels, one pre-
treatment and three post-treatment plasma samples were sent to the Clinical Pharmacology and 
Analytical Chemistry Core at the UNC Center for AIDS Research to determine plasma 
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concentrations. This analysis revealed drug levels that were significantly below the 90% inhibitory 
concentrations (IC90) of DGV (64 ng/ml) and FTC (51 ng/ml) [32, 33] and the 50% inhibitory 
concentration (IC50) of TDF (60 ng/ml) [34] for all three post treatment samples (Fig 3a). However, 
higher values were obtained after caretakers diluted the medication in more juice, which also 
resulted in a concomitant decline of viremia to 631 RNA copies/ml at the last time point. Since 
insufficient drug levels can lead to drug resistance [35], we used SGS to sequence full-length pol 
genes in pre- and post-treatment plasma samples. An amino acid alignment revealed the 
emergence of M184V and M184I mutations between the first and second post treatment samples 
collected at 3/12/15 and 9/25/15, respectively (Fig. 3b). These same mutations are known to 
confer resistance to FTC in HIV-1 infected humans, and usually are the first drug resistance 
mutations in a failing ART regimen [35, 36]. Mutations associated with TDF and DVG were not 
observed, even though drug levels were one log lower than the respective IC90 values. Following 
the discovery of the low drug concentrations and subsequent emergence of FTC resistance, the 
drug delivery strategy was changed from dissolving tablets in juice to adding crushed tablets to 
food.  
 Taken together, we report here the first case of clinical immunodeficiency in a captive 
western chimpanzee, who was experimentally infected with a naturally occurring SIVcpzPts 
strain.  While Cotton’s laboratory values do not meet the formal definition of AIDS (<200 CD4+ T 
cells per ul), his low CD4+ T cell count, refractory soft tissue infections, and marked clinical 
improvement after initiation of cART strongly suggests that SIVcpz caused his immunodeficiency. 
We also show that SIVcpz infection and associated immunodeficiency can be effectively treated 
with antiretroviral therapy developed for HIV-1, but that a lack of adherence to the drug regimen 
can result in the emergence of drug resistance mutations similar to what has been observed in 
HIV-1 infected humans.  Importantly, a considerable number of HIV-1 and SIVcpz infected 
chimpanzees are still housed in US primate centers. This study, together with previous reports of 
disease progression in experimentally HIV-1 infected chimpanzees [37-39], indicates that 
animalswith high viremia and reduced CD4+ T cell counts are at high risk of developing AIDS and 
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Fig. 3.  Emergence of resistance to FTC. (a) Plasma concentrations of tenofovir disoproxil fumarate (TDF, 
blue), emtricitabine (FTC, red), and dolutegravir (DTG, green) are shown for one pre-treatment and three 
post-treatment samples as depicted in Fig. 1b. Limits of detection (LOD) for FTC as well as TDF and DTG 
are shown as red and blue dotted lines, respectively.  (b) A map of the pol gene products is shown with 
mutations associated with TDF, FTC, and DTG resistance in HIV-1 infections outlined below. An amino acid 
alignment of the regions associated with resistance mutations is shown, with residues altered from the pre-
treatment consensus in color.  Residues identical to the pre-treatment consensus are shown in grey. 
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should be treated to prevent clinical disease.   
 This study also questions the hypothesis that SIVcpz may be intrinsically less pathogenic 
than HIV-1 or that SIVcpzANT is attenuated [17]. Of the six chimpanzees initially infected with this 
virus, three died of cardiomyopathy, a common cause of death in captive chimpanzees, with one 
of these animals (Niko) exhibiting a CD4+ T cell count of 276 cells/ul at the time of death [17].  In 
addition to Cotton, two other experimentally SIVcpz infected chimpanzees are still alive. One was 
reported to have a CD4+ T cell count of 115 cells per µl, which represents an AIDS-defining 
criterion [17], while the second animal (Ch-284) has thus far maintained low viral loads and 
normal CD4 counts 16 years post infection [17].  The average time to AIDS progression in 
untreated HIV-1 infected humans has been estimated to range between 10-15 years 
(www.who.int). Given the long survival times of some experimentally SIVcpz infected 
chimpanzees, it is possible that progression to disease is more protracted in captive settings, 
although the small number of animals that have been studied precludes definitive conclusions. 
The clinical and laboratory findings reported here for Cotton demonstrate that SIVcpz is a 
pathogenic lentivirus that can cause immunodeficiency and clinical disease both in captivity and 
in the wild.  
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Section 5.1  
 
Investigating SIVcpz Pathogenesis in the Gut 
 
 HIV-1 infection of humans is associated with significant gut pathology, including depletion 
of immune cells, disruption of intestinal barriers, immune activation, and diarrhea (4, 5).   
Consistent with this, several groups have associated dysbiosis of the gut microbiota with HIV-1 
infection (6-13).  To determine if SIVcpz infection has a similar impact on the gut of infected apes, 
I investigated the fecal microbiome of wild-living chimpanzees in Chapter 2.  Using 16S 
sequencing of longitudinal samples from 24 SIVcpz infected and 26 uninfected animals, I found 
no significant difference in bacterial abundances, or microbiome richness and evenness between 
these groups.  Principal coordinates analysis revealed that microbiomes of SIVcpz infected 
animals do not cluster together by beta diversity, and are instead interspersed with those of 
SIVcpz uninfected animals. These data suggest that unlike reports of HIV-1 infected humans, 
SIVcpz infection of chimpanzees is not associated with a distinct gut microbiome.  However, 
samples collected from animals within six months of their eventual AIDS-related death showed 
pronounced compositional shifts in the gut microbiota.  This destabilization was not observed in 
earlier samples from these animals, nor in samples taken from other animals within six months of 
non-AIDS-related deaths.  Studies of SIV infected rhesus macaques revealed an expansion of 
viral populations in fecal samples (14), so I also investigated the fecal virome of SIVcpz infected 
animals using metagenomic sequencing and quantitative PCR.  I found a trend towards increased 
titers of adenovirus, but no significant differences between infected and uninfected animals.   
 The disparity between reports of the microbiota in HIV-1 and SIVcpz infection could be 
due to differences in how the virus affects the gut or, alternatively, it could be due to differences in 
the cohorts tested.  The chimpanzees used in my study all share a common home range, diet, 
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have similar social interactions, and do not take any medications. Studies of humans are much 
harder to control for these factors.  Before the publication of my manuscript, studies of the gut 
microbiome of HIV-1 infected individuals utilized samples from European and American patients 
exclusively.  With sexual contact of men who have sex with men (MSM) being the most 
predominant mode of transmission in the US and Europe, samples from MSM likely comprised a 
majority of those tested.  Lifestyle differences (diet, exercise, etc.) are known to have a significant 
effect on the composition of the gut microbiota (15).  Thus, if not properly controlled, disparities 
between HIV-1 infected and uninfected individuals could be due to the lifestyle of HIV positive 
patients, rather than the infection itself.  In fact, a recent study published after the submission of 
my manuscript found that MSM had bacterial profiles very similar to those reported for HIV-1 
infected individuals, including a higher prevalence of Prevotella and increased richness and 
diversity compared to non-MSM individuals (16).  When controlling for sexual orientation, this 
group found no evidence for HIV-1 associated gut dysbiosis in two large European cohorts.  
Another group that investigated MSM HIV-negative controls found that these subjects exhibited a 
Prevotella-rich microbiome, previously associated with HIV-1 infection (17).  Only minor 
disturbances to the gut microbiome were observed in HIV positive individuals using this group of 
MSM controls (17). To my knowledge, no other group controlled for sexual practice in their 
studies of HIV and the microbiome.  Thus, the significant compositional changes observed in 
earlier reports of HIV-1 infected individuals may well be entirely the result of other factors 
associated with MSM individuals, instead of HIV-1 infection itself.  A recent report by Monaco and 
colleagues investigated the fecal microbiome of a cohort from Uganda, where heterosexual 
transmission predominates. They found that changes in microbiome composition and richness 
were only observed in patients with low CD4+ T cell counts (<200 cell/s ul), and were not 
associated with HIV status (18).  They also found an absence of clustering of HIV infected 
individuals using beta diversity measures, even in those with CD4+ T cell counts below 200 
cells/ul. While these findings require replication, they are consistent with our findings in SIVcpz 
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infected chimpanzees, with stability of the gut microbiome despite HIV-1/SIVcpz infection until 
progression to AIDS.   
 The virome of SIVcpz infected chimpanzees also seemed relatively unaffected compared 
to previous reports in the literature. A study of rhesus macaques showed dramatic expansion of 
gut viruses in SIVmac infected animals, including increased frequencies of multiple families of 
viruses (14). In comparison, I found only insignificantly increased frequencies of simian 
adenovirus. This may also be due to differences in the types of cohorts studied.  The SIVmac 
infected macaques used in the fecal virome study progressed very rapidly to AIDS, with several 
animals requiring euthanasia before the completion of the study.  In comparison, most of the 
animals included in my study had been infected for years with no observable signs of illness.  
Thus, proliferation of gut viruses might only be observed in animals experiencing the late stages 
of SIV infection.  In support of this, a more recent study of SIVmac infected macaques found an 
expansion of adenoviruses only in animals that rapidly succumbed to AIDS, and not those that 
survived through the duration of the study (19).  Importantly, these researchers also found that 
several families of viruses were significantly associated with gastrointestinal disease regardless 
of SIV infection, supporting the probable role of AIDS-related disease in virome expansion and 
not the infection itself.  A recent study of a Ugandan cohort found no differences in the 
frequencies of gut viruses between HIV-positive and negative subjects (18).  However, patients 
with a CD4+ T cell count less than 200 cells/ul showed increased frequencies of adenoviruses 
and anelloviruses.  Thus, two studies of both humans and macaques found adenoviruses to be 
associated with low CD4+ T cell counts. Adenovirus is a source of diarrheal disease and has 
been previously linked to SIV-associated pathology in the gut of infected macaques (14).  Long-
term longitudinal studies of clinical signs of illness in Gombe chimpanzees revealed that SIVcpz 
infected females showed significantly increased incidences of diarrhea (20).  In addition, an 
SIVcpz infected chimpanzee that exhibited diarrhea when sampled within a few months of his 
death showed the highest adenovirus titer of all of the animals tested in my study.  Thus, while 
not being a feature common to all infected animals, the insignificantly increased titers of 
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adenoviruses observed in SIVcpz infected wild chimpanzees may reflect SIV-associated 
pathology. 
 Based on my results and recent well-controlled studies in humans and macaques, 
dysbiotic microbiota seem to be associated only with late stages of disease and not HIV/SIV 
infection per se (Fig 5.1). Thus, it seems that many of the gut manifestations associated with HIV-
1 infection, including local CD4+ T cell depletion, immune activation, microbial translocation, and 
impairment of the gut barrier (4), are not sufficient to cause significant microbial dysbiosis.  
Instead, gut pathology associated with end-stage disease may be causing the observed 
alterations of gut microbiota. AIDS progression is often characterized by enteric disease, 
including the outgrowth of opportunistic infections that cause diarrhea (cytomegalovirus, 
Cryptosporidium, Giardia lamblia) and idiopathic diarrhea (21, 22). In addition, chronic wasting is 
a hallmark of AIDS, and is caused in part by gut malabsorption, highlighting the abnormal gut of 
AIDS patients. Thus, AIDS-associated symptoms such as diarrhea, gastrointestinal infections, 
lethargy, and decreased appetite may be to blame for the observed alteration of gut microbiota, 
rather than the virus itself, since these factors have been shown to also alter microbial 
communities in non-HIV infected patients (15, 23-26).  
Additional studies are needed to confirm the causes and consequences of SIVcpz and 
HIV-1-associated microbiome dysbiosis. Confirmation that HIV-1 infection is not sufficient to 
induce significant enteric microbial dysbiosis would require better-controlled studies of the 
American and European cohorts who originally showed microbiomes distinct from uninfected 
individuals.  Test groups and controls should have similar sexual practices, with similar diets and 
activity levels, and should be properly controlled for antibiotic and antiretroviral use. All of these 
factors impact gut microbial communities (15, 16, 27, 28) and may be significantly different 
between HIV-1 infected and uninfected individuals.   
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Fig. 5.1.  Model of the gut microbiome in SIVcpz infected chimpanzees based on results reported 
in Chapter 2, as well as studies in HIV-1 infected humans and SIV infected macaques. 
Destabilization of the gut microbiome occurs only at the end stages of SIVcpz infection. AIDS-
associated symptoms and gastrointestinal disease may destabilize gut microbial populations with 
opportunistic infections likely contributing. 
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Practical uses of the finding of dysbiotic bacteria in late-stage SIVcpz infection for the 
study of chimpanzees remains to be determined.  Given the lack of bacterial or viral species 
associated with progressive SIVcpz infection, the gut bacteriome and virome of SIVcpz infected 
chimpanzees are unlikely to be useful as markers of disease in non-habituated communities.  
However, detecting a rise of microbial beta diversity in a SIVcpz infected chimpanzee in Gombe 
could foreshadow rapid disease progression and death, prompting intensified observational 
studies to record signs of ill health associated with SIVcpz disease progression.  It could also help 
alert field workers to more closely track the animal’s whereabouts, in order to increase the 
likelihood of recovering tissues for necropsy, which is a rare occurrence in wild-living 
chimpanzees.   
A different fecal marker of disease progression would be extremely useful, especially in 
non-habituated ape communities where SIV-associated morbidity and mortality is near impossible 
to determine. In HIV-1 infected humans, plasma viral load is monitored as a sign of disease 
progression.  In wild chimpanzees, viral loads cannot be determined with accuracy, as 
quantitative RT-PCR (qRT-PCR) lacks the sensitivity to detect RNA in fecal samples. A qRT-PCR 
method was recently developed that targets the strong stop DNA region of viral genome and is 
broad enough to detect multiple groups of HIV-1 and SIVcpz and SIVgor strains (29).  I found that 
this method is able to detect SIVcpz in Gombe chimpanzee fecal samples, potentially because 
strong stop DNA is more stable than single stranded RNA.  However, I found fecal viral loads to 
vary substantially over time using this method.  The cause of this remains to be determined, but I 
suspect that sample degradation may strongly influence viral load estimations.  HIV-1 infection is 
known to cause inflammation of the gut (30), resulting in lymphocyte activation, increased virus 
replication, and accelerated disease progression (31, 32). Since it is impractical to assess 
cytokine mRNA levels or T cell activation markers in wild-living chimpanzees, we could use 
proteins associated with inflammation as alternative markers (33, 34). Fecal calprotectin, a by-
product of neutrophils, was found to be significantly increased in HIV-1 infected individuals (35, 
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36), and in preliminary studies, we have found this to also be true for SIVcpz infected 
chimpanzees. However, again we found fecal calprotectin values to be too variable in longitudinal 
samples to yield a reliable marker of disease progression.  Thus, further studies are needed to 
find a reliable marker of disease progression, which would also allow the monitoring of disease in 
non-habituated chimpanzees and SIV infected gorillas. 
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Section 5.2  
Anti-SIVcpz Interventions in Wild and Captive Chimpanzees 
 
 HIV-1 infection of humans can be readily controlled by antiretroviral therapy. However, 
treatment of wild-living chimpanzees with current antiretroviral regimens is not feasible.  
Nonetheless, chimpanzees are critically endangered by disease and habitat destruction, and 
SIVcpz infection is a component of their disease burden.  SIVcpz intervention strategies capable 
of translation to wild ape populations deserve further thought.  Broadly cross-reactive neutralizing 
antibodies (bnAbs) are exciting new tools being developed for long-term treatment and/or 
prevention of HIV-1.  In order to be useful for SIV infected chimpanzees, bnAbs would need to be 
capable of neutralizing diverse SIVcpz strains.  To test this, I examined the ability of existing HIV-
1 bnAbs for their ability to neutralize 11 SIVcpz strains derived from wild-living chimpanzees in 
Chapter 3.   I found that most bnAbs derived from chronically infected humans, including those 
targeting the CD4 binding site and glycan-dependent variable loop epitopes, failed to neutralize 
the majority of SIVcpz strains.  However, antibodies that mimic the CD4 or CCR5 (co)receptors 
were able to neutralize highly divergent SIVcpz strains.  In addition, antibodies that bind to CD4 
or CCR5 also potently blocked infection of SIVcpz strains.  This work provided new insight into 
the cross-reactivity of anti-HIV-1 reagents with SIVcpz, and also identified candidates that could 
be further developed for use in wild-living apes.  
 Given the very broad HIV cross-reactivity of some bnAbs, I was surprised to find only 
limited cross-neutralization of even the “best” anti-HIV-1 antibodies to SIVcpz.  All SIVcpz 
infectious molecular clones readily utilize human CD4 for entry, suggesting functional 
conservation of the CD4 binding site. In spite of this, all 10 of the most broad and potent CD4 
binding site antibodies failed to neutralize even a single SIVcpz strain, including at a high 
concentration of 10 ug/ml.  Analysis of the amino acid sequence of SIVcpz and HIV-1 strains 
revealed that the CD4 binding site of HIV-1 and SIVcpz are only conserved at CD4 contact 
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residues, and not surrounding motifs.  Most patient-derived antibodies targeting gp120 recognize 
complex conformational epitopes that span genetically and structurally flexible regions (37-40). 
Variation in the structure or sequence of these epitopes mediates resistance of HIV-1 strains to 
bnAbs (41).  The only envelope site of vulnerability that involves a linear epitope is the MPER 
domain (42, 43), which is uniquely sensitive to cross-neutralization of HIV-1 antibodies to SIVcpz 
strains.  Thus, variation in the structure, sequence, and glycosylation of the regions that are not 
required for effective entry likely preclude binding of anti-HIV-1 antibodies to SIVcpz. This 
suggests that the SIVcpz envelope could be conformationally distinct from HIV-1. SIVcpz has not 
been crystallized, so no structural information exists.  Structures of SIVcpz envelopes could 
reveal which sites are most highly conserved between HIV-1 and SIVcpz. These sites would likely 
include regions involved in HIV/SIV entry, and would contain the epitopes of antibodies that are 
most cross-reactive between HIV-1 and SIVcpz strains.  Such epitopes would not only be useful 
for generating reagents capable of neutralizing SIVcpz strains, they would also likely represent a 
highly conserved region amongst HIV-1 strains and could serve as targets for the development of 
HIV-1 antibodies through vaccination.   
 Engineered antibody-like proteins that mimic CD4/CCR5 and monoclonals that target 
CD4/CCR5 itself avoid the targeting of non-conserved regions.  These reagents are thereby 
capable of neutralizing diverse SIVcpz strains.  Considering the possibility of therapeutic or 
prophylactic use in chimpanzees, these reagents would need to be optimized to avoid clearance 
by the chimpanzee immune system, and to increase the potency to maximize their activity. To 
avoid anti-construct host immune responses, we could generate chimpanzee versions of the most 
potent constructs. Human and chimpanzee CD4 D1 domains differ at amino acids 34 (I34T), 55 
(A55V) and 88 (G88E). Of these, I34T creates an additional N-linked glycosylation site in close 
proximity to the HIV/SIV Env binding site, which may affect the neutralization properties of the 
immunoadhesins. Based on passive protection studies in macaques (44) and attainable rAAV-
mediated antibody expression levels (45-47), clinically suitable antibodies would need to 
neutralize SIVcpz with IC50 values of 0.01-0.1 µg/ml. Several anti-CD4 and CCR5 receptor 
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antibodies meet these criteria, since they neutralize 100% of SIVcpz strains with IC50 values 
<0.06 µg/ml both in human and chimpanzee cells. Immunoadhesins were also highly cross-
reactive, but neutralized SIVcpz strains with much reduced (up to 50-fold) potency compared to 
HIV-1. Of these, eCD4-Ig, which combines CD4 D1D2 with an IgG Fc and CCR5 mimetic 
sulfopeptides, is of particular interest because of its small size, exceptional potency against HIV-1 
and SIVmac (0.1 nM), and extensive in vitro and in vivo characterization (47). Recent data 
showed that the macaque version of eCD4-Ig was able to protect monkeys from multiple SHIV 
challenges when expressed from a recombinant AAV-vector (47). Since rh-eCD4-Ig also did not 
elicit unwanted anti-antibody responses in macaques, this receptor mimetic seems to represent 
an ideal candidate to combat SIVcpz infection. However, in order to be of clinical utility, its anti-
SIVcpz potency has to be increased. Modeling suggests that eCD4-Ig binds the HIV-1 Env trimer 
in a “claw-like” fashion, with two sulfopeptides and one CD4 moiety engaging two protomers 
within the same Env spike (47). I thus hypothesize that the architecture of the SIVcpz envelope 
differs from that of HIV-1 such that one or more of the eCD4-Ig interaction sites are altered or 
differently spaced. To test this hypothesis, we could utilize the “molecular ruler” approach 
developed in the Bjorkman laboratory, which utilizes DNA of known sizes to measure inter-
epitope distances on gp120 (48). Since successful cross-linking of spike protomers increases the 
neutralization potency of antibody-like molecules by more than 100-fold (48), we could use this 
approach to probe the overall architecture of the SIVcpz spike in comparison to that of HIV-1 and 
SIVmac, which are highly sensitive to eCD4-Ig. This information could then be used to modify the 
length and flexibility of the eCD4-Ig hinge region, which was previously shown to be critical for the 
neutralization capacity of eCD4-Ig in macaques. It is also possible that CCR5mim, a human CD4i 
antibody-derived peptide, does not optimally interact with the chimpanzee CCR5 co-receptor, 
which differs from human and macaque CCR5 in one and two amino acid residues near the N-
terminus, respectively (49). We could mutate this peptide in the chimpanzee version of eCD4-Ig, 
similar to what was done in human eCD4-Ig to improve its avidity and neutralization potency (50-
52).  We could also change the Fc portions of our antibodies or immunoadhesins to chimpanzee 
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IgG1 and/or IgG2 to ensure conservation of ADCC and other effector functions. 
 Before investigating safety and efficacy in chimpanzees, the candidate bNabs and 
immunoadhesins would first need to be tested in a smaller animal model.  Bone marrow-liver-
thymus (BLT) mice recapitulate human hematopoietic lineages in a mouse model (53-55), and 
may serve as an effective model given the ability of SIVcpz strains to establish infection in human 
PBMCs. One group recently investigated the ability of BLT mice to support SIVcpz infection, and 
found that multiple SIVcpz strains replicated efficiently in this model (56). Immunodeficient NSG 
mice could alternatively be reconstituted with chimpanzee PBMCs, as was already performed 
using macaque cells (165). I performed a small pilot study in NSG mice reconstituted with primary 
human CD4+ T cells (n=6) and found that SIVcpz replicates efficiently in these animals and that 
viral loads can be transiently reduced following the administration of potent antibodies. Two mice 
were treated with a cocktail (0.5 mg) of two CD4 immunoadhesins (eCD4-Ig and CD4-218.3-
E51mim2), as well as MPER antibody 10E8 and anti-CCR5 antibody PRO140, which resulted in 
a 4-fold reduction of virus load in one mouse (the other mouse died before a second blood 
sample could be obtained). Although these results are preliminary, they show that humanized 
mice are susceptible to SIVcpz infection and can be used to examine the efficacy of anti-SIVcpz 
neutralizing antibodies.  If a primate animal model were desired, a chimpanzee equivalent of the 
simian-human immunodeficiency virus (SHIV) could be generated, using a new and customizable 
technique developed by Hui Li and colleagues (57).  This method results in a virus containing a 
SIVmac backbone (allowing for effective replication in macaques) that expresses an HIV or 
SIVcpz envelope of your choosing (in order to test anti-envelope reagents) (57). bNabs and 
immunoadhesins should be tested as both preventatives and therapeutics, and tested individually 
and in combination to determine their combined potency.   
 The use of anti-SIVcpz interventions in the wild would only be considered if safety and 
efficacy was first proven in captivity, and if a chimpanzee community were in serious jeopardy at 
least in part due to SIVcpz infection.  Given the increasing threat of infectious pathogens to 
	  191	  
	  
chimpanzee survival, there is an urgent need to develop methods to curb the spread of disease in 
wild apes, and groups have already undertaken such interventions for other ape pathogens (58). 
Habituated chimpanzees like those in Gombe National Park would provide ideal candidates 
because field workers can easily identify infected individuals.  Thus, infected chimpanzees could 
be targeted individually with anti-SIVcpz therapy, benefiting the infected individual by preventing 
disease progression, but also benefiting the community by reducing the likelihood of 
transmission.  Using this approach, SIV uninfected chimpanzees would not need to be subjected 
to the intervention. Apes in sanctuaries could also benefit from treatment in order to prevent 
AIDS-like illness and transmission to other animals housed in the same facility (59).  In addition, 
orphaned chimpanzees who became SIV infected through vertical transmission could be treated 
before their release into the wild, preventing the introduction or spread of SIVcpz into their new 
community (60).  In these scenarios, long-lasting treatment would be useful, as daily oral ART 
may not be feasible.  Vectored antibody gene delivery, which results in extremely long-lasting 
antibody expression, could be combined with long-acting antiretrovirals, which are currently in 
development (61), in order to effectively reduce and maintain low levels of virus replication 
without the risk of viral escape (Fig. 5.2). The development of antibody-based therapies would 
also provide an important proof-of-concept that could be applied to other diseases that affect 
chimpanzee populations such as anthrax and Ebola (62, 63). Effective monoclonal antibodies 
could be delivered using the same gene therapy vector, resulting in a fast and long-lasting 
strategy to curb the spread of pathogens for which a safe and effective vaccine and/or therapy 
has not yet been developed. 
Over 100 chimpanzees have been subjected to HIV and SIV infection in captivity (64).   
Unlike wild chimpanzees, captive chimpanzees could be treated with daily ART.  However, the 
efficacy of existing ARVs against SIVcpz strains has not been reported. In Chapter 4, I described 
the SIVcpz-associated immunodeficiency and subsequent ARV treatment of a captive, 
experimentally infected chimpanzee. This work revealed several important findings that could 
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Fig. 5.2.  Potential uses of SIVcpz intervention strategies. Vectored antibody delivery involves the 
packaging of genes encoding a monoclonal antibody in a gene therapy vector. This is delivered to 
skeletal muscle via injection, which continuously produces the SIVcpz neutralizing antibody 
protein.  Antiretroviral therapy involves ingestion or injection of small molecules that block SIVcpz 
replication, usually by targeting enzymes essential for HIV/SIV reverse transcription, integration, 
and maturation.  Treatment of chimpanzees in the wild would require the long-lasting products of 
antibody gene delivery. Chimpanzees in a captive environment could be given daily ART. Animals 
with active SIV replication would require initial treatment with ART before antibody gene delivery 
to preclude antibody escape during the initial ramping stages of antibody concentrations.  
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 influence the veterinary care of captive chimpanzees infected with SIVcpz. First, SIVcpz is 
sufficient to drive immunodeficiency, even in animals with ready access to veterinary care and 
free of the pathogens and environmental hazards that may burden wild-living communities. 
Second, P. t. verus chimpanzees, a subspecies that is naturally free of SIVcpz infection, are 
susceptible to SIVcpz-associated immunodeficiency. Third, ARV regimens designed for treatment 
of HIV-1 infected humans can effectively reduce SIVcpz replication in vivo.  Fourth, insufficient 
levels of these drugs can drive viral escape through mechanisms similar to HIV-1 infected 
humans.  This has important implications for the care of captive SIVcpz infected chimpanzees.  
To our knowledge, no recommendations to monitor the infection and disease state of HIV and 
SIV infected captive chimpanzees exist in primate centers or sanctuaries.  These animals can 
progress to AIDS and possibly even transmit the infection, while existing ARV regimens designed 
for humans can prevent this unnecessary disease.  Thus, captive HIV/SIV infected chimpanzees 
would greatly benefit from regular viral load and CD4+ T cell enumerations and appropriate 
therapies.  
 In summary, these results contribute to the understanding of the biology of SIVcpz, as 
well as provide a foundation to combat this infection in chimpanzees.  Due to the endangered 
status of wild chimpanzees and the ethical inability to perform invasive studies in these animals, 
studies of SIVcpz in chimpanzees are inherently constrained. However, studies of noninvasively 
collected material have thus far yielded an understanding of the natural history of SIVcpz in its 
natural host, clues to its mechanism of pathogenesis, and potential methods to alleviate SIVcpz-
associated disease in chimpanzees. Further work and innovation could not only benefit 
chimpanzees, but also inform our understanding of HIV-1.   
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